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Hemolytic disease of the fetus and newborn (HDFN), caused by maternal red cell 
alloimmunization, has long been a major cause of perinatal morbidity and mortality. 
No antenatal treatment was available up to the 1960s. The only option was thus 
(preterm) induction, to enable neonatal treatment. This changed with the introduction 
of intrauterine intraperitoneal transfusion in 1963 by professor William Liley. However, 
in the early years, the complication risk of this X-ray guided intraperitoneal procedure 
was substantial. Outcomes gradually improved with more experience, the introduction of 
ultrasound-guided intravascular transfusions in the late 1980s, and advances in neonatal 
care.
Nowadays, both the incidence and risks of (antenatal treatment of) HDFN seem to have 
reached an ‘as good as it gets’ state in developed countries. In this thesis we aimed to 
summarize and evaluate current best practice, but often expert-based, management 
of HDFN. Furthermore, we assessed factors influencing the immunization risk and the 
severity of disease and evaluated standard and alternative treatment options.
In this chapter, an introduction to red cell alloimmunization and hemolytic disease of the 
fetus and newborn is provided.
RED CELL ALLOIMMUNIZATION
The origin of red cell alloantibodies
Red cell alloimmunization results from fetal-maternal blood group incompatibility: the 
fetus carries a red cell antigen, inherited from the father, that is unknown to the maternal 
immune system. Over 300 blood groups have been discovered so far, contributable to 
over 30 blood group systems1 and incompatibilities between mother and child can exist 
in every single one of these blood groups. Apart from the ABO blood group system, the 
Rh(esus) system is the most well-known. It was discovered in the Rhesus macaque in the 
1940s by Landsteiner and Wiener. This scientific milestone marks a major breakthrough 
in HDFN research and is therefore memorialized by the schematic illustration of a Rhesus 
macaque on the cover of this thesis.2
Fetal-maternal blood group incompatibility may lead to alloimmunization when 
fetomaternal hemorrhage (FMH) occurs during pregnancy or delivery (Figure 1). It is 
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known that FMH (often microtransfusions) can be detected in 45% of uncomplicated 
pregnancies during the third trimester and after 60% of deliveries.3
ABO incompatibility between mother and child is known to have a protective effect, 
reducing the chance of the alloimmunization. In the 1940s, Levine et al. already 
postulated this preventive effect when they noted that ABO incompatibility was less 
common among couples with D (formerly known as RhD) immunization in pregnancy, 
when compared to uncomplicated pregnancies.4 In this thesis, we aimed to evaluate 
whether ABO incompatibility is also preventive for non-D immunizations (other Rh such 
as C, c, E or e, non-Rh such as K (Kell), Fy (Duffy), Jk (Kidd), etc.).
Figure 1. The process of red cell alloimmunization. A: the mother is negative for a blood group antigen, 
the fetus is antigen-positive. During pregnancy or after delivery, fetal red cells enter the maternal circulation. 
B: maternal antibodies are formed against the fetal antigen. C: in the same or a next pregnancy, the antibodies 
are transported across the placenta and bind fetal red cells.
Prevention, screening and incidence
In order to prevent D immunization, D-negative women carrying a D-positive child receive 
both antenatal (at 28-30 weeks) and postnatal anti-D prophylaxis (RhIg) in most developed 
countries.5-7 Targeting the antenatal administration only to women with D-positive fetuses 
became possible with the introduction of cell-free fetal genotyping in maternal plasma.8 
This test can prevent that 40% of D-negative women unnecessarily receive antenatal 












Another common measure to prevent alloimmunization is matching blood transfusions 
for women of reproductive age for the D antigen, and, in the Netherlands, additionally 
for Kell, c and E.11,12
To date, the working mechanisms of RhIg remain partially unclear. To evaluate whether 
RhIg might function in a non-epitope specific manner, and because no prophylactic 
agent is available to prevent non-D immunization, the effect of RhIg on the occurrence 
of non-D antibodies was assessed in this thesis (Chapter 2).
As a result of the abovementioned prophylactic measures, the D immunization rate 
after delivering one D-positive child has decreased dramatically over the past decades, 
from 5.0% in the 1960s to 0.3% in 2008.5,13 The prevalence of D immunization amongst 
all pregnant women was 0.09% in 2016, based on our nationwide prospective study (this 
thesis, unpublished data) and the total number of screened pregnant women.14 To timely 
identify these pregnancies in which alloantibodies associated with HDFN (mainly Rh and 
K antibodies) do occur, all pregnant women are screened at the time of the first antenatal 
visit (preferably before 13 weeks’ gestation)15 as part of our free national population 
screening programme carried out by the National Institute for Public Health and the 
Environment (RIVM). Within this programme, D-negative women are again screened at 
27 weeks, before the prophylactic administration of RhIg. In addition, in the Netherlands, 
c-negative pregnant women are also screened for relevant antibodies at 27 weeks.
RISK OF HEMOLYSIS
Clinically relevant antibodies
The clinical relevance of alloantibodies in pregnancy depends on whether the fetus 
carries the antigen against which the antibodies are directed, whether it concerns IgG 
or IgM antibodies (IgM is not transported across the placenta) and on the ability of the 
antibody to induce hemolysis.16 In general, severe antenatal HDFN is most frequently 
caused by anti-D, anti-K or anti-c and only exceptionally by other Rh (E, C) and non-Rh 
antibodies such as anti-Fy or anti-Jk.17,18
Fetal phenotype
The first step to predict whether a pregnancy with alloantibodies is at risk for fetal 
hemolytic disease, is to determine whether the fetus carries the antigen against which the 
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antibodies are directed. If the father is found or known to be antigen-negative, no further 
fetal assessment is advised.19,20 Otherwise, non-invasive fetal genotyping by polymerase 
chain reaction (PCR) on cell-free fetal DNA in maternal plasma is nowadays usually the 
next step. This test is available with a high sensitivity (>95%) for D, C, c, E, (e) and K21 and 
can reliably be performed from the first trimester onwards(slightly later in gestation for 
K-typing). Therefore, the Royal College of Obstetricians and Gynaecologist (RCOG, United 
Kingdom) nowadays proposes that paternal testing might even be omitted.22
Serological testing
Assessment of the risk of fetal anemia in pregnancies with a positive antibody screening 
and an antigen-positive fetus is usually based on obstetric history and antibody titers, 
which is the highest dilution with positive agglutination test.17,23 In the Netherlands, an 
antibody-dependent cell-mediated cytotoxity assay (ADCC) is additionally performed for 
risk assessment. This bioassay measures the percentage of hemolysis that the maternal 
antibodies induce in vitro and shows a higher specificity (and equal sensitivity) compared 
to antibody titer for predicting fetal anemia in D immunization.24
The ‘critical titer’ to identify pregnancies at risk for hemolysis is set on 1:16 for most 
(clinically relevant) antibodies in the Netherlands, the ADCC on 10% for D and 30% for 
non-D antibodies.20 The ideal titer cut-off for K antibodies was long unclear and therefore 
set at 1:2. This was evaluated in a recent large study on K immunization in pregnancy, 
resulting in the recommendation to clinically monitor Kell-positive fetuses if antibody 
titer rises to or above 1:4.25
Recent studies have indicated that antibodies differ in their effector functions, as a 
result of differences in subclasses and glycovariants.26-28 Furthermore, IgG-Fc receptor 
polymorphisms, influencing the clearance of anti-D sensitized fetal red cells, are found to 
be associated with HDFN severity.29 These differences might be applicable in the future 
to predict which pregnancies are at risk for severe HDFN and which will only be subject 
to mild hemolysis.
Although most authors agree that HDFN severity increases in every subsequent 
pregnancy at risk, it is not well studied if and how obstetric history predicts outcome. 
We aimed to evaluate this by performing a nationwide cohort study amongst pregnant 












MONITORING OF PREGNANCIES AT RISK FOR FETAL ANEMIA
If the results of serological risk assessment tests rise above a set cut-off value, weekly 
fetal monitoring is indicated. From the late 1990s onwards, peak systolic velocity 
measurement of the middle cerebral artery (MCA-PSV) blood flow by Doppler is the 
golden standard for predicting fetal anemia.30 If MCA-PSV values exceed 1.5 multiples of 
the median (MoM) for gestational age, intrauterine transfusion (IUT) should urgently be 
performed, as measurements in this range strongly correlate with moderate to severe 
fetal anemia (sensitivity 100%, 12% false positive rate).
In the past, hydrops was often the first sign of fetal anemia due to red cell 
alloimmunization. This was alarming, as hydrops was associated with poor outcome on 
both the short and the long term.31,32 The current well-organized health care system of 
routine early alloantibody screening, national guidelines for management and referral 
of cases and pooling of expertise in national reference laboratories and a referral center 
for fetal therapy aims to enable intervention before the development of hydrops. In this 
thesis, we evaluated how this system influenced hydrops rates and outcome of hydropic 
fetuses (Chapter 4).
INTRAUTERINE TRANSFUSIONS
The cornerstone in antenatal therapy for fetal anemia is the ultrasound guided 
intravascular intrauterine transfusion (IUT), replacing intraperitoneal transfusion in the 
1980s.33 In Chapter 1 of this thesis, we summarize the literature on the preparations, 
setting and (long-term) outcome of this treatment.
Whereas outcome after treatment with IUT(s) was fairly poor in the early years after 
implementation in 1980s, it is now considered relatively safe in experienced hands. 
Transfusion techniques and complication rates however vary between fetal therapy 
centers, although it is know that transfusion into the intrahepatic part of the umbilical 
vein or the placental cord insertion are safest (Figure 2 and Chapter 5). The current 
transfusion techniques and risk factors for complications are assessed in this thesis 
(Chapter 5). Overall, the survival after IUT in experienced centers has now reached 
approximately 96% (range 89-100 %, see Chapter 1).
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We hypothesize that this increase could grossly be the result of three important changes: 
a reduction in complication rates, 2) more timely referral and therefore prevention of 
hydrops and 3) improvements in neonatal care. Both the complication rates and the 
prevention of hydrops were evaluated in this thesis (Chapters 4 and 5).
Figure 2. Intrauterine transfusion. Left: intrahepatic transfusion. Right: transfusion into the placental cord 
insertion (anterior placenta).
ALTERNATIVE TREATMENT
Several attempts have been made to assess the efficacy of non-invasive maternal 
treatment in pregnancies with severe (and early) HDFN. Most is known about therapeutic 
plasma exchange and/or intravenous immunoglobulins (IVIg). The literature on both of 
these alternative treatments is summarized in this thesis. Furthermore, we assessed the 
efficacy of IVIg in the multinational PETIT study. In this study, a cohort of patients with 
a history of early severe HDFN that was treated with IVIg, was compared to an equally 












AIM AND OUTLINE OF THIS THESIS
The first attempts for intrauterine treatment by Liley et al. arose from a back-against-
the-wall position: fetuses often died in-utero or suffered from extreme prematurity.34 
The founder of intrauterine transfusion in the Netherlands, professor Jack Bennebroek 
Gravenhorst, empirically introduced this treatment and stated:
‘Hoofdzaak is het bestrijden van de anemie. Bij het voortschrijden van de technische 
mogelijkheden en door uitgebreidere toepassing van de laatstgenoemde methode zal 
ongetwijfeld een elegantere methode gevonden worden voor de toediening van het bloed, 
waardoor bezwaren, die thans ongetwijfeld bestaan, uit de weg geruimd zullen worden.’
In English, this quote would be: ‘Main issue is to counter the anemia. The broadening of 
technical possibilities and more extensive application of the abovementioned method will 
undoubtedly lead to a more distinguished method for the administration of blood. Hereby the 
objections, that at present surely exist, will be eliminated.’35
This thesis aims to describe the gradual disappearance of these objections by addressing 
our unique care system for alloimmunized mothers, assessing transfusion techniques 
and complications and evaluating alternative treatment. Thereby, we wish to contribute 
to converting the management of and intrauterine transfusion for hemolytic diseae of 
the fetus from expert-based to evidence based.
PART 1: OVERVIEW
General introduction
Chapter 1 – Review of the available literature on antenatal management and outcome 
of HDFN. This includes a detailed description of important aspects of intrauterine 
transfusion, the golden standard treatment for fetal anemia, and evaluates the evidence 
on alternative therapeutic options.
PART 2: PATHOGENESIS AND SEVERITY OF HDFN
Chapter 2 – Case-control study including pregnant women with newly detected non-D 
antibodies, assessing whether ABO incompatibility has a preventive effect on formation 
of non-D alloantibodies. Subsequently, we evaluated a possible protective effect of RhIg 
in a subgroup with non-Rh antibodies only.
General Introduction
15
Chapter 3 – National cohort study amongst all pregnant women with D immunization, 
in which we assessed if, and how disease severity increases in subsequent pregnancies 
complicated by HDFN. Furthermore, we aimed to identify factors from the first pregnancy 
with D antibodies that predict severe disease in the subsequent affected pregnancy.
Chapter 4 - 30-year cohort study evaluating trends in the condition of fetuses treated 
with intrauterine transfusion for red-cell alloimmunization, at the time of first transfusion 
and at birth. This, in relation to our well-organized health care system for alloimmunized 
mothers.
PART 3: INTRAUTERINE TRANSFUSION AND OTHER TREATMENT 
OPTIONS
Chapter 5 – 27-year cohort study, assessing trends in complication and fetal death rates 
after intrauterine transfusion. We evaluated how IUT is most safely performed and aimed 
to identify factors leading to improved outcome.
Chapter 6 – International cohort study comparing pregnancies of women with a history 
of severe HDFN that are treated with or without intravenous immunoglobulins (IVIg) 
in a subsequent pregnancy. We aimed to assess whether IVIg could be a non-invasive 
alternative for (hazardous) early intrauterine transfusions.
Chapter 7 – Cochrane systematic review evaluating neonatal treatment with IVIg to 
reduce the need for neonatal exchange transfusions.
PART 4: SUMMARY AND DISCUSSION
This section summarizes the findings of the abovementioned studies, discusses their 
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Hemolytic disease of the fetus and newborn (HDFN) remains a serious pregnancy 
complication, which can lead to severe fetal anemia, hydrops and perinatal death.
Areas covered
This review focusses on the current prenatal management, treatment with intrauterine 
transfusion (IUT) and promising non-invasive treatment options for HDFN.
Expert commentary
IUTs are the cornerstone in prenatal management of HDFN and have significantly 
improved perinatal outcome in the past decades. IUT is now a relatively safe procedure, 
however the risk of complications is still high when performed early in the second 
trimester. Non-invasive management using intravenous immunoglobulin may be a safe 
alternative and requires further investigation.
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INTRODUCTION
Hemolytic disease of the fetus and newborn (HDFN) is still a serious complication 
in pregnancy. The condition is caused by maternal alloimmunization to fetal red cell 
antigens, inherited from the father, leading to fetal hemolysis and anemia. Untreated, 
progressing fetal anemia may result in hepatosplenomegaly, cardiomegaly, cardiac 
decompensation and eventually in fetal hydrops and perinatal death. If the fetus survives, 
persistent hemolysis may lead to severe neonatal hyperbilirubinemia and brain injury, 
an irreversible condition known as ‘kernicterus’. 36 Antibodies associated with severe 
HDFN are mostly of the anti-Rh(D) type, and to a lesser extent of the anti-Kell (anti-K1) 
or anti-Rh(c) type. Severe HDFN is occasionally caused by other Rh-antibodies, and only 
very rarely by non-Rh antibodies (Duffy, Kidd, or S).37
Prenatal screening for red cell antibodies and several preventive measures, such as 
matched blood transfusions for Rh- and K antigens and the antenatal and postnatal 
administration of anti-D immunoprophylaxis, have significantly reduced the incidence 
and severity of HDFN.5,38 Nowadays, approximately 1/300-1/600 pregnancies ending in 
live births are complicated by red cell immunization.39
If antibodies are detected in pregnancy, the risk of HDFN is estimated using 
maternal serum testing for antibody levels (quantification or titers) and, mainly in the 
Netherlands, antibody-dependent cell-mediated cytotoxicity (ADCC) assays for RhD 
immunizations.24,40-42 In most countries, a critical titer around 16, varying from 8 to 32, is 
used as a cut off for fetal monitoring,23,41 although this value has a false-positive rate of 
77% for predicting fetal anemia.24 Recent studies on antibody characteristics showed that 
lower core fucosylation of RhD-antibodies significantly correlated with increased disease 
severity28 and in anti-c immunizations, antibody galactosylation and sialylation best 
predicted fetal/neonatal disease.27 Furthermore, IgG1 anti-D subtypes are associated 
with increased severity, in contrast to IgG3.26 To our best knowledge, these interesting 
novel insights are not yet implemented in general practice. If either of these serum tests 
suggest an increased risk on fetal hemolysis, the patient will be monitored by serial 
Doppler measurements, as the peak systolic flow velocity (PSV) of the middle cerebral 
artery (MCA) is considered the most accurate noninvasive predictor of fetal anemia.30,43-48
Until the 1960s, no prenatal treatment options for severe HDFN were available. The 








prematurely, to enable neonatal treatment. HDFN was until then a major cause of 
perinatal mortality. In 1963, Liley described the intrauterine intraperitoneal blood 
transfusion (IPT), which considerably reduced mortality rates.34 However, the outcome 
of fetuses with alloimmune anemia <26 weeks’ gestation and of those with hydrops 
remained poor (32 and 42%, respectively).49 In 1981, direct intravascular intrauterine 
transfusions by fetoscopy (IUT) were first described,50 with initial survival rates around 
85%.51 In the years that followed, ultrasound guidance gradually replaced fetoscopy52 
and since then, intravascular IUT has been the cornerstone of treatment for fetal anemia 
due to red-cell alloimmunization.50,51,53 This review focusses on the current transfusion 
techniques, complications and promising non-invasive treatment options for HDFN.
PRENATAL TREATMENT OF HDFN
Intravascular intrauterine blood transfusion (IUT)
Transfusion preparation and details
Indication
IUT should be urgently performed if MCA-PSV Doppler exceeds 1.5 multiples of the 
median (MoM) and/or if signs of hydrops are present, as both correlate strongly with 
moderate to severe fetal anemia.30,39,46 Timing of subsequent IUTs can be done by 
calculating the expected decline in hematocrit and by MCA-PSV Doppler measurements.54 
Nowadays, since the prediction using the MCA Doppler is highly reliable, fetal blood 
sampling is preferably directly followed by IUT and not performed as a diagnostic tool 
without blood available for immediate transfusion.55,56 However, the degree of fetal 
anemia, assessed by the hemoglobin concentration in the pre-transfusion fetal blood 
sample, finally sets the conclusive IUT indication. The cut offs used for this decision differ 
amongst the various fetal therapy centers. However, authors agree that IUT should only 
be performed in case of moderate to severe anemia, usually defined as hemoglobin 
concentrations of four to five standard deviations below mean/median for gestational 
age23,57-59 or a hemoglobin deficit of 5 g/dL or more.60,61
Setting
In the Leiden University Medical Center (LUMC), the Dutch national referral center for 
fetal therapy, the operating team performing IUTs is composed of a staff-perinatologist, 
an experienced ultrasonographer and one or two operating nurses.55 This corresponds 
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to the approach of other centers, although in some centers an additional perinatologist 
or pediatrician is present.62-64
Authors agree that IUTs need to be performed under aseptic conditions, guided by 
continuous ultrasound/Doppler, using a 20-22 gauge needle 55,62,63,65,66. No data are 
available on the influence of needle size on procedure complications.
Premedication
Maternal premedication varies from local anesthetics only to routine indomethacin 
and/or pethidine/promethazine to combined spinal epidural analgesia,55,58,63 the latter 
being used to facilitate an emergency caesarian section if needed. There is no expert 
uniformity or scientific evidence supporting routine use of prophylactic antibiotics or 
corticosteroids60,63,67,68 at IUT and these prophylactic measures are not routinely used 
at our center.55
Fetal premedication consists of an intramuscularly (or intravenously) administered 
paralytic agent and/or fetal pain medication. Because of the reported lower risk of 
complications following IUT when applying fetal paralysis in all cases, routine use is 
advocated.55,57 For fetal paralysis, atracurium (0.4 mg/kg), vecuronium (0.1 mg/kg) 
or pancuronium (0.1 mg/kg) are the most commonly used products.69-72 Atracurium 
or vecuronium are often used as first-line premedication option due to the fact that 
these short-lasting agents give sufficient paralysis for IUT completion. Furthermore, 
pancuronium is associated with several cardiovascular side-effects.73
As the neurologic basis for nociception is present from 24-28 weeks’ gestation and 
hormonal and circulatory stress responses have been reported from as early as 18-20 
weeks’, fetal analgesia should be considered when performing invasive fetal procedures.74 
Authors advocate 10 µg/kg fentanyl to reduce the fetal stress response and possible 
fetal pain sensation.74 However, other authors have found that these fetal hemodynamic 
and stress hormone changes are more likely to be caused by volume expansion than by 
fetal stress, as the response was independent of insertion site.75,76
Transfusion volume
The transfusion volume is calculated by the method described by Rodeck in 1984,51 








sample (Ht1), donor blood hematocrit (Ht2) and the aimed fetal hematocrit post-
transfusion (Ht3):
Transfusion volume =V(Ht3-Ht1)/Ht2
Examples of used calculations for computing the fetoplacental volume (V) are:
 ۛ 0.1 mL volume/g of estimated fetal weight,77 or
 ۛ 0.15 mL volume/g of estimated fetal weight,78 or
 ۛ 1.046 + (fetal weight in grams) x 0.14.79
In order to simplify these formulas, Giannina et al.77 introduced a simplified equation and 
compared this to previously described methods:79,80
Transfusion volume = 0.02 x target increase in fetal Ht per 10% x g of estimated fetal weight,
assuming that donor blood hematocrit is approximately 75%. This equation was shown 
to be equally accurate as the formula introduced by Rodeck and is therefore very useful 
as a simplified calculation method for transfusion volume.51,77 Target hematocrit should 
be around 45%.55,68,72,78,80. Furthermore, fetal hemoglobin (Hb) testing prior to IUT is 
nowadays often used to precisely calculate the volume to transfuse.
Blood source
Intrauterine transfusions are usually carried out with O-negative, washed, irradiated, 
leukocyte depleted blood, negative for the antigens against which the mother is 
immunized.55,81 In the Netherlands, donor blood for IUTs is additionally matched with 
the maternal Duffy, Kidd and S blood group, to reduce the high risk on the formation of 
new antibodies.82 Donations are usually from an allogenic donor, as multiple maternal 
blood donations have been associated with adverse pregnancy outcome,83,84 although 
a direct cause–effect relation seems unlikely.85 Altogether, proposed advantages69,81,85,86 
usually do not outweigh these possible adverse effects of autologous donations.
Simple vs. exchange
Intrauterine exchange transfusion (IUET) has been proposed as an alternative to simple 
IUT as exchange transfusions may result in a more stable hematocrit87, potentially 
decrease the risks of (temporary) volume overload and increase the interval between 
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procedures. However, the risk of procedure-related complications associated with IUETs 
may be higher, due to longer duration and needle movements.88 Furthermore, the excess 
volume after simple IUT is thought to exit the intravascular compartment, decreasing the 
risk of volume overload and fetuses seem to tolerate single IUT quite well.89,90 In a recent 
(relatively small) cohort study in which IUT and IUET were compared,62 no differences in 
benefits or complications were found. However, data on the duration of the procedures 
were not available. Nowadays, most fetal therapy centers opt for simple transfusions 
rather than exchange transfusions.
Puncture site
Possible puncture sites or procedure access sites are: intrahepatic, placental cord 
insertion, transamniotic ‘free loop’ needling, intraperitoneal and (exceptionally) sites as 
the fetal heart or chorionic plate vein.57 All transfusions should be aimed intravenously, 
as arterial punctures are associated with high complication rates.57,91 The fetal liver and 
placental cord insertion are shown to be the safest puncture sites, whereas free loop 
needling is a higher risk procedure and should in our view best be avoided.57,58,66-68
Authors have postulated a beneficial effect of combined intravascular and intraperitoneal 
transfusion on the inter-procedure interval.89 In our center, the liver gained more and 
more popularity as a puncture site in the last decades and currently 57.1% of transfusions 
are performed intrahepatic, frequently combined with intraperitoneal transfusion. 
Analysis of the effect of this combined technique on transfusion interval is planned. 
Our recent cohort study showed that transplacental cord punctures were nowadays 
performed in 41.3% of procedures and a free loop of cord was the chosen puncture site 
in only 1.1% of IUTs. In 0.5% of procedures, blood was transfused intraperitoneally only.57
Outcome
Many fetal therapy centers have reported on their IUT results in recent years. Table 
1 contains a summary of survival after intravascular IUT from a selection of studies 
published in the last 10 years. Reported live birth rates after IUT vary from 81.9-
100%.57,58,64-68,92-94
(Procedure-related) complications
Possible complications during or following IUT are: bleeding from the puncture site, 
cord occlusion, brady- or tachycardia and PPROM or preterm (emergency) delivery.91,92 








procedure. These IUT complications may lead to maternal morbidity, an emergency 
cesarean section (CS) or even fetal death.
Table 1. Overall survival after intrauterine transfusion






Somserset, 2006 221 26.9 25 (16-32) IUST Liver 91
Weisz, 2009 154 11.1 26 (-) IUET - 88,9
Tiblad, 2011 284 11.8 - IUST Liver 91.8
Johnstone-Ayliffe, 2012 114 13 26 (17-35) IUST Liver 93.5
Birchenall, 2013 256 - 30 (16-35.4) - Liver or PCI 95.3
Walsh, 2013 242 16 29.1 (19.2-34.4) - PCI 95.1
Pasman, 2015 135 14 - IUST PCI 100
Sainio, 2015 339 11.5 29 (18-36) - Free loop 96.2
Deka, 2016 303 21.6 26.9 (19.7-33.8) - PCI 96.1
Zwiers, 2016b 937 12.9 27 (16-36) IUST Liver 97
Overall 95.2
N: number of transfusions; GA: gestational age; IUT: intrauterine transfusion; Overall survival: live birth rate; 
IUST: intrauterine single transfusion; IUET: intrauterine exchange transfusion; PCI: placental cord insertion.
aweeks, median (range) or mean (range).
bresult of cohort since 2001 shown.
We recently reported the largest cohort study on procedure-related complications after 
1678 IUTs (741 unto 2000 and 937 from 2001 onwards).57 We found a 1.2% procedure-
related complication rate per procedure in the new cohort (3.3% per fetus), compared 
to 3.4% per procedure (9.8% per fetus) before 2001 (P=0.003 and 0.001, respectively). In 
experienced hands, 1.8% of fetuses died as a direct result of the procedure, indicating a 
0.6% procedure-related fetal demise rate per procedure. Refraining from fetal paralysis, 
arterial and free loop needling were found to be important risk factors for adverse 
outcome.57 Furthermore, operators should perform at least 10 IUTs per year to retain 
their competence.95
A summary of (procedure-related) complications in recent studies is shown in Table 
2.57,58,65-68,92,93
IUTs performed early in the second trimester, before 20-22 weeks of gestation, carry 
substantially higher risks on (procedure-related) complications and fetal loss compared 
to later IUTs, due to technical challenges of early procedures and severity of disease 
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57,66,91,96. Reported survival rates for IUT series started before 20-22 weeks lie around 76-
88%.96-99 Lindenburg et al. found a fourfold risk of perinatal death after IUTs <20 weeks’ 
gestation, compared to IUTs later in gestation.98
Table 2. Procedure-related complications and fetal loss
Author, year N PR complications (%) Fetal loss (%) PR fetal lossa (%)
Somserset, 2006 67/221 - 2.1 -
Weisz, 2009 54/154 - 11.1 -
Tiblad, 2011 85/284 16.5/4.9 5.9 4.7/1.4
Johnstone-Ayliff, 2012 46/114 13/5.2 6.5 2.1/0.9
Pasman, 2015 56/135 3.6/1.5 0 0
Sainio, 2015 104/339 23.1/7.1 3.8 3.8/1.2
Deka, 2016 102/303 8.8/3 3.9 4.9/1.65
Zwiers, 2016b 334/937 3.3/1.2 3 1.8/0.6
Overall 848/2487 7.8/2.7 3.9 1.9/0.8
N: number of fetuses/transfusions; PR: procedure related.
PR complications: infection, PPROM or preterm delivery within 7 days, emergency cesarean section, fetal 
loss. Numbers shown per fetus/per procedure.
aper fetus/per procedure.
bresult of cohort since 2001 shown.
To improve the perinatal outcome in this specific group with fetal anemia early in the 
second trimester, several alternative strategies have been proposed. The intrahepatic 
transfusion route is probably the preferred route, as the surrounding tissue makes 
it easier to keep the needle in place, despite the small vessel size in early pregnancy 
(<3-5 mm before 20 weeks’ gestation).66,78 Some authors promote intraperitoneal 
transfusions instead100 or noninvasive treatment options to postpone early intravascular 
transfusions.98
Non-invasive options
Several non-invasive treatment options have been proposed to postpone IUT in early 
severe HDFN, not as a sole treatment if fetal anemia is already present.78
Therapeutic plasma exchange (TPE)
In TPE, the patient’s plasma is removed and replaced with albumin-rich fluid by passing 
the patient’s blood through a cell separator.101 The maternal antibodies directed against 
fetal red cell antigens are then removed. TPE may cause a decrease in antibody titers 








the beneficial value of TPE alone to postpone IUT in early severe HDFN was found to 
be disappointing.78,98,101-103 The deficiency of therapeutic plasma exchange as a single 
treatment is possibly due to a rebound effect, causing a rapid rise in antibody levels 
to amounts equal as or higher than before TPE was performed, even if the pheresis is 
continued.98,102
Although the use of TPE is considered safe in pregnancy,101 side and adverse effects 
do occur. For example, an increase in antibody-dependent cell-mediated cytotoxicity 
after TPE has been described, apart from the above-mentioned rebound phenomenon 
of antibody concentrations.104 Second, placental blood flow might be altered during 
TPE, as fluctuations in pressure or electrolyte levels may cause variations in maternal 
blood pressure. Furthermore, with maternal serum extraction, coagulation factors and 
immunoglobulin levels in maternal blood fall, causing increased risks on postpartum 
hemorrhage and maternal and neonatal infections.103,105
As all available knowledge regarding TPE for severe HDFN is derived from observational 
case series, only category III recommendations can be made and decision-making should 
be individualized.101 The decision to apply this technique for postponing an early IUT could 
be made in cases with a history of severe HDFN and should be individualized. Authors 
agree that, if at all, it is best used combined with intravenous immunoglobulins (IVIG), 
as described below.105,106
Intravenous immunoglobulins (IVIG)
The effect of IVIG in HDFN may result from various mechanisms including (1) inhibition 
of Fc-mediated antibody passage across the placenta, (2) negative feedback on 
maternal antibody production and/or (3) reticuloendothelial Fc-receptor saturation/
blockage, amongst others resulting in decreased uptake of opsonized fetal cells by 
macrophages.102,107-111 Although IVIG may prevent or reduce fetal hemolysis, it does not 
treat fetal anemia.112
In most fetal therapy centers applying IVIG, it is started at 400 mg/kg maternal weight/day 
for 5 consecutive days, repeated every 2-3 weeks.108,110,112,113 An alternative regime could 
be 500 mg-1 g/kg maternal body weight weekly.106,114 At our center, the first administration 
of IVIG is preferably planned in the 12th week of pregnancy in an outpatient setting 
usually at a dose of 500 mg/kg, followed by weekly infusions of the same dose. These 
follow-up infusions are offered as a home service by Sanquin Diagnostics, the national 
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blood and plasma product supply organization in the Netherlands, reducing the burden 
of frequent hospital visits.
Few fetal therapy centers administrate IVIG directly to the fetus after gaining 
intraperitoneal or intravascular access.115-117 The increased volume given to the fetus 
could lead to cardiac compromise.
IVIG as a sole treatment to postpone early IUTs has shown promising results in several 
case series.111,113 The only prospective study on maternal IVIG administration was 
performed by Margulies et al. and reported on 24 severely Rh-sensitized patients. In 
total, three fetal demises occurred (12.5%), in hydropic fetuses. IVIG treatment caused 
a significant decline in anti-D titers and hemolysis rate and even averted invasive IUT in 
this severely affected group if started before 28 weeks’ gestation. Nevertheless, they 
concluded that for hydropic fetuses and for fetuses with advanced fetal anemia, IUT is 
inevitable.118 In a retrospective study of the same group, patients receiving IVIG before 20 
weeks had significantly less hydropic fetuses and a lower fetal mortality rate compared 
to patients treated with IUT alone.112
However, in another small series of four cases of severe RhD immunization, IVIG did not 
seem to have any effect on transfusion frequency, maternal antibody titers or hydrops.119 
Recently, a prospective case-control study in 34 women compared IUT with fetal IVIG 
infusion to IUT alone and described a slower hematocrit decline after IUT in the IVIG 
group.117 Similar results were found before, but no impact on perinatal outcome was 
reported.115,116
An occasionally used strategy is the combination of IVIG and TPE. This treatment strategy 
is thought to oppose the previously mentioned rebound effect of TPE alone and might 
intensify the effect of IVIG and TPE on perinatal outcome. IVIG transfer to the fetus in 
HDFN is thought to start from 10–12 weeks’ gestation, supporting treatment schedules 
starting from this gestational age.102 A possible schedule could be: 3 serial TPE treatments 
in the 12th week of pregnancy, followed by weekly IVIG administration,106 although 
evidence for this schedule is scarce.120 Authors agree that this combined technique 
should be reserved for the most severe cases. The largest series reports on 9 severe 
HDFN cases, in which a combined regimen of three TPE procedures and weekly IVIG was 








were alive and well at birth.106 Several case reports have been published with favorable 
outcome following this combined approach.114,121-125
Reported side effects of IVIG are rare but may include: headache, fever, myalgia and low 
back pain, rush or chills, urticaria, nausea and vomiting, tachycardia, chest tightness, 
hypotension and shortness of breath.72,78,126,127 These events usually occur 30-60 min after 
admission and especially the headache could be prevented by 1000 mg acetaminophen 
before infusion.72 Although very rare, renal failure, aseptic meningitis, anaphylaxis (mainly 
in case of IgA deficiency), hemolytic anemia, thromboembolism and pulmonary edema 
are described.78,126,127
Last, IVIG is an expensive treatment, with reported prices around $6000/week.128 The 
costs and benefits of IVIG should be weighed against those of early IUT. Importantly, 
early IUT may result in more complications, which also carries along additional costs.98 
Furthermore, IVIG treatment might even prevent perinatal deaths to occur, a situation 
associated with a high psychological burden and of which the costs are difficult to quantify.
Recommendations are based on observational studies only and are therefore weak. 
However, there seems to be a beneficial effect of IVIG (with or without TPE) to postpone 
early transfusions and therefore it should be considered in patients with a history of 
severe HDFN.
EXPERT COMMENTARY
In the past decades, improved prevention and screening strategies have greatly 
reduced the incidence of severe HDFN and it is nowadays considered a rare disease. 
Consequently, yearly IUT numbers per fetal therapy center decrease and centralization 
of this highly specialized care becomes more and more important. Fetal therapy centers 
from all over the world collaborate and invest in high-quality research to deliver the best 
possible patient care in this field. Not only did the incidence of HDFN decline, a dramatic 
improvement in prognosis of HDFN was achieved. With the introduction of intravascular 
IUTs and the availability of valuable noninvasive diagnostics for fetal anemia, survival 
increased remarkably. Several adjustments in transfusion technique, such as transfusing 
through the intrahepatic vein or placental cord insertion instead of using a free loop of 
cord and applying routine fetal paralysis, have further improved outcome. Procedure-
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related complication rates are currently as low as 3.3% per fetus and 1.2% per procedure 
in experienced hands.57 Nonetheless, preventable fetal losses do occur, especially in 
fetuses in need for IUT before 20–22 weeks.98 A truly evidence -based noninvasive 
approach to further reduce fetal loss rates is however not yet available. Nevertheless, the 
use of intravenous immunoglobulins to postpone these hazardous early IUTs, potentially 
combined with TPE, shows promising results in case series and single center case-control 
studies.112,118 Therapeutic plasma exchange alone seems unable to create similar results.
FIVE-YEAR VIEW
Ideally a randomized controlled trial should be performed to assess the efficacy and 
benefits of IVIG in early severe HDFN. However, the auspicious results of IVIG published 
so far have possibly made it unethical to randomly assign patients with a history of 
severe HDFN to a ‘non-IVIG’ study group. Therefore, an international multicenter cohort 
study on the effect of IVIG is currently performed, in which IVIG cases are compared to 
a reference group with similar disease severity but without IVIG treatment. Depending 
on the results of this study, a randomized trial could still be considered, taking above-
mentioned ethical dilemmas into account. If IVIG treatment proves to be disappointing, 
other options such as stem cell treatment and gene therapy will be investigated.
KEY ISSUES
 ۛ Although prophylaxis has strongly reduced the incidence of maternal immunization 
against fetal red cell antigens, HDFN is still a serious pregnancy complication which 
may lead to severe fetal anemia, hydrops and perinatal death.
 ۛ Intravascular intrauterine transfusions are the cornerstone in prenatal management 
and have significantly improved perinatal outcome in the past decades.
 ۛ Several risk factors for adverse outcome after IUT have been defined, such as 
refraining from fetal paralysis, arterial puncture and free loop needling. Avoiding 
these hazardous techniques causes continuously rising survival rates worldwide.
 ۛ Performing IUTs before 20-22 weeks’ gestation greatly increases the risk on 
complications.
 ۛ The use of IVIG is an emerging non-invasive strategy to postpone these early IUTs. 








ABO INCOMPATIBILITy AND RHIG 
IMMUNOPROPHyLAXIS PROTECT 








C. Ellen van der Schoot





Hemolytic disease of the fetus and newborn (HDFN) is caused by maternal antibodies 
against fetal red blood cell antigens, most often anti-D, -K or -c. ABO incompatibility 
between mother and child and anti-D immunoprophylaxis (RhIG) are known to reduce 
the risk of D immunization and subsequent HDFN. However, no immunoprophylaxis has 
been developed to prevent non-D immunizations.
Study design and methods
We evaluated whether ABO incompatibility has a preventive effect on formation of non-D 
alloantibodies, by performing a case-control study including pregnant women with newly 
detected non-D antibodies, identified within a nationwide data set, immunized during 
their first pregnancy and/or delivery. Subsequently, we assessed a possible protective 
effect of RhIG in a subgroup with non-Rh antibodies only. The proportions of previous 
ABO incompatibility and of RhIG administrations of these women were compared to 
the known rate of 19.4% ABO incompatibility and 9.9% RhIG administrations (D- women 
carrying a D+ child) in the general population of pregnant women.
Results
A total of 11.9% of the 232 included immunized women had a possible ABO incompatibility 
in their first pregnancy (vs. expected 19.4%; 95% confidence interval [CI], 7.3-18.8; 
P=0.036). Furthermore, 1.0% of women with non-Rh antibodies were D-, delivered a D+ 
child and had therefore received RhIG, whereas 9.9% was expected (95% CI 0.18-5.50; 
P=.003).
Conclusion
We found that ABO incompatibility and RhIG reduce the risks not only for D, but also for 
non-Rh immunizations, suggesting that antibody-mediated immune suppression in this 
condition is not antigen specific.
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INTRODUCTION
Hemolytic disease of the fetus and newborn (HDFN) is a serious pregnancy complication, 
caused by maternal antibodies against fetal red blood cell (RBC) antigens. These 
antibodies may provoke fetal hemolysis, resulting in fetal anemia, hydrops, and even 
death if left untreated.17,37 HDFN is most frequently caused by antibodies with anti-D 
specificity, followed by anti-K, anti-c, anti-E, other Rh antibodies, or exceptionally, anti-Fy 
(Duffy) or anti-Jk (Kidd).16,17,37,129
Already in 1943, Levine et al. did the pivotal observation that ABO incompatibility occurred 
less in patients with D immunization during pregnancy compared to couples without D 
immunization, indicating a preventive effect of ABO incompatibility on the formation of 
D antibodies.4 This observation was confirmed by others, of which Nevannlina and Vainio 
most widely studied the effect of mother-child ABO incompatibility on D immunization.130 
These observations eventually led to the hypothesis that the development of anti-D 
immunoglobulin prophylaxis (RhIG) could prevent D immunization.131
Indeed, postnatal prophylaxis with RhIG, introduced in the 1960s, and additional 
antenatal prophylaxis in the 1990s, have drastically reduced the risk for D immunizations 
by pregnancy or birth.5 As a consequence, RhIG is a very effective measure to prevent 
D immunizations. Several possible pathways have been hypothesized and thoroughly 
studied in the past decades, although the exact mechanisms of action of RhIG still 
remain unclear.132-136
Clinically relevant RBC alloantibodies directed against other RBC antigens (non-D RBC 
alloantibodies), in the absence of D antibodies, were found at screening in the first 
trimester of pregnancy in 0.33% of all pregnancies in the Netherlands between 2002 and 
2004.16 As mentioned, non-D antibodies might also cause HDFN, although to a lesser 
extent than anti-D.16 To prevent non-D alloimmunization, women of reproductive age (<45 
years) in need for RBC transfusions receive K-matched (from 2004 onward) and c- and 
E-matched (2011 onward) blood units in the Netherlands.11 So far, no immunoprophylaxis 
has been developed to prevent non-D alloimmunization, although the clinical relevance 









It is not known whether the immunization against non-D RBC antigens might be 
preventable by administration of an immunoprophylaxis, like in D immunization. 
Therefore, we first assessed whether ABO mismatch in pregnancy also reduces the 
risk of immunization toward non-D RBC antigens. Subsequently, we investigated if the 




We performed a case-control study, comparing pregnant women with one previous 
delivery and non-D alloantibodies detected at first trimester screening that most likely 
were immunized by RBC antigens of their first child (cases), to the Dutch population of 
pregnant women (control population).
Study population
Previously, all women with non-D alloantibodies, but no D antibodies, found at first 
trimester screening in the Netherlands between September 1, 2002 and June 1, 2003, 
and between October 1, 2003 and July 1, 2004, were included in the prospective OPZI 
(Opsporing en Preventie Zwangerschapsimmunisatie/Detection and Prevention of 
Pregnancy Immunisation) study.16 These cases were identified at Sanquin Diagnostics, 
the Dutch national reference laboratory, or BIBO (Bijzonder Instituut voor Bloedgroepen 
Onderzoek/Special Institute for Blood Group Investigation), where the specificity 
of all RBC alloantibodies found at first trimester screening in regional laboratories is 
determined. All women with non-D alloantibodies from the OPZI study were initially 
included in this study as cases. To facilitate subgroup analyses of different antibody 
specificities, additionally, women with newly detected anti-E, anti-K, anti-Fy or anti-Jk, 
and without D antibodies, identified at the laboratory of Sanquin Diagnostics between 
July 2012 and September 2015 and between January and September 2016 were included. 
Subsequently, to compose a group of women that was most likely immunized by one 
previous pregnancy or delivery, multiparous or nulliparous women were excluded, as 
well as women with blood transfusions after a negative antibody screen in their previous 
pregnancy, and women with partners negative for the antigen against which the maternal 
antibodies were directed. The likelihood that part of the population was not immunized 
by their previous delivery, but by a miscarriage or abortion in between was considered 
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nihil, as we previously found that these factors are not associated with an increased risk 
of alloimmunization.129
Cases were compared to the general pregnant Dutch population. If ABO incompatibility 
or RhIG administration would have a protective effect on any type of immunization, this 
would be indicated by a low incidence of ABO incompatibility or RhIG administrations 
in our case group compared to the general population. Therefore, we compared the 
probability of ABO incompatibility of the cases with the calculated proportion in the 
general population, based on the distribution of AB antigens in a Caucasian population.1 
Second, the proportion of cases that previously received RhIG was compared to the 
proportion of D negative women with D+ fetuses in the general Caucasian population, 
assuming a 100% coverage of the national prevention program for pregnancy 
immunization. 139 We hypothesize that the preventive effect of RhIG on non-Rh 
immunizations is limited to D+ fetal RBCs and would be less profound or absent in 
pregnancies of D- women carrying a D- child. Therefore, we considered D- women with 
D- fetuses, who received untargeted antenatal prophylaxis before the introduction of 
fetal D typing in maternal blood in 2011, as not having received RhIG.
Data collection
From the OPZI database we collected laboratory data (antibody type; paternal antigen 
phenotype; blood group of mother, father and second child), data on the obstetric history 
and data on blood transfusions after a previous negative antibody screen in the first 
pregnancy.16 Laboratory data (antibody type, paternal antigen phenotype, ABO blood 
group of mother and father) concerning the additional cases were collected from the 
Sanquin database. After written informed consent from the women, additional clinical 
data were obtained from the patients’ midwife, gynecologist or general practitioner.
Ethical considerations
As patients were not subjected to additional interventions due to this study, formal 
ethical approval was not mandatory in the Netherlands and was therefore not obtained. 
All participants gave informed consent.
Statistics
To compare proportions, 95% confidence intervals (CI) and concordant p values were 









The probability of ABO incompatibility in the first pregnancy in cases was estimated twice: 
1) based on the ABO blood group of the cases and their partners and, more accurately, 
2) based on the ABO blood group of the cases and their partners, as well as the ABO 
blood group of the children born from the pregnancy with alloantibodies, and compared 
to population probabilities on incompatibility using the same variables. All calculations 
are shown in Tables S1 through S6 (available as supporting information in the online 
version of this paper).
We assessed the comparability of cases and general population in respect to RhIG 
administrations by comparing the number of D negative mothers in both groups. 
Subsequently, to compare the number of RhIG administrations in the cases and the 
general population, we planned to analyze two separate subgroups, the Rh (non-D, anti-C/
Cw and anti-E) and non-Rh antibodies, as the risk to develop anti-Rh antibody specificities 
is dependent on the D phenotype of the mother. Since there is a strong linkage between 
RHCE (e.g., RHce) and D, almost all D- women are c- and e+. As a consequence, women who 
develop anti-c, anti-e or anti-f are virtually always D+ and never receive RhIG. Therefore, 
these antibody specificities were excluded in the planned Rh subgroup analyses.
RESULTS
In total, 1326 women with new non-D antibodies were included (Figure 1). After excluding 
women in their first ongoing pregnancy or with more than one previous birth, women 
with an antigen-negative partner, or with a history of RBC transfusion after a negative 
antibody screen in their previous pregnancy, 232 women remained and were included in 
the analysis. E antibodies were most frequently found, followed by anti-K, anti-c, anti-C, and 
anti-Jk. The median maternal age at first alloantibody detection was 32 (range 19-40) years.
ABO incompatibility
Data on ABO blood group of all women with non-D antibodies were complete and for 201 
of 232 partners (Table S5). Based on these data, we determined that the first pregnancy 
was surely compatible in at least 74.6% of the cases, whereas in the total population this 
is only in 66.5% (p=0.015). The probability of an ABO incompatible first pregnancy was 
14.1% in cases (28/201) versus 19.4% in the general population (95% CI, 9.9-19.6; p=0.058; 
Tables S1, S2, and S5). The accuracy to estimate whether the first pregnancy was ABO 
incompatible was increased by taking the blood group of the second child into account. 
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These data were available for 124 of the 232 cases (Table S6) and this more accurate 
estimation showed that the first pregnancy had surely been compatible in 79.0% of the 
cases, compared to 66.5% in the general population (p=0.003; Tables S3, S4, and S6). 
The probability of an ABO-incompatible first pregnancy in this specific group is shown in 
Table 1. In total, the first pregnancy might have been ABO incompatible in 11.9% of cases, 
significantly less than the 19.4% in the Dutch population (95% CI, 7.3-18.8; p=0.036; Tables 
Figure 1. Selection of cases. The total number of antibodies may differ from 232 as women may have devel-
oped more than one antibody.
Table 1. ABO incompatibility in previous pregnancy per maternal ABO blood groupa
Maternal blood group
Probability of incompatible first pregnancyb
PCases, n/nc Cases, % (95% CI) Population, %
O 11.7/50 23.34 (13.78-36.70) 30.72 .26
A 2/54 3.70 (1.02-12.53) 6.09 .46
B 1.1/12 9.43 (1.83-36.68) 24.60 .22
AB 0/8 0 0 1
All blood groups 14.8/124 11.94 (7.34-18.81) 19.36 .04
aWilson score used for 95% CI and concordant P-values.
bBased on combination of ABO blood group of mother, father and second child. See supplemental tables 3,4 
and 6 for calculations.
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S3, S4, and S6). The group was too small to calculate a potential difference in protective 
effect between anti-A and anti-B.
RhIG administrations
In total, four of 232 cases received RhIG in their previous pregnancy and/or after 
their first delivery. In the general (Caucasian) population, this is 9.9%.1 One D– woman 
received untargeted antenatal prophylaxis while carrying a D– child and was therefore 
considered as not having received RhIG prophylaxis. We planned to analyze Rh and 
non-Rh specificities separately. We found that, in the subgroup of women with anti-E 
or anti-C, the proportion of women being D– was far lower than expected (2/83 [2.4%] 
vs. 22.3% and 1/9 [11.1%] vs. 78.4%, respectively).1 Therefore, we did not continue the 
planned separate analysis for Rh antibodies.
In cases with non-Rh antibodies, the percentage of D– women without necessity of 
RhIG prophylaxis was approximately as expected (5/99, 5.1% vs. 7.0% expected [16.9% 
D– women of whom 41.2% were carrying a D– child and therefore without an indication 
for prophylaxis1]). Table 2 therefore shows the results of this subgroup of cases with 
non-Rh antibodies and separate analyses for different non-Rh antibody specificities. Only 
one of 99 (1%) women with non-Rh antibodies received RhIG in her previous pregnancy 
and/or after her first delivery, significantly less often than the expected number of 10 
women based on calculations for the general population (16.9% D– women of whom 
58.8% were carrying a D+ child).
Table 2. Subgroup analyses of RhIG administrations in 99 cases with non-Rh antibodies compared 
to the populationa
Number/proportion of RhIG 
administrations 95% CI P
Antibody specificity Cases, n/total Cases, %b
 All non-Rh 1/99c 1.0 0.18-5.50 .003
 Anti-K 1/37 2.7 0.48-13.82 .14
 Anti-Jk 0/37 0 0-9.41 .04
 Anti-Fy 0/14 0 0-21.53 .21
 Other 0/34 0 0-10.15 .05
aWilson score used for 95% CI and concordant P-values.
bCompared to 9.9%, the calculated probability of D- women carrying a D+ fetus.1
cThe sum of different antibodies may differ from 99 as women may have developed more than one antibody.
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DISCUSSION
In this study, we assessed whether ABO mismatch in pregnancy may reduce the risk of 
immunization towards non-D RBC antigens. In 232 women with non-D alloantibodies due 
to their first ongoing pregnancy or delivery, we found a significantly smaller proportion 
of possible ABO incompatible first pregnancies in cases than in general population, 
implicating a preventive effect of ABO incompatibility on non-D antibody formation.
Subsequently, we evaluated whether RhIG also prevents non-Rh immunizations and 
found that only 1% had previously received RhIG prophylaxis, whereas approximately 
10% was expected. This underrepresentation of D– pregnant women with previous 
RhIG prophylaxis indicates a possible protective effect of RhIG on formation of non-Rh 
alloantibodies. These findings also suggest that, in general, for all pregnant women, 
non-Rh immunizations might be preventable via a mechanism similar to prevention of D 
immunizations. The prophylactic effect of both ABO mismatch and RhIG is not absolute, 
as is also not the case for RhIG and ABO incompatibility in D immunization.5,130,140
Our finding that ABO incompatibility also protects against non-D immunizations 
is in line with early studies of Levine, reporting on a protective effect on c and K 
immunizations.140,141 Later, Stern142 also postulated an effect of ABO incompatibility 
on other types of immunization, although the possible influence of a previous blood 
transfusion was not completely clear in this study.
The found preventive effect on non-D immunizations may be clinically relevant, as 
severe HDFN may also be caused by anti-K (prevalence, 1.02/1000), anti-c (0.71/ 1000 
pregnancies), and (rarely) by other Rh and non-Rh antibodies.16,143 If anti-K or anti-c is 
present, this can lead to severe HDFN in 26%16 to 53% of pregnancies with K+25 and in 
10% of pregnancies with c+ children.16 It was not possible to determine whether anti-D 
immunoprophylaxis might prevent c immunizations, as women at risk for development 
of c antibodies are virtually always D+ and therefore never receive RhIG.
The strength of this study is that we assessed only women with one previous birth and 
thereby we selected a group of women exposed to approximately the same amount of 
fetal RBCs. Furthermore, in this matter we effaced the possible immunosuppressive 
effect of RhIG administrations in pregnancies (ending in miscarriage or termination) 








with a high probability of being immunized by their previous pregnancy or delivery, as 
we excluded women with antigen-negative partners and those with blood transfusions 
after their first pregnancy or delivery.
We believe that the retrospective study design does not reduce this study’s value, as 
RhIG coverage is more than 98% in the Netherlands139 and therefore the comparison in 
RhIG administration between cases and Dutch population could well be made. Moreover, 
the cases were prospectively collected in the OPZI study. Another strong point is that, 
although the ABO blood group of the first child and therefore the true proportion of 
incompatible first pregnancies was unavailable, a distinct approximation could be made 
as in approximately 50% of cases, the ABO blood group of mother, father, and second 
child was known.
By not including women who developed D antibodies, part of the D– population (of 
which a considerable proportion might be ‘high-responders’,134 very prone to develop 
additional antibodies) was excluded. This exclusion did not affect the found preventive 
effect of RhIG on the development of non-Rh antibodies, as we previously found that 
in primiparous women with newly detected D antibodies and without a previous blood 
transfusion, non-Rh antibodies in addition to D antibodies are rarely developed.144
However, a limitation of our study is that by not including women with D antibodies, we 
were not able to evaluate the effectiveness of RhIG in preventing the development of Rh 
antibodies. This is reflected by the observation that we found barely any D– women with 
anti-E and anti-C. Because of the linkage disequilibrium between RHD and RHCE alleles, 
anti-C and anti-E are mainly formed in pregnancies with D+ children. As the D antigen is 
a more immunogenic antigen than E or C, women in whom RhIG fails will make anti-E/C 
most likely in addition to anti-D. Possibly, in this manner, RhIG not only protects strongly 
against D immunizations, but also against anti-E or anti-C.
Furthermore, we are limited to a relatively small sample size in the subgroup analysis with 
non-Rh antibodies only, to assess a protective effect of RhIG. However, even in this small 
sample the difference between the expected (10) and observed (1) number of women 
who previously received RhIG is statistically significant.
Although several studies have previously addressed the possible mechanisms of action 
of RhIG, the exact mechanism(s) remain unclear.134-136,145,146
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Whereas the antigen masking or steric hindrance hypothesis appears to be the prevailing 
mechanism in the antibody-mediated immune suppression model with sheep RBCs in 
mice,147 this mechanism insufficiently explains RhIG function in humans, based on the low 
level of opsonization sufficient to exert suppression.132-134 Furthermore, antigen masking 
is an antigen-specific mechanism and if this was the main explanation for RhIG function, 
it would not prevent development of other RBC alloantibody specificities as found in our 
study. In agreement with our findings, in a mouse model it was shown that antibodies 
directed against a nonimmunogenic Fy antigen could mediate immune suppression 
toward the immunogenic antigen (HEL), although in these studies the Fy and HEL were 
expressed on the same protein (HOD).148
Furthermore, the recently postulated antigen-specific “antigen-modulation hypothesis”, 
in which the preventive effect of anti-KEL sera on KEL immunization was attributed to 
the complete removal or substantial modulation of the KEL antigen, is not in line with 
our findings.137,146 A possible explanation to this discrepancy is that antibody responses 
might function through different mechanisms for different antigens.
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Table S1. Calculation of ABO incompatibility in general population based on the ABO blood group of 
mother and father





Probability of genotype child based 









combination OO OA OB AA AB BB
OO 0.48 OO 0.48 0.2304 1 - - - - -
OO 0.48 OA 0.34 0.1638 0.5 0.5 - - - -
OO 0.48 OB 0.08 0.0405 0.5 - 0.5 - - -
OO 0.48 AA 0.06 0.0291 - 1 - - - -
OO 0.48 AB 0.03 0.0144 - 0.5 0.5 - - -
OO 0.48 BB <0.01 0.0018 - - 1 - - -
OA 0.34 OO 0.48 0.1638 0.5 0.5 - - - -
OA 0.34 OA 0.34 0.1164 0.25 0.5 - 0.25 - -
OA 0.34 OB 0.08 0.0288 0.25 0.25 0.25 - 0.25 -
OA 0.34 AA 0.06 0.0207 - 0.5 - 0.5 - -
OA 0.34 AB 0.03 0.0102 - 0.25 0.25 0.25 0.25 -
OA 0.34 BB <0.01 0.0013 - - 0.5 - 0.5 -
OB 0.08 OO 0.48 0.0405 0.5 - 0.5 - - -
OB 0.08 OA 0.34 0.0288 0.25 0.25 0.25 - 0.25
OB 0.08 OB 0.08 0.0071 0.25 - 0.5 - - 0.25
OB 0.08 AA 0.06 0.0051 - 0.5 - - 0.5 -
OB 0.08 AB 0.03 0.0025 - 0.25 0.25 - 0.25 0.25
OB 0.08 BB <0.01 0.0003 - - 0.5 - - 0.5
AA 0.06 OO 0.48 0.0291 - 1 - - - -
AA 0.06 OA 0.34 0.0207 - 0.5 - 0.5 - -
AA 0.06 OB 0.08 0.0051 - 0.5 - - 0.5 -
AA 0.06 AA 0.06 0.0037 - - - 1 - -
AA 0.06 AB 0.03 0.0018 - - - 0.5 0.5 -
AA 0.06 BB <0.01 0.0002 - - - - 1 -
AB 0.03 OO 0.48 0.0144 - 0.5 0.5 - - -
AB 0.03 OA 0.34 0.0102 - 0.25 0.25 0.25 0.25 -
AB 0.03 OB 0.08 0.0025 - 0.25 0.25 - 0.25 0.25
AB 0.03 AA 0.06 0.0018 - - - 0.5 0.5 -
AB 0.03 AB 0.03 0.0009 - - - 0.25 0.5 0.25
AB 0.03 BB <0.01 0.0001 - - - - 0.5 0.5
BB <0.01 OO 0.48 0.0018 - - 1 - - -
BB <0.01 OA 0.34 0.0013 - - 0.5 - 0.5 -
BB <0.01 OB 0.08 0.0003 - - 0.5 - - 0.5
BB <0.01 AA 0.06 0.0002 - - - - 1 -
BB <0.01 AB 0.03 0.0001 - - - - 0.5 0.5
BB <0.01 BB <0.01 <0.0001 - - - - - 1
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Probability of phenotype child based on 
phenotype mother and fathera
Probability of 
incompatible 
pregnancyO A B AB
O O 1.00 - - - -
O A 0.42 0.58 - - 0.58
O B 0.48 - 0.52 - 0.52
O AB - 0.50 0.50 - 1.00
A O 0.42 0.58 - - -
A A 0.18 0.82 - - -
A B 0.20 0.28 0.22 0.30 0.52
A AB - 0.50 0.21 0.29 0.50
B O 0.48 - 0.52 - -
B A 0.20 0.28 0.22 0.30 0.58
B B 0.23 - 0.77 - -
B AB - 0.24 0.50 0.26 0.50
AB O - 0.50 0.50 - -
AB A - 0.50 0.21 0.29 -
AB B - 0.24 0.50 0.26 -
AB AB - 0.25 0.25 0.50 -
Grey cells reflect possible incompatible combinations








Table S3. Calculation of ABO incompatibility in the first pregnancy in general population based on 










Probability of genotype first child 




















































combination OO OA OB AA AB BB
OO 0.48 OO 0.48 OO 1 0.2304 1 - - - - -
OO 0.48 OA 0.34 OO 0.5 0.0819 0.5 0.5 - - - -
OO 0.48 OB 0.08 OO 0.5 0.0203 0.5 - 0.5 - - -
OO 0.48 AA 0.06 OO - - - 1 - - - -
OO 0.48 AB 0.03 OO - - - 0.5 0.5 - - -
OO 0.48 BB <0.01 OO - - - - 1 - - -
OO 0.48 OO 0.48 OA - - 1 - - - - -
OO 0.48 OA 0.34 OA 0.5 0.0819 0.5 0.5 - - - -
OO 0.48 OB 0.08 OA - - 0.5 - 0.5 - - -
OO 0.48 AA 0.06 OA 1 0.0291 - 1 - - - -
OO 0.48 AB 0.03 OA 0.5 0.0072 - 0.5 0.5 - - -
OO 0.48 BB <0.01 OA - - - - 1 - - -
OO 0.48 OO 0.48 OB - - 1 - - - - -
OO 0.48 OA 0.34 OB - - 0.5 0.5 - - - -
OO 0.48 OB 0.08 OB 0.5 0.0203 0.5 - 0.5 - - -
OO 0.48 AA 0.06 OB - - - 1 - - - -
OO 0.48 AB 0.03 OB 0.5 0.0072 - 0.5 0.5 - - -
OO 0.48 BB <0.01 OB 1 0.0018 - - 1 - - -
OO 0.48 OO 0.48 AA - - 1 - - - - -
OO 0.48 OA 0.34 AA - - 0.5 0.5 - - - -
OO 0.48 OB 0.08 AA - - 0.5 - 0.5 - - -
OO 0.48 AA 0.06 AA - - - 1 - - - -
OO 0.48 AB 0.03 AA - - - 0.5 0.5 - - -
OO 0.48 BB <0.01 AA - - - - 1 - - -
OO 0.48 OO 0.48 AB - - 1 - - - - -
OO 0.48 OA 0.34 AB - - 0.5 0.5 - - - -
OO 0.48 OB 0.08 AB - - 0.5 - 0.5 - - -
OO 0.48 AA 0.06 AB - - - 1 - - - -
OO 0.48 AB 0.03 AB - - - 0.5 0.5 - - -
OO 0.48 BB <0.01 AB - - - - 1 - - -
OO 0.48 OO 0.48 BB - - 1 - - - - -
OO 0.48 OA 0.34 BB - - 0.5 0.5 - - - -
OO 0.48 OB 0.08 BB - - 0.5 - 0.5 - - -
OO 0.48 AA 0.06 BB - - - 1 - - - -
OO 0.48 AB 0.03 BB - - - 0.5 0.5 - - -
OO 0.48 BB <0.01 BB - - - - 1 - - -
OA 0.34 OO 0.48 OO 0.50 0.0819 0.5 0.5 - - - -
OA 0.34 OA 0.34 OO 0.25 0.0291 0.25 0.5 - 0.25 - -
OA 0.34 OB 0.08 OO 0.25 0.0072 0.25 0.25 0.25 - 0.25 -
OA 0.34 AA 0.06 OO - - - 0.5 - 0.5 - -
OA 0.34 AB 0.03 OO - - - 0.25 0.25 0.25 0.25 -
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Probability of genotype first child 




















































combination OO OA OB AA AB BB
OA 0.34 BB <0.01 OO - - - - 0.5 - 0.5 -
OA 0.34 OO 0.48 OA 0.50 0.0819 0.5 0.5 - - - -
OA 0.34 OA 0.34 OA 0.50 0.0582 0.25 0.5 - 0.25 - -
OA 0.34 OB 0.08 OA 0.25 0.0072 0.25 0.25 0.25 - 0.25 -
OA 0.34 AA 0.06 OA 0.50 0.0103 - 0.5 - 0.5 - -
OA 0.34 AB 0.03 OA 0.25 0.0026 - 0.25 0.25 0.25 0.25 -
OA 0.34 BB <0.01 OA - - - - 0.5 - 0.5 -
OA 0.34 OO 0.48 OB - - 0.5 0.5 - - - -
OA 0.34 OA 0.34 OB - - 0.25 0.5 - 0.25 - -
OA 0.34 OB 0.08 OB 0.25 0.0072 0.25 0.25 0.25 - 0.25 -
OA 0.34 AA 0.06 OB - - - 0.5 - 0.5 - -
OA 0.34 AB 0.03 OB 0.25 0.0026 - 0.25 0.25 0.25 0.25 -
OA 0.34 BB <0.01 OB 0.50 0.0006 - - 0.5 - 0.5 -
OA 0.34 OO 0.48 AA - - 0.5 0.5 - - - -
OA 0.34 OA 0.34 AA 0.25 0.0291 0.25 0.5 - 0.25 - -
OA 0.34 OB 0.08 AA - - 0.25 0.25 0.25 - 0.25 -
OA 0.34 AA 0.06 AA 0.50 0.0103 - 0.5 - 0.5 - -
OA 0.34 AB 0.03 AA 0.25 0.0026 - 0.25 0.25 0.25 0.25 -
OA 0.34 BB <0.01 AA - - - - 0.5 - 0.5 -
OA 0.34 OO 0.48 AB - - 0.5 0.5 - - - -
OA 0.34 OA 0.34 AB - - 0.25 0.5 - 0.25 - -
OA 0.34 OB 0.08 AB 0.25 0.0072 0.25 0.25 0.25 - 0.25 -
OA 0.34 AA 0.06 AB - - - 0.5 - 0.5 - -
OA 0.34 AB 0.03 AB 0.25 0.0026 - 0.25 0.25 0.25 0.25 -
OA 0.34 BB <0.01 AB 0.50 0.0006 - - 0.5 - 0.5 -
OA 0.34 OO 0.48 BB - - 0.5 0.5 - - - -
OA 0.34 OA 0.34 BB - - 0.25 0.5 - 0.25 - -
OA 0.34 OB 0.08 BB - - 0.25 0.25 0.25 - 0.25 -
OA 0.34 AA 0.06 BB - - - 0.5 - 0.5 - -
OA 0.34 AB 0.03 BB - - - 0.25 0.25 0.25 0.25 -
OA 0.34 BB <0.01 BB - - - - 0.5 - 0.5 -
OB 0.08 OO 0.48 OO 0.50 0.0203 0.5 - 0.5 - - -
OB 0.08 OA 0.34 OO 0.25 0.0072 0.25 0.25 0.25 - 0.25 -
OB 0.08 OB 0.08 OO 0.25 0.0018 0.25 - 0.5 - - 0.25
OB 0.08 AA 0.06 OO - - - 0.5 - - 0.5 -
OB 0.08 AB 0.03 OO - - - 0.25 0.25 - 0.25 0.25
OB 0.08 BB <0.01 OO - - - - 0.5 - - 0.5
OB 0.08 OO 0.48 OA - - 0.5 - 0.5 - - -
OB 0.08 OA 0.34 OA 0.25 0.0072 0.25 0.25 0.25 - 0.25 -
OB 0.08 OB 0.08 OA - - 0.25 - 0.5 - - 0.25
OB 0.08 AA 0.06 OA 0.50 0.0026 - 0.5 - - 0.5 -
OB 0.08 AB 0.03 OA 0.25 0.0006 - 0.25 0.25 - 0.25 0.25
OB 0.08 BB <0.01 OA - - - - 0.5 - - 0.5

















Probability of genotype first child 




















































combination OO OA OB AA AB BB
OB 0.08 OA 0.34 OB 0.25 0.0072 0.25 0.25 0.25 - 0.25 -
OB 0.08 OB 0.08 OB 0.50 0.0036 0.25 - 0.5 - - 0.25
OB 0.08 AA 0.06 OB - - - 0.5 - - 0.5 -
OB 0.08 AB 0.03 OB 0.25 0.0006 - 0.25 0.25 - 0.25 0.25
OB 0.08 BB <0.01 OB 0.50 0.0002 - - 0.5 - - 0.5
OB 0.08 OO 0.48 AA - - 0.5 - 0.5 - - -
OB 0.08 OA 0.34 AA - - 0.25 0.25 0.25 - 0.25 -
OB 0.08 OB 0.08 AA - - 0.25 - 0.5 - - 0.25
OB 0.08 AA 0.06 AA - - - 0.5 - - 0.5 -
OB 0.08 AB 0.03 AA - - - 0.25 0.25 - 0.25 0.25
OB 0.08 BB <0.01 AA - - - - 0.5 - - 0.5
OB 0.08 OO 0.48 AB - - 0.5 - 0.5 - - -
OB 0.08 OA 0.34 AB 0.25 0.0072 0.25 0.25 0.25 - 0.25 -
OB 0.08 OB 0.08 AB - - 0.25 - 0.5 - - 0.25
OB 0.08 AA 0.06 AB 0.50 0.0026 - 0.5 - - 0.5 -
OB 0.08 AB 0.03 AB 0.25 0.0006 - 0.25 0.25 - 0.25 0.25
OB 0.08 BB <0.01 AB - - - - 0.5 - - 0.5
OB 0.08 OO 0.48 BB - - 0.5 - 0.5 - - -
OB 0.08 OA 0.34 BB - - 0.25 0.25 0.25 - 0.25 -
OB 0.08 OB 0.08 BB 0.25 0.0018 0.25 - 0.5 - - 0.25
OB 0.08 AA 0.06 BB - - - 0.5 - - 0.5 -
OB 0.08 AB 0.03 BB 0.25 0.0006 - 0.25 0.25 - 0.25 0.25
OB 0.08 BB <0.01 BB 0.50 0.0002 - - 0.5 - - 0.5
AA 0.06 OO 0.48 OO - - - 1 - - - -
AA 0.06 OA 0.34 OO - - - 0.5 - 0.5 - -
AA 0.06 OB 0.08 OO - - - 0.5 - - 0.5 -
AA 0.06 AA 0.06 OO - - - - - 1 - -
AA 0.06 AB 0.03 OO - - - - - 0.5 0.5 -
AA 0.06 BB <0.01 OO - - - - - - 1 -
AA 0.06 OO 0.48 OA 1 0.0291 - 1 - - - -
AA 0.06 OA 0.34 OA 0.50 0.0103 - 0.5 - 0.5 - -
AA 0.06 OB 0.08 OA 0.50 0.0026 - 0.5 - - 0.5 -
AA 0.06 AA 0.06 OA - - - - - 1 - -
AA 0.06 AB 0.03 OA - - - - - 0.5 0.5 -
AA 0.06 BB <0.01 OA - - - - - - 1 -
AA 0.06 OO 0.48 OB - - - 1 - - - -
AA 0.06 OA 0.34 OB - - - 0.5 - 0.5 - -
AA 0.06 OB 0.08 OB - - - 0.5 - - 0.5 -
AA 0.06 AA 0.06 OB - - - - - 1 - -
AA 0.06 AB 0.03 OB - - - - - 0.5 0.5 -
AA 0.06 BB <0.01 OB - - - - - - 1 -
AA 0.06 OO 0.48 AA - - - 1 - - - -
AA 0.06 OA 0.34 AA 0.50 0.0103 - 0.5 - 0.5 - -
AA 0.06 OB 0.08 AA - - - 0.5 - - 0.5 -
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Probability of genotype first child 




















































combination OO OA OB AA AB BB
AA 0.06 AA 0.06 AA 1 0.0037 - - - 1 - -
AA 0.06 AB 0.03 AA 0.50 0.0009 - - - 0.5 0.5 -
AA 0.06 BB <0.01 AA - - - - - - 1 -
AA 0.06 OO 0.48 AB - - - 1 - - - -
AA 0.06 OA 0.34 AB - - - 0.5 - 0.5 - -
AA 0.06 OB 0.08 AB 0.50 0.0026 - 0.5 - - 0.5 -
AA 0.06 AA 0.06 AB - - - - - 1 - -
AA 0.06 AB 0.03 AB 0.50 0.0009 - - - 0.5 0.5 -
AA 0.06 BB <0.01 AB 1 0.0002 - - - - 1 -
AA 0.06 OO 0.48 BB - - - 1 - - - -
AA 0.06 OA 0.34 BB - - - 0.5 - 0.5 - -
AA 0.06 OB 0.08 BB - - - 0.5 - - 0.5 -
AA 0.06 AA 0.06 BB - - - - - 1 - -
AA 0.06 AB 0.03 BB - - - - - 0.5 0.5 -
AA 0.06 BB <0.01 BB - - - - - - 1 -
AB 0.03 OO 0.48 OO - - - - 0.5 - - -
AB 0.03 OA 0.34 OO - - - - 0.25 0.25 0.25 -
AB 0.03 OB 0.08 OO - - - - 0.25 - 0.25 0.25
AB 0.03 AA 0.06 OO - - - 0.5 - 0.5 0.5 -
AB 0.03 AB 0.03 OO - - - 0.25 - 0.25 0.5 0.25
AB 0.03 BB <0.01 OO - - - 0.25 - - 0.5 0.5
AB 0.03 OO 0.48 OA 0.50 0.0072 - - 0.5 - - -
AB 0.03 OA 0.34 OA 0.25 0.0026 - - 0.25 0.25 0.25 -
AB 0.03 OB 0.08 OA 0.25 0.0006 - - 0.25 - 0.25 0.25
AB 0.03 AA 0.06 OA - - - - - 0.5 0.5 -
AB 0.03 AB 0.03 OA - - - - - 0.25 0.5 0.25
AB 0.03 BB <0.01 OA - - - - - - 0.5 0.5
AB 0.03 OO 0.48 OB 0.50 0.0072 - 0.5 0.5 - - -
AB 0.03 OA 0.34 OB 0.25 0.0026 - 0.25 0.25 0.25 0.25 -
AB 0.03 OB 0.08 OB 0.25 0.0006 - 0.25 0.25 - 0.25 0.25
AB 0.03 AA 0.06 OB - - - - - 0.5 0.5 -
AB 0.03 AB 0.03 OB - - - - - 0.25 0.5 0.25
AB 0.03 BB <0.01 OB - - - - - - 0.5 0.5
AB 0.03 OO 0.48 AA - - - 0.5 0.5 - - -
AB 0.03 OA 0.34 AA 0.25 0.0026 - 0.25 0.25 0.25 0.25 -
AB 0.03 OB 0.08 AA - - - 0.25 0.25 - 0.25 0.25
AB 0.03 AA 0.06 AA 0.50 0.0009 - - - 0.5 0.5 -
AB 0.03 AB 0.03 AA 0.25 0.0002 - - - 0.25 0.5 0.25
AB 0.03 BB <0.01 AA - - - - - - 0.5 0.5
AB 0.03 OO 0.48 AB - - - 0.5 0.5 - - -
AB 0.03 OA 0.34 AB 0.25 0.0026 - 0.25 0.25 0.25 0.25 -
AB 0.03 OB 0.08 AB 0.25 0.0006 - 0.25 0.25 - 0.25 0.25
AB 0.03 AA 0.06 AB 0.50 0.0009 - - - 0.5 0.5 -

















Probability of genotype first child 




















































combination OO OA OB AA AB BB
AB 0.03 BB <0.01 AB 0.50 0.0001 - - - - 0.5 0.5
AB 0.03 OO 0.48 BB - - - 0.5 0.5 - - -
AB 0.03 OA 0.34 BB - - - 0.25 0.25 0.25 0.25 -
AB 0.03 OB 0.08 BB 0.25 0.0006 - 0.25 0.25 - 0.25 0.25
AB 0.03 AA 0.06 BB - - - - - 0.5 0.5 -
AB 0.03 AB 0.03 BB 0.25 0.0002 - - - 0.25 0.5 0.25
AB 0.03 BB <0.01 BB 0.50 0.0001 - - - - 0.5 0.5
BB <0.01 OO 0.48 OO - - - - 1 - - -
BB <0.01 OA 0.34 OO - - - - 0.5 - 0.5 -
BB <0.01 OB 0.08 OO - - - - 0.5 - - 0.5
BB <0.01 AA 0.06 OO - - - - - - 1 -
BB <0.01 AB 0.03 OO - - - - - - 0.5 0.5
BB <0.01 BB <0.01 OO - - - - - - - 1
BB <0.01 OO 0.48 OA - - - - 1 - - -
BB <0.01 OA 0.34 OA - - - - 0.5 - 0.5 -
BB <0.01 OB 0.08 OA - - - - 0.5 - - 0.5
BB <0.01 AA 0.06 OA - - - - - - 1 -
BB <0.01 AB 0.03 OA - - - - - - 0.5 0.5
BB <0.01 BB <0.01 OA - - - - - - - 1
BB <0.01 OO 0.48 OB 1 0.0018 - - 1 - - -
BB <0.01 OA 0.34 OB 0.50 0.0006 - - 0.5 - 0.5 -
BB <0.01 OB 0.08 OB 0.50 0.0002 - - 0.5 - - 0.5
BB <0.01 AA 0.06 OB - - - - - - 1 -
BB <0.01 AB 0.03 OB - - - - - - 0.5 0.5
BB <0.01 BB <0.01 OB - - - - - - - 1
BB <0.01 OO 0.48 AA - - - - 1 - - -
BB <0.01 OA 0.34 AA - - - - 0.5 - 0.5 -
BB <0.01 OB 0.08 AA - - - - 0.5 - - 0.5
BB <0.01 AA 0.06 AA - - - - - - 1 -
BB <0.01 AB 0.03 AA - - - - - - 0.5 0.5
BB <0.01 BB <0.01 AA - - - - - - - 1
BB <0.01 OO 0.48 AB - - - - 1 - - -
BB <0.01 OA 0.34 AB 0.50 0.0006 - - 0.5 - 0.5 -
BB <0.01 OB 0.08 AB - - - - 0.5 - - 0.5
BB <0.01 AA 0.06 AB 1 0.0002 - - - - 1 -
BB <0.01 AB 0.03 AB 0.50 0.0001 - - - - 0.5 0.5
BB <0.01 BB <0.01 AB - - - - - - - 1
BB <0.01 OO 0.48 BB - - - - 1 - - -
BB <0.01 OA 0.34 BB - - - - 0.5 - 0.5 -
BB <0.01 OB 0.08 BB 0.50 0.0002 - - 0.5 - - 0.5
BB <0.01 AA 0.06 BB - - - - - - 1 -
BB <0.01 AB 0.03 BB 0.50 0.0001 - - - - 0.5 0.5
BB <0.01 BB <0.01 BB 1 <0.0001 - - - - - 1
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Table S4. Probability of incompatible first pregnancy based on the ABO blood group of mother, father 







Probability of phenotype 
first child based on 




first pregnancyO A B AB
O O O 1 - - - -
O A O 0.5 0.5 - - 0.5
O B O 0.5 - 0.5 - 0.5
O AB O - - - - -
O O A - - - - -
O A A 0.37 0.63 - - 0.63
O B A - - - - -
O AB A - 0.5 0.5 - 1
O O B - - - - -
O A B - - - - -
O B B 0.46 - 0.54 - 0.54
O AB B - 0.5 0.5 - 1
O O AB - - - - -
O A AB - - - - -
O B AB - - - - -
O AB AB - - - - -
A O O 0.5 0.5 - - -
A A O 0.25 0.75 - - -
A B O 0.25 0.25 0.25 0.25 0.5
A AB O - - - - -
A O A 0.37 0.63 - - -
A A A 0.16 0.84 - - -
A B A 0.18 0.32 0.18 0.32 0.5
A AB A - 0.5 0.21 0.29 0.5
A O B - - - - -
A A B - - - - -
A B B 0.23 0.23 0.27 0.27 0.54
A AB B - 0.5 0.25 0.25 0.5
A O AB - - - - -
A A AB - - - - -
A B AB 0.17 0.29 0.20 0.34 0.54
A AB AB - 0.5 0.18 0.32 0.5
B O O 0.5 - 0.5 - -
B A O 0.25 0.25 0.25 0.25 0.5
B B O 0.25 - 0.75 - -
B AB O - - - - -
B O A - - - - -
B A A 0.18 0.32 0.18 0.32 0.63
B B A - - - - -
B AB A - 0.25 0.5 0.25 0.5
B O B 0.46 - 0.54 - -














Probability of phenotype 
first child based on 




first pregnancyO A B AB
B B B 0.22 - 0.78 - -
B AB B - 0.24 0.5 0.26 0.5
B O AB - - - - -
B A AB 0.17 0.29 0.20 0.34 0.63
B B AB - - - - -
B AB AB - 0.23 0.5 0.27 0.5
AB O O - - - - -
AB A O - - - - -
AB B O - - - - -
AB AB O - - - - -
AB O A - 0.5 0.5 - -
AB A A - 0.5 0.21 0.29 -
AB B A - 0.25 0.5 0.25 -
AB AB A - 0.25 0.25 0.5 -
AB O B - 0.5 0.5 - -
AB A B - 0.5 0.25 0.25 -
AB B B - 0.24 0.5 0.26 -
AB AB B - 0.25 0.25 0.5 -
AB O AB - - - - -
AB A AB - 0.5 0.18 0.32 -
AB B AB - 0.23 0.5 0.27 -
AB AB AB - 0.25 0.25 0.5 -
Grey cells reflect possible incompatible combinations.
aCalculated from the probabilities per ABO genotype shown in supplemental Table 1.
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O x O - 45 (22.4) 23.0 22.4 23.0 - -
O x A 0.58 21 (10.5) 19.3 - - 6.0 11.1
O x B 0.52 8 (4.0) 4.2 - - 2.1 2.2
O x AB 1.00 1 (0.5) 1.4 - - 0.5 1.4
A x O - 43 (21.4) 19.3 21.4 19.3 - -
A x A - 34 (16.9) 16.2 16.9 16.2 - -
A x B 0.52 6 (3.0) 3.5 - - 1.6 1.8
A x AB 0.50 7 (3.5) 1.2 - - 1.7 0.6
B x O - 15 (7.5) 4.2 7.5 4.2 - -
B x A 0.58 6 (3.0) 3.5 - - 1.7 2.0
B x B - 2 (1.0) 0.8 1.0 0.8 - -
B x AB 0.50 2 (1.0) 0.3 - - 0.5 0.1
AB x O - 2 (1.0) 1.4 1.0 1.4 - -
AB x A - 4 (2.0) 1.2 2.0 1.2 - -
AB x B - 1 (0.5) 0.3 0.5 0.3 - -
AB x AB - 4 (2.0) 0.1 2.0 0.1 - -
Total 201 
(100)
100 74.6 66.5 14.1 19.4
aSee supplemental tables 1 and 2 for calculations.
bThe probability of an incompatible first pregnancy was 0.
cThe probability of an incompatible first pregnancy was >0.








Table S6. Calculation of ABO (in)compatibility in first pregnancy of cases and general population 
























O x O x O - 30 (24.4) 23.0 24.4 23.0 - -
O x A x O 0.5 6 (4.9) 8.2 - - 2.4 4.1
O x A x A 0.63 8 (6.5) 11.1 - - 4.1 7.0
O x B x O 0.5 2 (1.6) 2.0 - - 0.8 1.0
O x B x B 0.54 3 (2.4) 2.2 - - 1.3 1.2
O x AB x A 1 - 0.7 - - 0 0.7
O x AB x B 1 1 (0.8) 0.7 - - 0.8 0.7
A x O x O - 6 (4.8) 8.2 4.1 8.2 - -
A x O x A - 18 (14.6) 11.1 14.6 11.1 - -
A x A x O - 5 (4.1) 2.9 4.1 2.9 - -
A x A x A - 21 (17.1) 13.2 17.1 13.2 - -
A x B x O 0.5 - 0.7 - - - 0.4
A x B x A 0.5 1 (0.8) 1.0 - - 0.4 0.5
A x B x B 0.54 - 0.8 - - - 0.4
A x B x AB 0.54 - 1.1 - - - 0.6
A x AB x A 0.5 3 (2.4) 0.6 - - 1.2 0.3
A x AB x B 0.5 - 0.3 - - - 0.1
A x AB x AB 0.5 - 0.4 - - - 0.2
B x O x O - 5 (4.1) 2.0 4.1 2.0 - -
B x O x B - 4 (3.3) 2.2 3.3 2.2 - -
B x A x O 0.5 - 0.7 - - - 0.4
B x A x A 0.63 1 (0.8) 1.0 - - 0.5 0.6
B x A x B 0.5 1 (0.8) 0.8 - - 0.4 0.4
B x A x AB 0.63 - 1.1 - - - 0.7
B x B x O - 1 (0.8) 0.2 0.8 0.2 - -
B x B x B - - 0.6 - 0.6 - -
B x AB x A 0.5 - 0.1 - - - -
B x AB x B 0.5 - 0.1 - - - 0.1
B x AB x AB 0.5 - 0.1 - - - -
AB x O x A - - 0.7 - 0.7 - -
AB x O x B - 2 (1.6) 0.7 1.6 0.7 - -
AB x A x A - 1 (0.8) 0.6 0.8 0.6 - -
AB x A x B - - 0.3 - 0.3 - -
AB x A x AB - 1 (0.8) 0.4 0.8 0.4 - -
AB x B x A - - 0.1 - 0.1 - -
AB x B x B - - 0.1 - 0.1 - -
AB x B x AB - 1 (0.8) 0.1 0.8 0.1 - -
AB x AB x A - - - - - - -
AB x AB x B - 2 (1.6) - 1.6 - - -
AB x AB x AB - 1 (0.8) 0.1 0.8 0.1 - -
Total - 124 (100) 100 79.0 66.5 11.9 19.4
aSee supplemental tables 1 and 2 for calculations. bThe probability of an incompatible first pregnancy was 
0. cThe probability of an incompatible first pregnancy was >0. dCalculated from the probabilities per ABO 
genotype shown in supplemental Table 1.
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To evaluate whether the severity of HDFN increases in every subsequent pregnancy with 
D immunization and a D-positive child.
Methods
This study was part of the Dutch nationwide OPZI 2.0 study, including all pregnant women 
with D antibodies from July 1, 2014 to March 31, 2015 and from August 1, 2015 to February 
28, 2017. Women with two subsequent D immunized pregnancies with D-positive children 
were included in the present analysis. Data on all previous pregnancies of the women 
were collected. The severity of HDFN was compared between the first and subsequent 
pregnancy at risk using a Wilcoxon Signed Rank Test. Predictive factors for severe disease 
in the subsequent pregnancy were assessed by multivariate analysis.
Results
The cohort comprised of 62 D immunized women with a total of 150 D-positive children 
after immunization occurred. In general, the severity of HDFN increased significantly in the 
subsequent pregnancy, compared to the first immunized pregnancy (P<.001). The severity 
however remained equal or even decreased in 44% of the cohort. Especially if antibodies 
were already detected at first trimester screening in the first immunized pregnancy, no 
significant increase in severity of HDFN was noted (P=.197). If no therapy or only non-
intensive phototherapy was indicated during the first pregnancy in this group, also no or 
only mild HDFN was observed in the next pregnancy. Contrarily, women with antibodies 
detected late (>= 27th week) during the first immunized pregnancy, most often even before 
they had ever given birth to a D-positive child, were most prone for increasing severity 
(P<.001) and for severe disease in a subsequent pregnancy. The highest ADCC test result 
in the first immunized pregnancy appeared a reliable predictor for severe disease in the 
next pregnancy: if the ADCC test did not exceed 10% in the first pregnancy, 74-99% of 
subsequent D-positive children will not be treated with intrauterine transfusion(s).
Conclusion
Whereas severity of D-mediated HDFN in general increases in every subsequent 
pregnancy with a D-positive child, this does not apply to 44% of cases. Based on the time 
of antibody detection, severity in the first immunized pregnancy and the ADCC result, 
the risk of severe disease in a subsequent pregnancy can be assessed.
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INTRODUCTION
Hemolytic disease of the fetus and newborn (HDFN) is a serious, and nowadays rare, 
condition, caused by maternal alloantibodies against fetal red blood cells (RBCs). The 
destruction of RBCs may result in neonatal anemia and hyperbilirubinemia, evoking the 
need for phototherapy, red cell transfusions or exchange transfusions. In severe cases, 
anemia occurs prenatally and intervention with intrauterine transfusion(s) (IUT) is needed. 
A recent national cohort study on all IUTs performed in the Netherlands reported that 
between 2011 and 2016 83% of these procedures are performed for D immunization.150 
D immunization is thus not only the most frequent type of immunization,17 it also causes 
the great majority of severe HDFN cases.
Maternal alloimmunization may occur as a result of an incompatible pregnancy or blood 
transfusion. As blood transfusions are always ABO- and D-matched, D alloimmunization 
is now mostly the result of maternal exposure to foreign fetal red cell antigens, inherited 
from the father.11 The risk of alloimmunization depends on the duration and amount of 
fetomaternal hemorrhage, characteristics of the maternal immune system and of the 
red blood cell antigens.17
To prevent D immunization induced by pregnancy, D-negative mothers carrying 
D-positive fetuses receive both antenatal and postnatal anti-D prophylaxis (RhIg) in most 
developed countries. As a result, the immunization rate of D-negative women after giving 
birth to a D-positive child has been reduced impressively from 5% in the early 1960s to 
0.3% nowadays.5,7,13
A generally accepted idea is that the severity of HDFN increases in every subsequent 
pregnancy complicated by D immunization, although the course of disease varies and can 
also be surprisingly mild.23 As HDFN becomes more rare, the exposure of obstetricians 
to alloimmunized mothers in clinical practice decreases. As a result, fewer clinicians 
are familiar with the natural course of the disease. In order to properly counsel and 
manage these women after a first D immunized pregnancy, accurate data on the severity 
of HDFN in subsequent pregnancies are needed. This current study therefore aims to 
assess if, and so, how the severity of HDFN increases in consecutive pregnancies with D 










In the Netherlands, all pregnant women are screened for the presence of allo-antibodies 
in the first trimester of pregnancy. Furthermore, D-negative and c-negative women are 
additionally screened in week 27. The coverage of this screening program is almost 
100%.14 All maternal blood samples with a positive screening result, identified at routine 
screening or at any other moment in pregnancy, are sent to one of the two national 
referral laboratories (Sanquin Diagnostic services and Special Institute for Blood 
group Investigations (BIBO)). Here, the clinical relevance of the antibody is evaluated 
by assessing the antibody specificity, IgG or IgM type, and by assessing whether the 
fetus is antigen-positive. Although this assessment is nowadays often made directly by 
non-invasive genotyping of the fetus, serological typing of the father was still the first 
step in most of the pregnancies in this study. If the fetus is D-positive, the risk on fetal 
hemolysis is assessed by serially determining the antibody titer and antibody-dependent 
cell-mediated cytotoxicity (performed only at Sanquin Diagnostic Services), a monocyte 
based assessment of the destructive capacity of the antibodies.24,151
Study design and population
This study was part of the OPZI 2.0 study, a nationwide cohort study on D immunization 
in pregnancy. All pregnant women with a positive screening for D antibodies, identified at 
Sanquin Diagnostic Services during our study period, were eligible for inclusion. Positive 
screenings as a result of a RhIg administration were not included. Women were identified 
from two time periods (for practical reasons): from July 1, 2014 to March 31, 2015 and 
from August 1, 2015 to February 28, 2017.
The local care provider of eligible pregnant women was contacted in order to obtain 
patient’s informed consent. If written consent was obtained, clinical data were collected 
from the care provider by means of a detailed questionnaire. In case outcome data were 
incomplete, the researchers made at least three attempts to contact care providers or 
study participants directly in order to obtain complete data. Furthermore, if it was unclear 
whether women received RhIg in a previous pregnancy, this information was obtained 
from the Department for Vaccine Supply and Prevention Programs (RIVM-DVP). Women 
were excluded if the mother additionally had another antibody with a titer higher than 
that of D (and an antigen-positive child).
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To test the hypothesis that HDFN is more severe in the subsequent pregnancy with D 
immunization than in the first immunized pregnancy, we selected all women with more 
than one pregnancy with D antibodies and D-positive fetuses from the OPZI 2.0 cohort. 
In order to assess the risk of selection and non-response bias, characteristics of included 
and non-included cases were compared (supplemental text).
Sample size calculation
Based on the literature5,152 and an interim analysis, we expected approximately 20% of 
cases to be treated with IUT, exchange transfusion or ending in fetal or neonatal death 
in the first immunized pregnancy, and 45% in the second pregnancy. With a significance 
of 0.05 and a power of 0.8, a total of 56 women with two immunized pregnancies of 
D-positive fetuses would be required.
Data collection and outcome definitions
Relevant clinical data from all previous non-immunized and immunized pregnancies 
were collected in the OPZI 2.0 database: data on maternal characteristics (age, ethnicity, 
moment of antibody detection) and pregnancy and birth details (possible sensitizing or 
boosting events, all RhIg administrations, mode of delivery of both child and placenta, 
perinatal bleeding, etc.). Furthermore, we obtained treatment details to assess the 
severity of HDFN of all pregnancies with D antibodies and D-positive fetuses 
(intrauterine transfusion details, hospital stay, neonatal bilirubin and hemoglobin levels, 
duration and intensity of phototherapy, red blood cell or exchange transfusions). From 
Sanquin Diagnostic Services, laboratory data was retrieved (including antibody titers, 
ADCC results and the presence of additional antibodies).
In the current study, ‘first immunized pregnancy ’ is defined as the first pregnancy with 
D antibodies and a D-positive child. ‘Subsequent pregnancy’ is defined as the second 
pregnancy with D antibodies and a D-positive child.
Our main outcome was disease severity, which was based on HDFN treatment and 
categorized as follows:
1. No HDFN: no antenatal or postnatal treatment
2. Mild HDFN: non-intensive phototherapy (≤2 lamps), or only one day intensive 
phototherapy (>2 lamps), with or without a red blood cell transfusion during the 








3. Moderate HDFN: intensive phototherapy (>2 lamps) for more than one day or 
neonatal exchange transfusion (in the Netherlands neonatal exchange transfusion 
has been gradually replaced by intensive phototherapy)
4. Severe HDFN: intrauterine transfusion or HDFN-related death.
In case of missing data on disease severity, patients were assigned to a disease category 
based on the other, non-missing disease parameters (laboratory results, phototherapy 
duration and intensity, etc.).
Ethical considerations
The medical ethics committee of the Leiden University Medical Center approved the 
protocol (P15.101/NV/nv). Written informed consent was obtained from all mothers 
included in this study.
Statistical analysis
All outcomes were analyzed according to a predefined analysis strategy that was 
conducted in collaboration with our clinical epidemiologist ( JGB).
For our main outcome, sensitivity and subgroup analyses on the difference in severity 
of HDFN between two subsequent pregnancies, a Wilcoxon Signed-Rank test was used. 
Differences in severity of HDFN between two non-paired groups were analyzed with 
a multinomial logistic regression. In other, non-paired analyses, the Pearson’s Chi-
square test or logistic regression (or Fisher’s exact test if appropriate) was used for the 
comparison of proportions. Comparisons of non-parametric outcomes were analyzed 
with the Mann-Whitney U test. A sensitivity analysis was performed among patients in 
whom all the information on disease outcome was available. As the risk of HDFN might 
be different if D-antibodies are found at first trimester screening or around 27 weeks in 
the first immunized pregnancy, a subgroup analysis was performed in these ‘early’ and 
‘late’ groups.
In order to identify factors possibly predicting severe HDFN (IUT or death) in a subsequent 
pregnancy for counseling purposes, a prediction model was constructed including all 
variables known or thought to be associated with increasing HDFN severity from the 
literature, the potential predictors. All potential predictors with a P-value<.25 in univariate 
analysis were included in a multivariate logistic regression model. The prediction model 
was further improved by applying manual backward selection, excluding the variable with 
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the highest P-value at every step. Eventually, all variables with a P-value<.1 remained in 
the final prediction model (supplemental Table 3).
RESULTS
Selection and characteristics of study population
During the study period, 311 pregnant women with D immunization were found eligible 
for inclusion in the OPZI 2.0 study. Figure 1 shows how the study population for the 
present analysis on HDFN severity in subsequent pregnancies was selected (N=62 
women). Of the 62 women included, 19 experienced three pregnancies with D antibodies 
and a D-positive child, three women had four pregnancies, and one woman delivered 
six D-positive children after her D antibodies were detected, including a total of 150 
D-positive children. Table 1 shows the characteristics of included women and their 
children.
Screened positive for D 
antibodies in pregnancy during 
study perioda
311 women
Women who delivered at least 
two D-positive children in the 
presence of D antibodies
62 women
Additional antibodies with 





Subsequent pregnancy with D-







Never delivered a D-positive 
child after first detection of D 
antibodies (only miscarriages or 
D-negative children)
33
Women who delivered at least 
one D-positive child in the 
presence of D antibodies
175
Figure 1. Composition of the 
study population. aNewly immu-
nized women or a new pregnancy 
after previous immunization. bIn 21 
of these women the antibody was 
first detected at 27th week screen-
ing and no subsequent pregnancy 








Table 1. Baseline characteristics of 62 women with two or more pregnancies with D antibodies and 
a D-positive child
First immunized pregnancy
Caucasian origin 44 (73)
Maternal age at first positive screening 27 [19-35]
Number of previous births (D-positive and D-negative) 1 [0-3]
Gestational age at first positive screening
 Early first trimester screening 21 (34)
 Delayed ‘first trimester’ screening, ≥20 weeks 2 (3)
 27th week screening 35 (57)
 Between 27th week screening and birth 4 (7)
Between first and subsequent pregnancy with a D-positive child
Time, yearsa 2 [1-15]
Number of (spontaneous) abortions 0 [0-5]






















Data presented in N (%) or median [range].
The first immunized pregnancy is the first pregnancy with D antibodies and a D-positive child, the 
subsequent pregnancy is the second pregnancy with D antibodies and a D-positive child.
aYears between due dates of first and subsequent immunized pregnancy.
Severity of HDFN in the first immunized and the subsequent pregnancy
In this cohort of 150 D-positive children out of pregnancies complicated by D antibodies, 
no children died as a result of HDFN. One fetal death occurred to a cause other than 
HDFN. In the third pregnancy of this mother, antibodies were first detected at 27th week 
screening and upon referral to a gynecologist, perinatal death was noted at 34 weeks 
and 3 days. The highest antibody titer was 1:4 and the highest ADCC result 10%, both 
indicating a low risk of fetal hemolysis. A severe growth restriction was noted (between 
the third and fifth percentile), the baby was non-hydropic and pathological examination of 
the placenta showed approximately 20% infarction. The fetal death was thus considered 
the result of placental dysfunction. Symptoms and severity of HDFN of this and the 
next D-positive child of this mother are not reported in tables and figures and was not 
analyzed.
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No HDFN 19 (30) 11 (18) <.001
Mild HDFN 22 (35)b 14 (23)c
Moderate HDFN 20 (32) 17 (28)
Severe HDFN 2 (3) 19 (31)
Data shown in n (%). Wilcoxon Signed Rank test performed to compare HDFN severity in first and subsequent 
immunized pregnancy.
a61 women, two twins (all mild disease).
bIntensity of phototherapy missing in one child (2 days of phototherapy), interpreted as mild.
cIntensity of phototherapy missing in one child (‘short phototherapy’), interpreted as mild.
Table 2 demonstrates that overall the severity of HDFN was significantly higher in the 
subsequent pregnancy, compared to the first immunized pregnancy (P<.001). HDFN was 
more severe in the subsequent pregnancy in 34/61 women (56%, maximum of three 
categories more), equally severe in 19/61 (31%) and less severe in 8 women compared 
to the first immunized pregnancy (13%, maximum of one HDFN category less). For two 
patients, the intensity of phototherapy was missing in one of two pregnancies and 
HDFN severity was therefore imputed, the sensitivity analysis without these patients 
with imputed HDFN severity showed a similar result (P<.001). Figure 2 demonstrates 
the severity of HDFN in subsequent pregnancies in relation to the severity in the first 
immunized pregnancy.
Figure 2. Severity of HDFN in the first and subsequent immunized pregnancy in 61 women (63 vs. 61 
D-positive children). Outcome of woman with fetal death to a cause other than HDFN not shown. aIntensity 
of phototherapy missing in one child (2 days of phototherapy), interpreted as mild. bIntensity of phototherapy 
missing in one child (‘short phototherapy’), interpreted as mild.


































Characteristics of D immunized women and their sequential 
D-positive children
Table 3 presents the raw data on indicators of HDFN and treatment details in first 
immunized pregnancies and in subsequent pregnancy with a D-positive child. Most 
of these factors were more severe in the second immunized compared to the first 
immunized pregnancy.
Severity of HDFN according to the time of antibody detection
Supplemental figures 1a and 1b demonstrate severity of HDFN in subsequent pregnancies 
in relation to the severity in the first immunized pregnancy for the subgroups with D 
antibodies detected either at first trimester screening (‘early’) or around the 27th week 
screening (‘late’) in the first immunized pregnancy. The change in HDFN severity between 
the first and subsequent pregnancy at risk was significantly different between patients 
with antibodies detected early (median 0 HDFN categories change, range -1 to +1) and 
late (median +1, range -1 to +3, P=.015). In the early detected subgroup, HDFN became 
less severe in the subsequent pregnancy of 5 women (22%), was equally severe in 8 
(35%) women and more severe in 10 women (43%). This difference in severity was not 
significant (P=.197). All 13 women in the group with early detected antibodies having no 
or only mild HDFN in the first immunized pregnancy also had a subsequent child with 
no or mild disease. From the 11 women with moderate to severe HDFN, 9 continued to 
have moderate or severe HDFN in the subsequent pregnancy.
In contrast, if antibodies were detected late in the first immunized pregnancy, the severity 
of HDFN increased significantly in the subsequent compared to the first immunized 
pregnancy (P<.001), as HDFN was less severe in 3 out of 37 women (8%), equal in 11 (30%) 
and more severe in 24 women (65%). This was most pronounced when the antibody was 
detected during the first pregnancy of a D-positive child, before RhIg could even have 
been administered (supplemental Table S2).
Predicting severe disease in the second pregnancy with D antibodies
Factors from the first immunized pregnancy possibly predicting severe disease 
(intrauterine treatment) in the subsequent pregnancy with a D-positive fetus were 
assessed in a multivariate prediction model (supplemental Table S3). After univariate 
preselection and manual backward selection, the highest ADCC result in the first 
immunized pregnancy remained as the only significant predicting factor for receiving 
intrauterine transfusion(s) in the subsequent pregnancy.
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Additional antibodies present 14 (23) 24 (39)
 Rh (C, E, G) 12 22
 Non-Rh (Fy(a), Jk(a), Wr(a) 2 2
Highest ADCC result 30 [10-80] 50 [10-80]
Highest antibody titer 64 [1-4000] 128 [2-2000]
Perinatal death as a result of HDFN 0 0
Fetuses treated with intrauterine transfusion(s) 2 (3) 19 (31)
Gestational age at first IUT 20+2 and 35+4 (N=2) 30+4 [20-34] (N=19)
Gestational age at birth, weeks+days 37+5 [33-43] 37+2 [35-41]
Births induced before 37 weeks’ gestation for HDFN 2 (4) 15 (25)
Arterial umbilical cord pH 7.24 ± 0.08 7.25 ± 0.08
First neonatal hemoglobin, g/dL 15.4 ± 3.1 13.2 ± 3.4
First neonatal hematocrit, % 46% ± 9.2 40% ± 10.4
First neonatal bilirubin, mg/dL 4.5 ± 3.9 4.9 ± 2.5
Lowest hemoglobin in first week of life, g/dL 14.1 ± 3.2 11.9 ± 3.2
Lowest hematocrit in first week of life, % 42% ± 8.1 34% ± 8.9
Highest bilirubin in first week of life, mg/dL 12.3 ± 5.5 12.8 ± 4.6
Neonates treated with phototherapy 43 (68) 50 (82)
Neonates treated with exchange transfusion 10 (16) 6 (10)
Neonates treated with red cell transfusion in first month 
after birth
14 (23) 20 (33)




Data presented in N(%), median [range] or mean ± standard deviation.
The first immunized pregnancy is the first pregnancy with D antibodies and a D-positive child, the 
subsequent pregnancy is the second pregnancy with D antibodies and a D-positive child.
a61 women, two twins (all mild disease), one fetal death with a cause other than HDFN not shown.
The predictive value of this test is summarized in Table 4. The negative predictive value 
of an ADCC test result >10% (thus ADCC result ≤10%) appeared most useful: if the ADCC 
test did not exceed 10% in the first pregnancy, 74-99% of subsequent D-positive children 
will not be treated with intrauterine transfusion(s).
Disease severity in third and later pregnancies at risk for HDFN
Compared to the second pregnancy with D antibodies and D-positive children, HDFN 
severity in the third pregnancy at risk (N=23) was less severe in 23%, equal in 46% 








children without treatment, 6 that were mildly affected (26%), 6 moderate (26%) and 6 
severe (26%) in third pregnancies at risk. Supplemental Table S4 provides a more detailed 
description of the outcome of the four women with more than three pregnancies at risk.
Table 4. The predictive value of the highest ADCC result in the first pregnancy on severe disease in 











Area under the 
curve*
>10% 94 (73-99) 46 (31-62) 94 (74-99) 44 (30-60) Area .767
95% CI (.636-.898)
P=.002a
>30% 65 (41-83) 65 (49-79) 80 (63-91) 46 (28-65)
>50% 65 (41-83) 78 (63-89) 83 (67-92) 58 (36-77)
80% or higher 35 (17-59) 89 (75-96) 75 (61-85) 60 (31-83)
*Area under the curve of ADCC as a continuous variable.
DISCUSSION
In this unselected national cohort of 150 D-positive children of 62 women with D 
antibodies, HDFN severity in the first pregnancy with anti-D antibodies with a D-positive 
child and subsequent pregnancies at risk was evaluated. Although we found that in 
general the severity of HDFN was more profound in the second immunized (‘subsequent’) 
pregnancy compared to the first, the severity remained equal or even decreased in 
44% of the cohort. Especially in the group with antibodies detected early in the first 
immunized pregnancy, no significant increase in severity of HDFN was noted. If no 
therapy or only non-intensive phototherapy was indicated during their first pregnancy, 
also no or only mild HDFN was observed in the next pregnancy. Contrarily, women with 
antibodies detected late (>= 27th week) during the first immunized pregnancy, most 
often even before they had ever given birth to a D-positive child, were most prone for 
increasing severity and for severe disease in a subsequent pregnancy.
The major strength of our study is the unselected study population: as coverage of the 
national screening program is near 100% in the Netherlands14 and serological assessment 
(titers and ADCC tests) for the risk on HDFN is performed at Sanquin Diagnostic services 
only, all women with D antibodies in the Netherlands that were pregnant during our study 
period were identified. Single center or regional studies inevitably deal with the referral 
status of the clinic(s), causing a selection bias.
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Another strong point of this study was our satisfactory response rate of 73% (see 
supplemental text), indicating that also the risk of non-response bias is low. To assess 
this risk, we evaluated whether the moment of antibody detection, an important factor 
influencing our main outcome, was equally distributed among women with or without 
consent or complete data. Reassuringly, this was indeed the case (supplemental text). 
Furthermore, no selection bias seems to be induced by selecting women with two or 
more subsequent pregnancies only, as having a subsequent pregnancy or not was not 
associated with HDFN severity in the first pregnancy (supplemental text and Table S1).
A limitation of this study is however that the clinical rationale of treatment decisions is 
unclear in retrospect and might vary over time. This means that cut-offs for the disease 
categories used to assess the course of subsequent pregnancies with HDFN inevitably 
remain subject to a certain amount of arbitrariness. Our main finding that disease 
severity in general increases in subsequent pregnancies at risk is however supported 
by the increase in almost all raw disease characteristics in Table 3.
In this study, severe HDFN occurred more often in subsequent (31%) compared to 
first immunized (3%) pregnancies, in line with findings of others. For example, Tiblad 
et al. found 1.7% (5/288) severe HDFN in first immunized pregnancies, according to 
our definitions, and 19% in the second pregnancy at risk.152 Similar to our findings, 
second children at risk of mothers that were already immunized during their first 
pregnancy received more treatment for HDFN, although not significantly. Other authors 
observed 0% severe disease in first immunized pregnancies and 19% in ‘reactivation’ 
of D immunization.153 Our study is however the first study directly comparing the 
first and subsequent immunized pregnancy of the same D immunized woman, which 
demonstrated that the severity of HDFN did not increase in 44% of the cohort. This 
challenges the general accepted concept that every next child at risk for HDFN will be 
more severely affected.
We found that the severity of HDFN increased only significantly in women with antibodies 
first detected at 27th week screening of their first immunized pregnancy, after a negative 
early screening. This increase has a logical explanation: the relatively short exposure 
to maternal antibodies in the first immunized pregnancy may not induce substantial 
hemolysis, and the pathogenic response of the antibodies thus appears in the subsequent 
pregnancy. However, 13 fetuses of the 37 (35%) women with late detected antibodies 








detected group). Almost all of these 13 mothers had never given birth to a D-positive 
child before immunization occurred and were thus immunized before RhIg could even 
have been administered (Table S2). Based on these findings, immunization during the 
first pregnancy of a D-positive fetus, detected around the 27th week of pregnancy, seems 
to be a sign of a strong maternal respondership, possibly related to a combination of 
genetic risk factors such as carrying HLA-DRB1*1501 and FCRIIC-ORF alleles.29,154,155 If 
in the future ‘high responders’ could be identified early, additional anti-D prophylaxis 
before the conventional antenatal administration might prevent immunization during 
the first pregnancy at risk. Severe disease hardly ever occurred in the women with late 
detected antibodies as a result of giving birth to a D-positive child, despite receiving full 
prophylaxis. This suggests that in these women the immune response presumably is not 
prevented but is merely suppressed, which has earlier been suggested by others.5,6,152,156
Our findings suggest that the time of first antibody detection and the severity of HDFN 
in the first immunized pregnancy is determining subsequent HDFN severity. If women 
get D immunized around the 27th week of their first pregnancy of a D-positive child, after 
a negative first trimester antibody screening, there is a substantial risk of severe HDFN 
in a next pregnancy. If women become immunized during delivery of a prior D-positive 
child, the D antibodies are detected early in the next (‘first immunized’) pregnancy and 
HDFN still remains mild, the risk of severe disease in a next pregnancy is virtually absent. 
In early detected cases with moderate and severe HDFN in their first pregnancy, there is 
a high risk of severe disease in the next pregnancy. The risk of HDFN has been found to 
correlate with the IgG-Fc-glycosylation profile of anti-D antibodies.27 Interestingly, we have 
previously shown that there exists immunological memory for this Fc-glycosylation profile, 
meaning that this profile is sustained in subsequent pregnancies28. Our observation that 
the ADCC result, which is greatly influenced by the Fc-glycosylation profile,28 is the best 
predicting factor for HDFN in the next pregnancy supports the hypothesis that the 
pathogenicity of the antibodies as revealed in the first pregnancy, remains stable and 
therefore predicts the severity of disease in the next pregnancy. We plan to test this 
hypothesis by analysing the glycosylation patterns in this cohort, comparing women 
with and without increasing disease severity. Lastly, an additional factor influencing the 
relation between severity in the first and subsequent immunized pregnancies might 
be the inherited fetal Fc-receptor profiles, as we have previously shown that this profile 
influences the risk of severe HDFN.29
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An important final note is that even if severe disease occurs, fetal death as a result of 
HDFN is nowadays very rare. Furthermore, the outcome of fetuses treated with IUT has 
improved significantly over time, due to strict and reliable monitoring, early referral (less 
fetal hydrops) and declining complication rates.57,150 In case of a very fulminant course 
of disease, indicated by the need for IUT, the presence of hydrops or even fetal death 
before 20 weeks’ gestation, non-invasive treatment with intravenous immunoglobulins 
or other (new) immunomodulatory agents should be considered.157
CONCLUSION
The severity of anti-D mediated HDFN in general, but not always, increases in subsequent 
pregnancies with D-positive fetuses. This is mainly observed in mothers with antibodies 
occurring during the first immunized pregnancy, detected at 27th week screening, often 
before RhIg can even be administered. Based on the moment of antibody detection, 
antibody characteristics as reflected by ADCC test results and the severity of HDFN in 
the first immunized pregnancy, the risk of severe HDFN in a subsequent pregnancy can 
























Number of previous births 1 [0-3] 1 [0-8] .001a .030
Maternal age at first 
positive screening
27 [18-35] 30 [18-42] <.001a <.001
Gestational age at first 
positive screening
.018b .797
 <20 weeks 26 (38) 61 (57)
 ≥20 weeks 42 (62) 46 (43)
HDFN severity
 No HDFN 20 (29) 40 (36) Refa Ref
 Mild HDFN 23 (33) 21 (19) .054 .367
 Moderate HDFN 23 (33) 37 (34) .568 .345
 Severe HDFN 3 (43) 12 (11) .323 .667
aLogistic regression
bChi-Square
During our study period, 311 women were found eligible for inclusion, as they were 
pregnant and screened positive for D-antibodies. 55 women were excluded because they 
had no subsequent pregnancy, only D-negative children or miscarriages after developing 
D antibodies or because they had other antibodies with higher titers than D. Of the 256 
remaining women, 186 gave informed consent and complete data was obtained, resulting 
in a response rate of 73%.
To assess the risk of non-response bias, the occasion of antibody detection was 
compared between women with and without consent or complete data. Of the women 
with consent and complete data, 75% were detected at first trimester screening and 
25% at 27th week screening. This was 77% and 23%, and thus similar, in the group with 
no consent or incomplete data.
Subsequently, the risk of selection bias was assessed, possibly introduced by selecting 
women with a subsequent pregnancy only. Data was collected on all pregnancies of 
women with a positive D antibody screening in pregnancy at the time of our study 
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period and thus not only if the pregnancy itself occurred during the study period. We 
were therefore able to determine that 68 of the 175 women with D immunization and a 
D-positive child became pregnant again after the first immunized pregnancy. To evaluate 
whether selecting women with two subsequent pregnancies induced selection bias, 
characteristics of these 68 women were compared to the characteristics of the 107 
women without a subsequent pregnancy (supplemental Table 1). The group with a 
subsequent pregnancy was associated with lower maternal age (P<.001) and less previous 
births (P=.030) and seemed not associated with HDFN severity and the occasion of first 








Severity of HDFN in consecutive pregnancies according to the moment 
of antibody detection
Supplemental Figure 1a. Disease severity in first and second pregnancies at risk for HDFN in 24 women 
(23 vs. 23 children), subgroup with antibodies detected early in the first pregnancy at risk. a1 child 
with at least mild disease (‘short phototherapy’), interpreted as mild.
Supplemental Figure 1b. Disease severity in first and second pregnancies at risk for HDFN in 37 women 
(40 vs. 38 children), subgroup with antibodies detected late in the first pregnancy at risk. a1 child with 
at least mild disease in first immunized pregnancy (2 days of phototherapy), interpreted as mild.
SUBSEQUENT IMMUNIZED PREGNANCY SUBSEQUENT IMMUNIZED PREGNANCY













































HDFN severity in subsequent pregnancies
Table S2. Severity of HDFN in cases with antibodies detected at 27th week screening, with and without 





Birth of a D-positive child before 
immunization











No HDFN 6 (23) 4 (29) 3 (12) 1 (8)
Mild HDFN 12 (46) 7 (50) 4 (16) 4 (31)
Moderate HDFN 8 (31) 3 (21) 6 (24) 7 (54)
Severe HDFN 0 0 12 (48) 1 (8)
a38 women, two twins in first pregnancy (all mild disease), one fetal death with a cause other than HDFN and 













































































































































































































































































































































































































































































































































































































































































HDFN severity in subsequent pregnancies
Disease severity in third and later pregnancies at risk for HDFN




First Second Third Fourth Fifth Sixt
1 Disease severity No No No No
Highest ADCC 10 10 10 10
GA at birth 41 40+6 41 41+2
2 Disease severity Moderate
(intensive PT)
Mild Mild Mild
Highest ADCC unknown 30 60 30
GA at birth 37+2 37+6 36+3 38
3 Disease severity Moderate
(ET)




Highest ADCC 60 50 80 80
GA at birth 38 37+1 31+2 37+1












Highest ADCC 10 25 80 80 80 80
GA at birth 39+5 37 37+1 31+5 36 37+1
PT:phototherapy; ET:exchange transfusion; IUT:intrauterine transfusion.








THE NEAR DISAPPEARANCE OF FETAL 
HyDROPS IN RELATION TO CURRENT 







Inge L. van Kamp





In this study, we aim to evaluate trends in the condition of fetuses and neonates with 
hemolytic disease at the time of first intrauterine transfusion (IUT) and at birth, in relation 
to routine first-trimester antibody screening, referral guidelines, and centralization of 
fetal therapy.
Method
We conducted a 30-year cohort study including all women and fetuses treated with 
IUT for red-cell alloimmunization at the Dutch national referral center for fetal therapy.
Results
Six hundred forty-five fetuses received 1852 transfusions between 1 January 1987 and 
31 December 2016. After the introduction of routine first-trimester antibody screening, 
the hydrops rate declined from 39% to 15% (OR 0.284, 95% CI, 0.19-0.42, P < 0.001). In 
the last time cohort, only one fetus presented with severe hydrops (OR 0.482, 95% CI, 
0.38-0.62, P < 0.001). Infants are born less often <32 weeks (OR 0.572, 95% CI, 0.39-0.83, 
P = 0.004) and with higher neonatal hemoglobin (P < 0.001). Neonatal hemoglobin was 
positively independently associated with gestational age at birth, fetal hemoglobin, and 
additional intraperitoneal transfusion at last IUT.
Conclusion
Severe alloimmune hydrops, a formerly often lethal condition, has practically disappeared, 
most likely as a result of the introduction of routine early alloantibody screening, use 
of national guidelines, and pooling of expertise in national reference laboratories and a 
referral center for fetal therapy.
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INTRODUCTION
Hemolytic disease of the fetus and newborn (HDFN) is a serious complication in 
pregnancy that has long been a major cause of perinatal mortality. The disease is caused 
by maternal alloimmunization to fetal red blood cell antigens, mostly concerning D, 
followed by K, c, and E.17 The maternal antibodies may cross the placenta and cause 
fetal hemolysis and anemia, which, if untreated, may lead to fetal heart failure, hydrops, 
and death.
In the 1980s, important progress in the treatment of fetuses with severe HDFN was made 
by the introduction of intravascular intrauterine transfusion (IUT), now the cornerstone 
in prenatal management.33 However, survival of especially severely hydropic fetuses 
remained significantly lower than that of anemic fetuses without hydrops.31 Severe 
hydrops is furthermore associated with neurodevelopmental impairment on the long 
term.32 Preventing hydrops is therefore of utmost importance to improve both survival 
and long-term outcome.
In the first 3 years after the introduction of intravascular IUT in the Netherlands (1987-
1989), the majority of cases (55%) presented with hydrops.53 A recent study from 
our group showed that the incidence of fetal alloimmune hydrops has declined to 
approximately 13%.57
In this study, we aimed to evaluate trends in the condition of fetuses and newborns with 
hemolytic disease at the time of first IUT and at birth and discuss possible contributing 
factors.
METHODS
Study design, setting and study population
We conducted a retrospective cohort study including all patients with red cell 
alloimmunization requiring IUT in the Leiden University Medical Center (LUMC) from 
January 1987 until January 2017. The LUMC serves as the Dutch national referral center 
for fetal therapy since 1965. In the Netherlands, the annual live born number was 187 000 








clinically relevant alloantibody (father positive for the antigen) at first-trimester screening 
was 0.14% to -0.33% in 2016.14
Patient data, IUT details, and information on pregnancy outcome of these patients were 
collected from our electronic prospectively filled Rhesus database. Cases were excluded 
if fetal or neonatal death occurred from causes other than red cell immunization. 
Diagnostic fetal blood samplings not followed by IUT, owing to adequate pre-transfusion 
fetal hemoglobin, were excluded. If the diagnostic fetal blood sampling confirmed fetal 
anemia, but the following transfusion failed due to technical difficulties or complications, 
the procedure was not excluded.
Suspected severe fetal anemia requiring IUT was defined as (1) a peak systolic velocity 
in the fetal middle cerebral artery (MCA) of 1.5 multiples of the median for gestational 
age (MoM), detected by Doppler measurement, and/or (2) the presence of other signs 
of anemia at ultrasound examination (cardiomegaly, ascites, hydrops), or (3) amniotic 
fluid delta optical density measurements reaching the upper part of the Liley’s zone II 
or zone III (only in the early years of this study).
Prevention, screening, diagnostics, and treatment
As a primary preventive measure, anti-D immunoglobulin (RhIg) is administered to 
all D-negative women, carrying a D-positive child, at 30 weeks’ gestation (since 1998) 
and after birth (since 1969).17 RhIg prophylaxis has nowadays reached a coverage of 
approximately 100% in the Netherlands.139
To prevent non-D immunizations, blood transfusions administered to women of 
reproductive age (<45 y) are K- (since 2004), c-, and E-matched in the Netherlands (since 
2011).11 The order of implementation of these and other preventive measures for red 
cell immunization in the Netherlands is summarized in Table S1.
Despite these preventive measures, alloimmunization may still occur. Since the late 
1960s, D-negative women are routinely screened for the presence of alloantibodies 
at week 32 of pregnancy. This screening was brought forward to 30 weeks in 1998 and 
again forward to 27 weeks in 2011. From 1998 onwards, all pregnant women (D-negative 
and D-positive) are routinely screened for antibodies in the first-trimester. Since 2011, 
the 27 weeks screening was furthermore broadened to include c-negative women.15
79
The near disappearance of alloimmune hydrops
If screened positive, the antigen status of the fetus is first assessed by testing the 
paternal zygosity or by cell-free DNA testing in maternal plasma (available for D, c/C, E, 
and K). If the fetus is assumed or determined to be antigen-positive, antibody titers and 
antibody-dependent cell-mediated cytotoxicity (ADCC) are measured every 2 weeks, to 
assess the risk of fetal hemolysis. All laboratory tests are performed at Sanquin Blood 
Supply in Amsterdam or the Special Institute for Blood Group Investigation in Groningen, 
the two national referral laboratories.15,20
In case of a high risk of severe hemolysis, indicated by serological testing or abnormal 
ultrasound findings, national obstetric guidelines advise the patient to be referred to the 
LUMC. The current screening and prevention protocol in the Netherlands is summarized 
in a recent review of de Haas et al and in a national obstetric guideline.17,20 Patients with 
D antibodies are to be referred to the LUMC when titers rise grossly above 1:16 or when 
the ADCC is higher than 50% (>1:16 and >30% for other Rh antibodies and 1:2 and 30% 
for anti-K). The management of pregnancies complicated by HDFN in our center consists 
of weekly monitoring with MCA Doppler until anemia is suspected and intervention is 
needed, and information is described in more detail previously.55,57
Data collection and outcome definitions
Data on maternal characteristics, primary antibody type, treatment details, the severity 
of fetal hemolytic disease (fetal Hb and presence of hydrops at first IUT), and perinatal 
outcome were collected.
In order to identify changes over time, all pregnancies were divided into time groups of 
6 years each, based on the year of first IUT (1987-1992, 1993-1998, 1999-2004, 2005-
2010, and 2011-2016).
Hydrops was classified as mild, if a distinct rim of ascites in the absence or presence of 
pericardial effusion was seen, whereas abundant ascites, in the absence or presence of 
pericardial and pleural effusion and skin edema, was considered as severe hydrops.31
Primary outcome was the presence of hydrops (total, mild and severe) at the time of first 
IUT. Furthermore, we assessed the fetal (Z)Hb concentration at first IUT, which is the 
number of standard deviations of fetal Hb from the mean for gestational age (1 SD = 1 
g/dL deviation).59 Other outcome measures were as follows: perinatal survival, defined 








after birth), neonatal Hb, and the proportion of neonates requiring postnatal exchange 
transfusion(s).
Perinatal survival in consecutive time cohorts was assessed for all fetuses and for those 
with or without alloimmune hydrops.
Ethical considerations
Only the caregivers knew the identity of their patients, and study data were analyzed 
anonymously. Therefore, the medical ethics committee of the LUMC approved this 
research (C15.094) and decided, according to the Medical Research Involving Human 
Subjects Act (WMO), that written informed consent was not needed.
Statistical analysis
As outcome of multiple pregnancies in the same woman might be interrelated, outcomes 
were compared using generalized estimating equations (GEE). Within the GEE, a linear, 
binary logistic or ordinal logistic model was used for comparison of estimated means or 
odds, respectively. “Time cohort” was used as a continuous predictor to assess a linear 
trend in variables over time, rather than an overall difference in the variable between 
all time groups.
Before the use of MCA Doppler became the gold standard to set the indication for IUT 
around 2000, amniotic fluid delta optical density measurements were used. These are 
now known to be less accurate in predicting moderate to severe anemia47 and therefore, 
a sensitivity analysis was performed for our main outcome analysis, with only patients 
treated from 2000 onwards.
Numerical outcomes that were not normally distributed were transformed to normality 
(log2 transformation for titers, gestational age at birth raised to the power of 10).
If important outcomes showed a significant trend over time, we assessed possible factors 
associated with this outcome by multivariate regression using backward selection (Table 
S2). The choice for inclusion of variables was made on theoretical grounds, and a P value 
of > 0.1 was used for exclusion of variables.
P values < 0.05 were considered statistically significant.
81
The near disappearance of alloimmune hydrops
RESULTS
Characteristics of the study population
During the 30-year study period, IUTs were started in 653 fetuses in 645 pregnancies of 
551 women. There were eight twin pregnancies in which both twins were treated with 
IUT and one more in which only one fetus required IUTs; the co-twin was D-negative. Six 
singleton pregnancies were excluded because fetal death occurred from causes other 
than red -cell alloimmunization, described in more detail previously.91 Two more cases 
were excluded, as fetal blood sampling did not reveal fetal anemia, and therefore, no 
transfusion was performed.















Number of IUTs 
per fetusa
2.9 ± 1.43 
[1-8]
3.4 ± 1.54 
[1-8]
2.9 ± 1.33 
[1-6]




2.7 ± 1.33 
[1-6]
0.003
Maternal age at 
first IUT
32 ± 4.5 31 ± 4.2 32 ±4.4 32 ± 4.3 32 ±5.0 32 ± 4.4 0.125
Antibody against
 D
524 (81) 80 (87) 110 (87) 126 (80) 113 (74) 95 (83) 0.074b
 K 83 (13) 7 (8) 11 (9) 22 (14) 29 (19) 14 (12)
 c 23 (4) 4 (4) 4 (3) 8 (5) 6 (4) 1 (1)
 Otherc 15 (2) 1 (1) 2 (2) 3 (2) 4 (3) 5 (4)







































Data in n (%), mean ± standard deviation or median [range] if not normally distributed.
aIf born alive.
bOrdinal logistic generalized estimating equations.
cOther include: E, e, Fya, Jka, and very infrequent antibodies.
dOverall GA over time.
A total of 645 fetuses remained for analysis in 637 pregnancies of 543 women, receiving 
a total of 1852 transfusions. In the first time cohort, fetuses received a median of 4 (range 
1-8) transfusions per pregnancy, declining to 3 (range 1-6) in the last time cohort (P = 
0.003); 55% of fetuses treated with IUT were male, and 45% female. Table 1 shows overall 
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Trends in fetal condition at first transfusion over time
All primary and secondary outcomes are shown in Table 2. In the total 30-year cohort, 
at the time of first transfusion, 23% of fetuses showed signs of hydrops. Hydrops was 
classified as mild in 14.4% and as severe in 8.8%. The incidence of hydrops declined 
significantly over time, from 41% in the first time cohort (1987-1992) to 6% in the final 
cohort, 2011-2016 (OR for the presence of hydrops in a later time cohort 0.556, 95% 
CI, 0.48-0.65, P < 0.001). In Figure 1, the proportion of fetuses with hydrops (mild and 
severe) at first transfusion is shown over time. Trends in hydrops are shown separately 







































PROPORTION OF HYDROPS AT FIRST IUT
Severe
Mild
% D with hydrops
% K with hydrops
Figure 1. Proportion of fetuses with hydrops at time of first intrauterine transfusion. The proportion 
of fetuses with alloimmune hydrops at first intrauterine transfusion, out of all fetuses treated with intrauter-
ine transfusion, is presented in columns per time cohort. The introduction of routine first-trimester antibody 
screening is marked by an arrow.
The great majority of cases with hydrops were associated with D, K, or c immunization 
(97%). Furthermore, we noted one hydrops case with anti-e, one with anti-Fya, and three 
cases in pregnancies with antibodies against low frequent red blood cell antigens: one 
anti-Cw and two pregnancies of a woman with “Verdegaal” alloimmunization.
After the introduction of routine first-trimester antibody screening in 1998, the hydrops 
rate declined significantly, from 39% (up to 1998) to 15% (after 1998, OR 0.284, 95% CI, 
0.19-0.42, P < 0.001); and the incidence of severe hydrops dropped from 18% to 4% (OR 
0.204, 95% CI, 0.11-0.37, P < 0.001). From 1999 onwards, 21 out of 65 fetuses (32%) with 
K immunization developed hydrops despite routine screening, compared with 40/334 








gestational age at first transfusion in K affected pregnancies was approximately 3 weeks 
earlier than in D immunizations (24 wk and 6 d, range 16-35, vs. 27 wk and 6 d [16-36], 
P < 0.001).
Sensitivity analysis
A sensitivity analysis was performed with only cases included treated from the year 
2000 onwards, thus excluding cases in which the decision for IUT was based on the Liley 
curve. For this analysis, the time cohort 1999-2004 was thus adjusted to 2000-2004, in 
which 32/138 (23%) of cases presented with hydrops at first IUT, significantly decreasing 
to 7/115 (6%) (OR for the presence of hydrops in a later time cohort 0.459, 95% CI, 0.30-
0.70, P < 0.001).
Substandard factors in the management of cases with severe hydrops
To identify possible substandard care factors that might have contributed to the 
development of hydrops, charts of the 18 pregnancies that presented with severe 
hydrops after the implementation of first-trimester screening were reviewed.
Eleven of these 18 patients (61%) were treated with IUT within a day after presentation 
with severe hydrops at our fetal therapy center, indicating a possible late referral. Detailed 
information was not available for one of these cases, and in two cases, hydrops resulted 
from patient delay (first prenatal visit at 20 and 25 wk, despite two previous affected 
pregnancies). In a fourth patient, first-trimester screening was negative, but severe 
hydrops was noted at a routine ultrasound around week 29 and appeared to result from 
immunization to a not previously detected private antigen (Verdegaal). The other seven 
patients were subject to protocol violations: delays in respectively diagnostics (N=1, blood 
sent to reference laboratory a month after positive screening in regional laboratory, 
father not typed for antigen against which antibodies were formed) and referral from 
midwife to gynecologist despite positive screening (N=3) and from gynecologist to our 
tertiary center although serological risk assessment prescribed referral (N=3). Most of 
these cases (5/7) occurred in the first 3 years after screening implementation.
Seven out of the 18 cases were timely referred to our center but still developed severe 
hydrops. Management factors that may be associated with the development of severe 
hydrops in these cases are as follows: alternating weekly monitoring with the referring 
hospital, not yet optimally skilled in MCA Doppler measurements (four cases prior to 
2000), postponing IUT to optimize birth timing despite amniotic fluid delta optical density 
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measurement in “Liley 2c” zone (1 case) and lack of monitoring in the time span awaiting 
paternal genotyping in a case with high risk of anemia (ADCC>80%). No substandard care 
factors were found in the last patient.
Trends in survival and neonatal condition over time
Trends in survival of hydropic and nonhydropic fetuses are shown in Figure 2 and in 
Table 2. Survival of fetuses without hydrops did not increase significantly (from 49/54 
[91%] in the first 6 years to 101/105 [96%] in the last 6 years of the study (OR for survival 
in a later time cohort 1.343, 95% CI, 0.89-2.02, P = 0.158), while survival of fetuses with 








































Figure 2. Survival rates of fetuses with and without hydrops. Lines reflect the proportion of fetuses 
treated with intrauterine transfusion for red cell alloimmunization that survived up to 28 d after birth (or until 
hospital discharge if admitted more than 28 d).
The rate of children born very prematurely (before 32-wk gestation) declined significantly 
over time, from 10% of all live born children in the early years to 2% in the last time cohort 
(OR for very premature birth in a later time cohort 0.572, 95% CI, 0.39-0.83, P = 0.004). 
Hemoglobin at birth increased significantly over time, from 9.2 to 12.6 g/dL in the last 
cohort (P < 0.001). Multivariate regression was performed to assess factors contributing 
to this rise; factors included in this analysis were as follows: number of IUTs performed, 
type of antibody (D or K), highest antibody titer, gestational age at birth, time interval 
between the last IUT and birth, transfusion volume (last IUT), additional intraperitoneal 








the use of backward selection with a P-out of 0.1, gestational age at birth and additional 
intraperitoneal transfusion and pretransfusion fetal hemoglobin at last IUT remained 
and were positively independently associated with a higher hemoglobin at birth (Hb 
0.187 g/dL higher with every week gestational age, P = 0.010, Hb 1.3 g/dL higher after 
intraperitoneal transfusion, P < 0.001, and Hb 0.62 g/dL higher/point less fetal Hb deficit, 
and P < 0.001). In the first years of the study, only 1.1% of patients received an additional 
intraperitoneal transfusion, increasing to 37.4% in the last time cohort.
Currently, only 17% of neonates treated with IUTs receive one or more exchange 
transfusions after birth, significantly declining from 91% in the first cohort (OR for 
receiving exchange transfusion(s) in a later time cohort 0.420, 95% CI, 0.36-.49, P < 0.001).
DISCUSSION
This 30-year cohort study describes factors that contribute to the gradual and near 
disappearance of severe alloimmune hydrops, a serious condition that has negatively 
influenced fetal survival and long-term outcome for decades. The hydrops rate at first 
IUT keeps declining since the introduction of routine first-trimester antibody screening in 
1998. In the last years of this study, less than 1% (1/115) of fetuses suffered from severe 
hydrops. Survival of fetuses with and without hydrops is nowadays almost equal, rising 
up to or above 95%. Furthermore, fetuses are nowadays born less anemic, which was 
associated with additional intraperitoneal transfusion at the last IUT.
Since the introduction of early screening of all pregnant women in the Netherlands in 
1998, the overall hydrops rate in fetuses requiring IUT declined from 39% to 15%, and 
the incidence of severe hydrops reduced more than fourfold, from 18% to 4%. This 
impressive currently low incidence of fetal hydrops indicates that fetuses with HDFN 
are nowadays identified and treated more timely. We hypothesize that this is mainly 
due to the implementation of national guidelines on management of alloimmunization 
in pregnancy, covering screening, laboratory, and clinical monitoring and protocols 
for timely referral to the (single) fetal therapy center. The hydrops rates we found are 
comparable with those reported in other Western countries with similar screening 
programs, which vary between 8% and 16%.58,62,64,66,67,93,159 A study from Belgium, also 
reported severe hydrops in 5% of red cell immunized pregnancies.58
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Although the hydrops rate in pregnancies complicated by K antibodies has declined 
impressively since the introduction of routine first-trimester antibody screening, the odds 
of developing hydrops are still 3.5 times higher than in D immunization and transfusions 
are performed approximately 3 weeks earlier in anti-K cases. To ensure timely referral 
to a tertiary center and prevent hydrops, fast determination of the fetal phenotype in K 
immunizations is therefore of uttermost importance.
In developing countries, where routine early antibody screening is less well organized or 
lacking,160 the incidence of hydrops at time of first IUT is remarkably higher. A group from 
Brazil reported a 34% hydrops rate in their cohort with mainly D immunized pregnancies, 
which they contributed to late referral.60 In the largest tertiary referral center in India, 
the hydrops rate was 22% in patients with D immunization requiring IUT between 2011 
and 2014. Equal to our findings, survival was approximately the same for hydropic and 
non-hydropic fetuses in this cohort (94% vs. 90%, respectively).65
An additional explanation for the declining incidence of hydrops is the optimization 
of diagnostic accuracy to predict severe fetal anemia over time. The previously used 
amniotic fluid delta optical density measurements161 showed limited accuracy in the 
second pregnancy trimester and in K immunized pregnancies47,162 and were gradually 
replaced by measuring the peak flow velocity in the MCA by Doppler ultrasound, which 
is standard diagnostic care since around 2000.30 To account for this change in diagnostic 
management, we performed a sensitivity analysis with only cases included from 2000 
onwards. This analysis showed a similar result to the main analysis: OR for the presence 
of hydrops in a later time cohort 0.459, P < 0.001.
An important finding is that survival of fetuses with hydrops increased significantly, 
leading to a similar survival rate in hydropic and nonhydropic fetuses in recent years. 
This confirms findings by others65,67 and is likely partly due to early detection and timely 
referral for treatment of fetal anemia. Thus, hydrops, if it occurs at all, is nowadays 
usually only mild, which is associated with favorable outcome. Furthermore, the increase 
in survival is most profound in cases with severe hydrops (OR 3.3). A more advanced 
gestational age at birth in later years of the study and/or advancements in prenatal and 
especially neonatal management in the past decades may have contributed, as well as 
a decrease in IUT complications.57 Centralization of fetal therapy and neonatal care in 








Infants born alive after treatment with IUT(s) seem to be in better neonatal condition 
nowadays, being less anemic at birth (despite longer intervals between the last 
transfusion and birth) and needing less exchange transfusions. We found that both 
additional intraperitoneal transfusion, in adjunct to intravascular transfusion, and more 
advanced gestational age at birth were independently associated with higher neonatal 
hemoglobin. As we previously demonstrated, transfusions through the intrahepatic 
route gained popularity over the years and are associated with less procedure-related 
complications.57 An additional advantage of this transfusion technique is the possibility to 
deposit some extra blood intraperitoneally with the aim to prolong the interval between 
transfusions or between the last transfusion and birth.89
We hypothesize that the found reduction in need for exchange transfusions is mainly 
caused by the gradual replacement of this invasive procedure by high quality intensive 
phototherapy and the corresponding more restrictive exchange transfusion protocol 
in 2004.163
This study is conducted in a well-organized health care system for alloimmunized 
pregnant women. The centralization of screening and treatment gives us great insight and 
overview in the prevalence of alloimmunization and the details of intrauterine therapy. 
A limitation might be that we were not able to include fetuses with hydrops, but without 
IUT. It is therefore possible that some women lost their fetuses to severe hydrops before 
referral to our national referral center or that labor was induced before performing an 
IUT. We hypothesize that the subsequent underestimation of hydrops deaths will be 
greatest in the early years of the study, as this scenario is highly unlikely in the present 
screening setting.
CONCLUSION
In summary, the incidence of alloimmune fetal hydrops has decreased importantly 
over the past decades, most likely as a result of the introduction of early screening for 
alloantibodies in all pregnancies, use of national guidelines, and the availability of both 
national reference laboratories and the pooling of knowledge and expertise in a referral 
center for fetal therapy. In particular, severe alloimmune hydrops, a formerly often lethal 
condition, has practically disappeared, not only leading to improved survival of HDFN 
but also diminishing risk of long term impairment.
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Table S1. Evolvement of national screening and prevention program in the Netherlands 
Year Preventive measure
1960s 3rd trimester screening for D antibodies in D-negative women
D-matching of RBC transfusions
1969 Postnatal RhIg prophylaxis for ABO compatible pregnancies in D-negative women without a 
living child
1970 Postnatal RhIg for D-negative women with one living child regardless of ABO blood group
1971 Postnatal RhIg for all D-negative pregnant women
1998 Antenatal 30 weeks RhIg prophylaxis for D-negative women without a living child
1st trimester screening for all pregnant women
2004 Additional K-matching of RBC transfusions in women <45 years of age
2008 Antenatal RhIg prophylaxis for all D-negative women
2011 3rd trimester antibody screening for c-negative women
Additional c- and E-matching of RBC transfusions in women <45 years of age
Fetal D-typing in maternal plasma introduced, allowing targeted antenatal prophylaxis for 
D-negative women carrying a D-positive child only
Table S2. Multivariate regression to identify factors associated with Hb at birth in fetuses with D or 




Step 1 Step 2 Step 3 Step 4 Step 5 Step 6
P B SE P
 Total number of IUTs performed .597 .714
 Type of antibody
 D (reference)
 K .243 .276 .223 .169 .205
 Highest antibody titera .561 .576 .501
 Gestational age at birth, weeks+days .256 .391 .362 .003 .011 .187 .07 .010
 Days between last IUT and birth .341 .444 .430 .208
 Fetal ZHb at last IUTb <.001 <.001 <.001 <.001 <.001 .619 .07 <.001
 Transfusion volume at last IUTc .743
 Complementary intraperitoneal 
transfusion performed at last IUT
<.001 <.001 <.001 <.001 <.001 1.302 .37 <.001
Grey boxes reflect the variables excluded at each step. Multivariate analysis perfomed by generalized 
estimating equation. Model fit tested with regular linear regression: adjusted R square .231, P F-test <.001.
aLog2 transformation performed, 1 step rise in titer reflects rise from 2 to 4 or 32 to 64, etc.
bNumber of standard deviations from the mean Hb for gestational age (1 SD=1g/dL).
cIntravenous volume + intraperitoneal volume.
CHAPTER 5
COMPLICATIONS OF INTRAUTERINE 
INTRAVASCULAR BLOOD TRANSFUSION: 







Inge L. van Kamp





Maternal alloimmunization to fetal red blood cell antigens is a major cause of fetal 
anemia, which can lead to hydrops and perinatal death if untreated. The cornerstone 
of management during pregnancy is intrauterine intravascular blood transfusion (IUT). 
Although this procedure is considered relatively safe, complications continue to occur. 
The aim of this study was to evaluate rates of procedure-related complications and 
perinatal loss following IUT, and their change over time, in order to identify factors leading 
to improved outcome.
Methods
This was a retrospective analysis of IUTs for red-cell alloimmunization performed at 
the national referral center for fetal therapy in the Netherlands, from 1988 to 2015. 
Differences in complication rates and their associations with alterations in transfusion 
technique before and after 2001 were assessed.
Results
Between 1988 and 2015, 1678 IUTs were performed in 589 fetuses. For IUTs performed 
in 2001 and onwards, there was significant improvement in survival (88.6% vs 97.0%, 
P<0.001) and a decline in procedure-related complication rates per fetus (9.8% vs. 
3.3%, P=0.001) and per procedure (3.4% vs. 1.2%, P=0.003) compared with those before 
2001. Procedure-related perinatal loss declined from 4.7% to 1.8% per fetus (P=0.053). 
Beneficial changes in transfusion technique were routine use of fetal paralysis increased 
use of intrahepatic transfusion and avoidance of arterial puncture.
Conclusions
IUT has become an increasingly safe procedure in recent years when performed by 
experienced hands. The chosen technique should be fine-tuned according to the 
patient’s individual situation. The declining complication rates are most likely related 
to center volume: this rare procedure is best performed in experienced fetal therapy 
centers.
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INTRODUCTION
Since its introduction in 1981, intrauterine intravascular blood transfusion (IUT) has 
become the cornerstone of treatment for fetal anemia in pregnancies complicated by 
red-cell alloimmunization.50 In experienced hands, it is nowadays considered a safe 
procedure, significantly improving perinatal outcome in fetuses suffering with severe 
anemia.53,55
One way to improve fetal outcome further is to minimize the occurrence of procedure-
related (PR) complications associated with IUT. A PR fetal-loss rate of approximately 
2% per procedure was reported in a review by Schumacher and Moise.69 However, the 
small studies included in their review used a variety of definitions for complications and 
treatment techniques. In 2005, we reported PR complications and fetal-loss rates of 3.1% 
and 1.6% per procedure, respectively, in a single-center series of 740 IUTs.91 In our study, 
transamniotic ‘free loop’ needling, inadvertent arterial puncture and refraining from the 
use of fetal paralysis were identified as risk factors for adverse outcome.91 Apart from the 
technical aspects, operator and team experience are known to be of utmost importance 
for performing successful and safe IUTs.95
In recent years, a few smaller studies have been performed on this subject, revealing 
no relevant new insights or tools to improve perinatal outcome further after IUT.58,66
Our study aimed to evaluate PR complications and perinatal loss rates after IUT, including 
assessment of their change over time, over a period of nearly three decades in a national 
single-center cohort, in order to identify factors leading to improved outcome.
METHODS
Patients
We included all patients treated with IUT between January 1988 and January 2015 at the 
national referral center for fetal therapy in Leiden, The Netherlands, for fetal anemia 
caused by red-blood-cell alloimmunization. The findings of IUTs performed between 








Patient data, technical aspects of IUT and complications were collected from our custom-
built electronic Rhesus database. As early IUT is known to be associated with higher 
perinatal loss rates,96-99 we compared outcomes performed after IUTs before and after 
20 weeks’ gestation, to determine whether expected improvements in survival also apply 
to very young anemic fetuses. To identify changes in procedural techniques and perinatal 
outcome, pregnancies were divided into two cohorts, according to year of procedure. The 
first cohort included patients with a first IUT before January 2001, described previously,91 
and the second cohort included patients with a first IUT performed from 1 January 2001 
onwards. This policy was chosen as it was assumed that the findings of our first study in 
200591 may have resulted in gradual changes in transfusion techniques and therefore 
also in perinatal survival.
Complications after IUT were classified independently into (PR) or non-procedure 
related (NPR)91 by two operators (I.L.v.K, D.O.). In summary, fetal condition before IUT 
was assessed by ultrasound (presence of hydrops, biophysical profile), fetal heart 
rate tracing in fetuses > 26 weeks’ gestation and blood gas analysis of the fetal blood 
sample obtained before transfusion (a blood gas result of ≤ 7.25 was considered a sign 
of compromise).91 If a complication occurred during or after a complicated procedure in 
a fetus with a reasonable condition prior to IUT based on the abovementioned findings, 
the complication was considered to be related to the procedure i.e. PR. In fetuses with 
an unfavorable condition prior to an uncomplicated procedure, the complication was 
classified as not related to the procedure i.e. NPR. If the experts could not agree on 
classification, the complication remained unclassified.
The following complications were taken into account: rupture of membranes or preterm 
delivery within 7 days after IUT, if occurring before 34 weeks of gestation; and intrauterine 
infection and fetal distress resulting in either emergency Cesarean section (CS) within 
24 hours after IUT or fetal or neonatal death.
Primary outcomes assessed were perinatal survival and PR complications. Furthermore, 
we assessed primary antibody type, gestational age at first IUT, fetal hemoglobin 
concentration and presence of hydrops at first IUT, procedure access site and other 
technical details of IUT, number of transfusions per fetus and gestational age at delivery.
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Diagnostics
Patients with red-cell alloimmunization were referred, according to national guidelines, to 
our center in Leiden, The Netherlands, which has served as the national referral center 
for fetal therapy since 1965. Indication for referral is based on type and titer of antibody, 
level of antibody-dependent cell-mediated cytotoxicity assay,24 and obstetric history.
In the first decade of the study period, amniotic fluid delta optical density measurements 
at 450 nm were used to assess the likelihood of fetal anemia. In later years, the peak 
systolic velocity in the fetal middle cerebral artery (MCA-PSV) was used to determine 
the optimal timing of first and subsequent IUTs.30,46,63 Cordocentesis was performed if 
MCA-PSV exceeded 1.5 multiples of the median and/or if signs of hydrops were detected 
on ultrasound, and was followed by transfusion if the fetal blood sample showed fetal 
anemia.
Intrauterine intravascular blood transfusion technique
Our IUT technique has been described comprehensively in a previous publication.55 No 
routine antibiotic prophylaxis or corticosteroid was administered prior to IUT. In nearly 
all recent cases, atracurium was given intravenously (or intramuscularly) to the fetus 
prior to transfusion to cause fetal paralysis.
IUT was carried out under aseptic conditions, using a 20- or 22-G needle. In this study, all 
IUT attempts were made intravascularly. As a result of our prior study,91 fetal paralysis was 
applied more often and known risk factors for PR complications, such as transamniotic 
needling (also known as ‘free loop’ needling) and arterial puncture, were avoided more 
consciously in the second half of the study. A tailored mode of transfusion was chosen 
depending on the fetal anatomy, preferably transfusing into the placental cord insertion 
in the case of an anterior placenta and into the fetal intrahepatic umbilical vein in the case 
of a posterior placenta, often in combination with additional intraperitoneal transfusion. 
For both time cohorts, a maximum of four experienced operators were involved, all 
capable of applying different transfusion techniques. IUT was considered to be successful 
if more blood than was acquired for fetal blood sampling was transfused to the fetus, 
as verified by ultrasound.
Fetal condition was monitored before, during and after transfusion. If the condition of 









To compare proportions, Fisher’s exact test (or Pearson’s chi-square test, when 
appropriate), binary logistic regression (Wald test) or Mann – Whitney U-test was used. 
The independent t-test was used for comparison of means. All variables with P-value 
of ≤ 0.15 in univariate analysis were included in a multiple logistic regression model to 
identify possible independent risk factors for severe PR complications (emergency CS 
or death). A P-value of < 0.05 was considered statistically significant.
RESULTS
During the 27-year study period, 595 fetuses in 587 pregnancies of 497 women received 
a total of 1685 IUTs, of which 740 were described previously.91 In eight twin pregnancies, 
both twins had anemia as a result of red-cell immunization and received IUTs. In one 
additional twin pregnancy, one fetus was affected and was included in this study; the 
co-twin was Rhesus D (RhD) negative.
Six singleton pregnancies, in which fetal death occurred from causes unrelated to red-
cell alloimmunization, were excluded, as described in detail previously.91 Therefore, 589 
fetuses were treated with a total of 1678 IUTs in 581 pregnancies of 491 women. Of these, 
741 procedures were performed in 255 fetuses before 2001 and 937 procedures were 
performed in 334 fetuses from 2001 onwards.
Overall perinatal survival was 93.4%, significantly increasing from 88.6% in the first time-
cohort to 97.0% in the second time-cohort (odds ratio (OR), 4.2 (95% CI, 2.0 – 8.7), P < 
0.001). Characteristics of the study population in both time-cohorts are summarized in 
Table1.
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Table 1. Characteristics of 1678 intrauterine intravascular blood transfusions (IUTs) in 589 fetuses 










 Rhesus D 217 (85.1) 255 (76.3) 0.009
 Kell 25 (9.8) 53 (15.9) 0.037
 Othera 13 (5.1) 26 (7.8) 0.242
GA at first IUT (weeks) 27 (17 to 36) 27 (16 to 35) 0.787
Hydrops at first IUT 97 (38.0) 43 (12.9) <0.001
Hemoglobin at first IUT (g/dL) 4.8 (1.1 to 13.2) 6.3 (1.5 to 12.9) <0.001
Z-Hemoglobin at first IUTb -8.3 (-12.2 to -0.24) -6.9 (-11.7 to -0.5) <0.001
∆ Hemoglobin (after IUT – before IUT) (g/dL) 4.5 (-0.5 to 11.2) 4.4 (0.5 to 9.2) 0.039
Number of IUTs per fetus 3 (1 to 7) 3 (1 to 6) 0.337
GA at delivery of liveborn (weeks) 37 (30 to 39) 36 (28 to 39) <0.001
Data are given as n (%) or median (range). GA: gestational age.
aRhesus c, E or e, Duffy (Fya), Kidd ( Jka), rare or low-frequency antigens
bNumber of SDs from median concentration for gestational age.
The main type of immunization was for RhD, although this significantly decreased from 
85.1% before 2001 to 76.3% from 2001 onwards (P = 0.009), whereas the proportion of 
Kell immunization increased (9.8% to 15.9%, P = 0.037, Table 1). In the second time-cohort, 
four patients were treated with intravenous immunoglobulin prior to the first transfusion.
Complications
In a total of 1678 IUTs, 69 complications occurred. Forty-four of these were considered 
as being directly related to the procedure (PR). In eight patients, one PR complication led 
to another (five emergency CSs followed by perinatal death, two intrauterine infections 
followed by perinatal death and one intrauterine infection followed by emergency CS). 
After correction for this, the actual PR complication rates for the total cohort over 27 
years were 6.1% per fetus and 2.1% per procedure. Survival and PR complications are 
listed in Table 2.
In the first time-cohort, there were 51 complications (seven women each had two 
complications; actual complication rate = 5.9% per procedure) and in the second time-
cohort there were 18 (one women had two complications; actual complication rate = 








complications significantly declined in the second cohort, from 9.8% to 3.3% per fetus 
(OR, 0.3 (95% CI, 0.2–0.7), P = 0.001) and from 3.4% to 1.2% per procedure (OR, 0.3 (95% 
CI, 0.2 – 0.7), P = 0.003). The risk of PR perinatal loss decreased over time from 4.7% to 
1.8% per fetus and from 1.6% to 0.6% per procedure (Table 2).
Preterm prelabor rupture of membranes and preterm delivery
In three cases, preterm prelabor rupture of membranes (PPROM) occurred within 7 
days after transfusion, leading to preterm delivery before 34weeks. One PR and one 
NPR classified PPROM are described in more detail in our previously published cohort 
study.91 In the second time-cohort, PPROM occurred in one case, the day after the first 
IUT at 30 weeks’ gestation. The baby was liveborn 8 days later. As it took three attempts 
to complete the transfusion successfully, this complication was classified as PR. The 
PR-PPROM rate was thus low in both cohorts and did not differ significantly (Table 2).
Table 2. Outcome and procedure-related complications after 1678 intrauterine intravascular blood 
transfusions (IUTs) in 589 fetuses with anemia caused by red-cell alloimmunization, according to 







fetuses/937 IUTs) OR (95% CI) P
Survival (n (%))a 226 (88.6) 324 (97.0) 4.16 (2.0-8.7) <0.001
Procedure-related complication (n) 32 12
 Per fetus (n (%))b 25 (9.8) 11 (3.3) 0.31 (0.2-0.7) 0.001
 Per procedure (n (%))b 25 (3.4) 11 (1.2) 0.34 (0.2-0.7) 0.003
Procedure-related PPROM (n) 1 1
 Per fetus (%) 0.4 0.3 0.76 (0.0-12.3) 1.000
 Per procedure (%) 0.1 0.1 0.79 (0.0-12.7) 1.000
Procedure-related infection (n) 2 1
 Per fetus (%) 0.8 0.3 0.38 (0.0-4.2) 0.581
 Per procedure (%) 0.3 0.1 0.40 (0.0-4.4) 0.587
Procedure-related emergency CS (n) 17 4
 Per fetus (%) 6.7 1.2 0.17 (0.1-0.5) <0.001
 Per procedure (%) 2.3 0.4 0.18 (0.1-0.5) <0.001
Procedure-related loss (n) 12 6
 Per fetus (%) 4.7 1.8 0.37 (0.1-1.0) 0.053
 Per procedure (%) 1.6 0.6 0.39 (0.1-1.0) 0.059
CS: Cesarean section; OR: odds ratio; PPROM: preterm prelabor rupture of membranes.
aAlive at discharge from tertiary center.
bActual number and rate (eight patients had two interrelated complications).
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Infection
Three cases of culture-proven intrauterine infection with Escherichia coli were observed, 
and all three were classified as PR. Two cases were part of our previously published 
cohort with IUTs before 2001.91 A third case occurred in the second cohort after IUT at 
18 weeks. The infection led to fetal loss and was considered to be PR. The decrease in PR 
infections over time, from 0.8% to 0.3% per fetus and from 0.3% to 0.1% per procedure, 
was not significant (Table 2).
Emergency Cesarean section
Within 24h after IUT, 24 fetuses were delivered by emergency CS for fetal distress, which 
was considered PR in 21 cases. Five children died subsequently; all deaths were PR 
and have been described previously.91 As fetal condition in two of the six cases in the 
second cohort was unfavorable prior to an uncomplicated IUT, these complications were 
considered NPR. One case of PR intrauterine infection resulted in emergency CS.91
In one case, emergency CS was performed at 34 weeks’ gestation for persistent 
tachycardia after transfusion, probably triggered by volume overload, and was considered 
as PR. The three remaining cases of CS at 32, 34 and 35 weeks were all classified as 
PR. All neonates in the second cohort survived after emergency CS. In summary, the 
occurrence of PR emergency CS decreased from 6.7% in the first. In one case, emergency 
CS was performed at 34 weeks’ gestation for persisting tachycardia after transfusion, 
probably triggered by volume overload, and this complication was considered PR. The 
three remaining CSs at 32, 34 and 35 weeks were all classified as procedure-related. All 
neonates in the new cohort survived after emergency CS. In summary, the occurrence 
of procedure-related emergency CS declined from 6.7% of fetuses in the first cohort to 
1.2% in the second cohort (P < 0.001) and from 2.3% to 0.4% per procedure (P < 0.001).
Fetal or neonatal death
During the study period, a total of 39 cases of fetal or neonatal death occurred after IUT, 
of which 10 occurred from 2001 onwards. In this second cohort, one patient with RhD 
immunization was treated initially with (a possibly incomplete) interstitial laser for twin 
reversed arterial perfusion syndrome and fetal death was detected the day after the 
third uncomplicated IUT. Because of the complexity of this case, this complication could 
not be clearly classified as PR or NPR. Three of the nine remaining cases of loss were 
considered to be NPR. One NPR loss occurred after the decision to stop intrauterine 








was caused by antibodies against a low-frequency antigen. In the two other cases, fetal 
death was detected 19 and 22 days after an uncomplicated IUT and, because of the time 
lapse between the procedure and the death, these deaths were considered as being NPR.
Therefore, a total of six PR losses occurred in the second cohort, including one with E.coli 
infection that was described earlier. In three patients, multiple attempts at intravenous 
access led to bradycardia during the procedure, leading to fetal loss directly, and at 1 
and 8 days later. Two other PR fetal losses occurred within 1week after IUTs at 16 and 
26weeks in fetuses with a reasonable condition prior to IUT. We thus saw a decrease 
in PR death rates from 4.7% to 1.8% per fetus (P = 0.053) and from 1.6% to 0.6% per 
procedure (P = 0.059).
Fetal death occurred after eight (17.0%) of 47 IUTs performed before 20 weeks. Four of 
these were classified as NPR and four as PR, one of the latter was preceded by infection. 
Fetal demise in the total cohort occurred more often before 20 weeks than after 20 
weeks, accounting for both NPR (8.5% vs 1.0% per procedure; P=0.002) and PR (8.5% 
vs 0.9%; P = 0.001) fetal death. No significant difference was found in PR fetal-loss rate 
before 20weeks between the first and the second time-cohort (P = 0.083).
Technical details
In the second time-cohort, significantly more procedures were completed successfully 
than in the first time-cohort (96.8% vs 99.0%, P = 0.001). The number of attempts per 
procedure decreased (median, 1 (range, 1 – 7) vs 1 (range, 1 – 5), P < 0.001). From 2001 
onward, the fetal liver was the most frequently chosen procedure access site (48.0% in 
the second cohort vs 13.8% in the first cohort, P < 0.001). Trends in procedure access 
sites over time are presented in Figure 1.
Fetal paralysis was applied significantly more frequently (97.8% vs 81.3%, P < 0.001) and 
transamniotic needling in a free loop of cord was performed less frequently (3.7% vs 
33.1%, P < 0.001) from 2001 onwards compared with before 2001. No arterial punctures 
were performed after 2001 (0.0% vs 3.2%, P < 0.001).
In Table 3, procedures that were followed by severe PR complications (fetal distress 
resulting in emergency CS or death) are compared with the remaining procedures 
by univariate analysis. Hydrops was not associated with severe PR complications (P = 
0.315). Z-hemoglobin (number of SDs from median concentration for gestational age), 
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fetal paralysis, procedure access site and unsuccessful IUT were included in a multiple 
regression model. A positive association with severe PR complications was found for 
transamniotic (P = 0.030) and arterial (P < 0.001) transfusion sites, compared with 
transfusion into the fetal liver. There was a negative association of PR complications with 
fetal paralysis (P = 0.034). Intrahepatic and placental cord insertion sites were equally 
safe (P = 0.597).
DISCUSSION
In this cohort of 589 fetuses treated with 1678 IUTs for fetal anemia caused by red-cell 
immunization, we found an improvement in perinatal survival over time, from 88.6% in 
1988–2000 to 97.0% from 2001 onwards. The incidence of PR complications decreased 
significantly in the last decade. PR loss rates declined from 4.7% to 1.8% per fetus and 
from 1.6% to 0.6% per procedure, a decrease that approached statistical significance. 
In spite of our policy not to apply routine antibiotics prior to transfusion, PR infection 
rate was extremely low (0.1% per procedure). These results suggest that intrauterine 
treatment for red-cell immunization has become significantly safer in the past decade.
Recently, three other European fetal therapy centers reported on PR complications and 
loss rates.58,66,67 Pasman et al. found a comparable PR complication rate (1.5%) in 135 
procedures performed between 2000 and 2014, although no perinatal death occurred in 
Figure 1. Trends in procedure access sites for intrauterine intravascular blood transfusion between 


















































the 56 fetuses in their study.58 We found lower overall PR perinatal loss rates compared 
with another recent European study by Tiblad et al., in which four of 85 fetuses died as a 
direct result of the procedure (4.7% per fetus, 1.4% per procedure) performed between 
1990 and 2010,66 and with the third study by Sainio et al., which had a 3.8% PR fetal-loss 
rate.67 None of these studies compared trends in results over time.
The increase in survival in our study may be explained, in part, by reduced severity of 
the disease at referral in the second cohort, reflected by a lower hydrops rate and higher 
hemoglobin concentrations at first IUT.55,164 This improvement reflects the optimization 
of the Dutch program for detection and prevention of red-cell antibodies.16,17
Table 3. Characteristics of intrauterine transfusions followed by severe procedure-related 
complications, compared to remaining procedures
Characteristic







Hydrops at IUT 7 (20.6) 231 (14.1) 1.6 (0.7 - 3.7) 0.315
GA at IUT (weeks) 31.1 (16.0 to 35.1) 29.9 (16.4 to 37.0) - 0.411
Z-hemoglobin at IUTb -7.4 (-12.2 to -3.6) -6.8 (-11.7 to 1.4) 0.8 (0.7 - 1.0) 0.016
Fetal paralysis 23 (67.6) 1440 (87.6) 0.2 (0.1 - 0.5) 0.001
Procedure access site
 Liver 6 (17.6) 546 (33.2) 0.4 (0.2 - 1.0) 0.065
 Placental cord insertion 11 (32.4) 787 (47.9) 0.5 (0.3 - 1.1) 0.083
 Transamniotic ‘free loop’ 10 (29.4) 270 (16.4) 2.1 (1.0 - 4.5) 0.060
 Artery 4 (11.8) 20 (1.2) 10.8 (3.5 - 33.6) 0.001
 Intraperitoneal 0 (0) 13 (0.8) - 1.000
 Otherc 3 (8.8) 8 (0.5) 19.8 (5.0–78.2) 0.001
Unsuccessful IUT 3 (8.8) 30 (1.8) 5.2 (1.5 - 18.0) 0.027
Data are given as n (%) or median (range). OR: odds ratio.
 aProcedures followed by fetal distress resulting in emergency Cesarean section within 24 h or fetal death.
 bNumber of SDs from median concentration for gestational age (GA).
cUnknown vessel, heart, chorionic vein.
We showed previously that fetal hydrops was associated with adverse outcome, both 
short- and long-term,31,164 but not with occurrence of PR complications, 91 as confirmed in 
the present study. The decline in number of RhD immunizations during the study period 
is probably best explained by the introduction of routine prophylactic administration of 
anti-D in the 30th week of gestation in 1998,5 in addition to postnatal anti-D.
103
Complications of intrauterine transfusions
It is likely that the most important factor associated with our low complication rates is the 
large number of IUTs performed annually at our center (mean, 62 per year vs 10, 14 and 
38 per year in Tiblad et al.,7 Pasman et al.8 and Sainio et al.,13 respectively), which enhances 
operator and team experience and thus also diminishes PR complication rates.95
We hypothesize that the extensive decline in PR complications is the result of avoiding 
possibly hazardous techniques in the more recent procedures. Risk factors for adverse 
outcome were identified previously91 and were confirmed in the current study as being 
arterial puncture, transamniotic ‘free loop’ needling and refraining from fetal paralysis. 
These technical aspects occurred significantly less frequently in procedures performed 
from 2001 onwards in our study, compared with procedures carried out before this 
timepoint. Furthermore, the fetal liver gained impressive popularity as a procedure access 
site, as this is associated with very low complication and loss rates and is considered to 
be a safe route of access.91,92,165 In the previously mentioned studies with higher reported 
complication rates, 15.5%7 and 63.8%13 of transfusions were transamniotic.
Our current study shows that early IUT is still a hazardous procedure, as both NPR 
and PR complications occur more often before 20 weeks. Early IUT is technically more 
challenging, resulting in a higher complication risk. Unfortunately, evidence-based studies 
on the benefit of intravenous immunoglobulin treatment to postpone the first IUT are 
still lacking. We are currently evaluating the effect of intravenous immunoglobulin in an 
international multicenter cohort study.
One of the strengths of our study is that all complications were independently and 
thoroughly classified as PR or NPR. Furthermore, the size of our cohort is considerably 
larger than those in other published studies. The retrospective design of this study 
carries some limitations. For example, the rationale for decisions on technical details 
of procedures by individual operators is difficult to determine retrospectively. However, 
because of the available evidence supporting transfusion techniques, randomization 
into different strategies to identify risk factors prospectively could be considered as 
unethical.58,91 Another limitation of this study could be that we did not address neonatal 
outcomes other than death. This was a deliberate choice, as our focus was on severe PR 
complications. Furthermore, short- and long-term outcomes of IUTs have recently been 








Our study demonstrates that IUTs should be a tailored treatment, with the chosen 
technique fine-tuned to the patient’s situation. We advocate that every operator should 
master all transfusion techniques and maintain experience by performing a sufficient 
number of transfusions per year in an experienced team. A minimum number of 10 
transfusions annually for experienced operators has been suggested.95 In order to 
achieve this target, centralization of fetal therapy is necessary.
In summary, we found that IUT for red-cell immunization has become a safer treatment 
option for fetal anemia. We believe that our current PR fetal-loss rates (1.8% per fetus 
and 0.6% per procedure) can be considered ‘as good as it gets’ in experienced hands. 
For the future, we are focusing our research on non-invasive treatment, such as 
immunomodulation with intravenous immunoglobulin.
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Intrauterine transfusion for severe alloimmunization in pregnancy performed before 20 
weeks’ gestation is associated with a higher fetal death rate. Intravenous immunoglobulins 
may prevent hemolysis and could therefore be a non-invasive alternative for early transfusions.
Objective(s)
We evaluated whether maternal treatment with intravenous immunoglobulins defers 
the development of severe fetal anemia and its consequences in a retrospective cohort 
to which 12 fetal therapy centers contributed.
Study design
We included consecutive pregnancies of alloimmunized women with a history of severe 
hemolytic disease and by propensity analysis compared index pregnancies treated with 
intravenous immunoglobulins (n=24) with pregnancies managed without intravenous 
immunoglobulins (n=28).
Results
In index pregnancies with intravenous immunoglobulin treatment, fetal anemia developed 
on average 15 days later compared to previous pregnancies (8% less often before 20 
weeks’ gestation). In pregnancies without intravenous immunoglobulin treatment anemia 
developed 9 days earlier compared to previous pregnancies (10% more before 20 weeks), 
an adjusted 4-day between-group difference in favor of the immunoglobulin group 
(95%CI -10 to 18, P=.564). In the subcohort in which immunoglobulin treatment was 
started before 13 weeks, anemia developed 25 days later and 31% less before 20 weeks’ 
gestation (54% compared to 23%) than in the previous pregnancy. Fetal hydrops occurred 
in 4% of immunoglobulin-treated pregnancies and in 24% of those without intravenous 
immunoglobulin treatment (OR 0.03, 95%CI 0 to 0.5, P=.011). Exchange transfusions were 
given to 9% of neonates born from pregnancies with and in 37% without immunoglobulin 
treatment (OR 0.1, 95%CI 0 to 0.5, P=.009).
Conclusion(s)
Intravenous immunoglobulin treatment in mothers pregnant with a fetus at risk for hemolytic 
disease seems to have a potential clinically relevant, beneficial effect on the course and 
severity of the disease. Confirmation in a multicenter randomized trial is needed.
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INTRODUCTION
Hemolytic disease of the fetus and newborn (HDFN) is caused by maternal 
alloimmunization against fetal red blood cells. The maternal antibodies can destruct fetal 
red blood cells and consequently cause fetal anemia, hydrops and perinatal death.17,166 
Intrauterine blood transfusion (IUT) is currently the only treatment option to prevent 
fetal death and reduce neurological impairment of these fetuses.55
Although relatively safe in experienced hands, IUT remains an invasive procedure, and 
complications may occur.57 Early transfusions are technically challenging, especially 
when performed before 22 weeks’ gestation, and carry a significantly higher risk of 
fetal loss compared with procedures performed later in gestation.96,97,99 In the largest 
single-center cohort series from the Leiden University Medical Center (LUMC) (the 
Netherlands), procedure-related fetal death rates after intravascular intrauterine 
transfusions performed either before or after 20 weeks’ gestation were 8.5% and 0.9% 
per procedure, respectively.57 Alternatively, some suggested the use of technically easier 
intraperitoneal transfusions.100,167 To date, no other treatment option for fetuses suffering 
from severe anemia early in pregnancy has been proven to be effective.
The use of intravenous immunoglobulin(s) (IVIg) may postpone or even replace invasive 
intrauterine treatment in fetuses of mothers with severe alloimmunization in previous 
pregnancies.112,167,168 IVIg may theoretically dilute circulating maternal antibodies and 
induce competition at the placenta, reducing transplacental transfer of maternal 
antibodies. Furthermore, it might increase antibody turnover and thus lower maternal 
alloantibody levels and, after transfer to the fetus, block fetal macrophage function.169,170 
As a result, IVIg might prevent hemolysis, but cannot treat existing fetal anemia.118
Administration of IVIg in pregnancy is considered safe, although side effects may include 
urticaria, myalgia, chills, headache, nausea or fever.171 Another disadvantage is that IVIg 
treatment is relatively expensive (approximately $6,000/week).128
A few single-center case series have reported on the possible effects of intravenous 
immunoglobulins on morbidity and mortality in hemolytic disease of the fetus and 
newborn.126,167,168 In the largest study, from the 1990s, IVIg appeared to lead to a major 








Although several fetal therapy centers occasionally use IVIg treatment in pregnancies at 
risk for recurrence of severe HDFN, there is still much uncertainty about the indications 
and true effects of IVIg. In this study, we gathered the international experience of 
treatment with IVIg to evaluate whether (early) administration in high-risk alloimmunized 
pregnancies is successful in delaying the onset of severe fetal anemia and thus 
diminishing its clinical consequences.
MATERIAL AND METHODS
Study design, setting and study population
We conducted a retrospective multicenter cohort study. The cohort consisted of 
pregnancies of women with an earlier pregnancy with severe HDFN (‘previous pregnancy’), 
managed in the first trimester of a new pregnancy between January 2010 and June 2016 
(‘index pregnancy’). A list of participating centers is provided as supplemental data. 
Patients from the Leiden University Medical Center (LUMC) were included from 2001 
onward, as the antenatal management of HDFN has not changed since the early 2000’s 
in our center.57
In all included current (‘index’) pregnancies women were either treated with IVIg (‘IVIg 
group’) or were managed without IVIg (‘non-IVIg group’). Severe HDFN was defined as 
either a previous fetal and neonatal death as a result of HDFN, or the need for IUT prior 
to 24 weeks’ gestation in the previous pregnancy.
All eligible pregnancies of all mothers were included. We excluded pregnancies in which 
a previous fetal or neonatal death was the result of a lack of diagnostic or therapeutic 
care, rather than caused by severe HDFN.
In the participating centers, 10 to140 women with red cell immunization are seen 
annually, receiving 5-60 IUTs that are performed by 1-4 operators. A 20 or 22 Gauge 
needle was used for intrauterine intravascular transfusion in all participating centers. The 
preferred transfusion access sites were the placental cord insertion and the intrahepatic 
part of the umbilical vein.
Treatment with IVIg was preferably started before 13 completed weeks’ gestation. 
Most cases were treated with Nanogam® or Privigen® IVIg. Alternatively, Gammagard®, 
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Intragam®, Vigam®, Flebogamma® or a combination was used. Most centers dosed IVIg 
at 1g/kg maternal weight and administered it in weekly doses.
We documented patient characteristics, laboratory results, Doppler measurement 
results, data on additional treatments, IUT details, delivery details and data on neonatal 
outcome (up to three months of age) from all pregnancies. Furthermore, details on IVIg 
treatment were collected of all index pregnancies.
Outcome definitions
We chose the difference in gestational age at onset of severe fetal anemia, requiring 
IUT, between the index and previous pregnancy (‘delta gestational age’) as our primary 
outcome, because the expert opinion is that fetal anemia tends to occur earlier in 
gestation in subsequent pregnancies of the same alloimmunized mother.72 As anemia 
may be present for days before it is diagnosed, the exact onset of severe anemia is 
impossible to determine. Therefore, we use ‘onset of severe anemia’ when we mean 
‘diagnosis of severe anemia’ throughout this manuscript. The (diagnosis of) onset of 
severe anemia was defined as either the day of IUT, the day fetal death was diagnosed, 
or the day the Doppler peak systolic velocity in the middle cerebral artery (MCA-PSV)30 
was measured above 1.5 MoM, in case fetal death followed at an unknown time point.
We elected the need for IUT before 20 weeks as a secondary outcome, because of the 
clinical relevance of this endpoint due to the associated increased risk for procedure-
related complications.57
Furthermore, we assessed perinatal survival, fetal hemoglobin (Hb) and Z hemoglobin 
(ZHb) and the presence of hydrops at time of the first IUT, the occurrence of complications 
(premature rupture of membranes, emergency cesarean section and fetal or neonatal 
death), the number of IUTs per pregnancy and the proportion of neonates needing 
exchange transfusions. ZHb is the deviation of fetal Hb from the mean for gestational 
age (1 standard deviation corresponds to 1 g/dL deviation).59
Ethical considerations
Depending on the local regulations of the participating centers, this research was 
approved by the relevant institutional review boards or ethics committees and 
accordingly, written informed consent was obtained if prescribed. All study data were 








Therefore, the medical ethics committee of the LUMC approved this research (P15.327/
SH/sh) and decided, according to the Medical Research Involving Human Subjects Act 
(WMO), that written informed consent was not needed from Dutch cases.
Statistics
All primary and secondary outcomes were analyzed in collaboration with our statistician 
and clinical epidemiologist.
As several women were included with more than one index pregnancy and because 
pregnancies of the same woman are interrelated, outcomes were compared using 
generalized estimating equations (GEE). Within the GEE, a binary logistic or linear model 
was used for comparison of estimated odds or means, respectively.
To adjust for possible confounding by indication, propensity scores were calculated that 
represent the probability that women would be selected for IVIg treatment by their 
caregivers in the index pregnancy.172 Factors included were gestational age at onset of 
anemia in the previous pregnancy, pregnancy interval and the number of previous births, 
type of antibody (D or Kell), maternal BMI and number of IUTs performed in the previous 
pregnancy. More information on how these factors were included in the propensity score 
is available as supplemental data. We used inverse probability of treatment weighing 
(IPTW) based on the generated propensity score in all GEE analyses.
Seven sensitivity analyses were performed for the primary outcome and one for the 
secondary outcome hydrops. Details on in- and excluded cases and the results of these 
analyses are available as supplemental data.
RESULTS
Characteristics of the mothers and their pregnancies
A total of 50 pregnancies of women with a severe HDFN were included. Five of these 
women had more than one pregnancy eligible for inclusion; four women were included 
with two and one woman with three index pregnancies. One woman was included as a 
non-IVIg case with her 9th pregnancy. In her 10th pregnancy she received IVIg.
111
Prenatal IVIg for severe HDFN
After exclusion of four pregnancies because death in the previous pregnancy did not 
result from the severity of HDFN, but was most likely caused by lack of timely diagnostics 
or treatment options, a total of 52 pregnancies remained; 28 in the non-IVIg group and 
24 in the IVIg group. One mother started IVIg treatment at the time of her first IUT and 
this pregnancy was therefore analysed in the non-IVIg group for outcomes at the time 
of first transfusion only (gestational age, Hb, hydrops) and excluded for other outcomes. 
Table 1 shows the baseline characteristics of all index pregnancies/fetuses.
In previous pregnancies of the IVIg group, more women had experienced a fetal or 
neonatal death (63% vs. 44%), anemia occurred 3 weeks earlier (20 vs. 23 weeks) and 
more IUTs were performed per pregnancy (5 vs. 4), compared to the group that was 
not treated with IVIg in their current (index) pregnancies. These and other patient 
characteristics were used to generate propensity scores.
In 51 of 52 index pregnancies an IUT was needed. There was only one index pregnancy 
without IUT, of a woman with a previous neonatal death at 36 weeks and 5 days. IVIg 
was started from 13 weeks onwards and no signs of fetal anemia were detected. In the 
first week of life, the Hb was 9.7 g/dL.
Gestational age at onset of severe fetal anemia
Primary and secondary outcomes are shown as unadjusted and adjusted data in Table 2. 
The gestational age at onset of severe fetal anemia in the pregnancies with IVIg treatment 
was on average 15 days later (95% confidence interval (CI) 0 to +31 days) than in the 
mother’s previous pregnancy, whereas this was 9 days earlier (CI -20 to +2) in the non-IVIg 
group. The adjusted estimated mean difference in this ‘delta gestational age’ between 
treatment groups was 4 days (CI -10-18, P=.564). If IVIg was started before 13 weeks’ 
gestation, anemia occurred 25 days later than in the previous pregnancy (unadjusted 
data).
The gestational age at onset of severe anemia in the individual cases is provided by Figure 
1. This figure also illustrates that in both groups (those with and without IVIg treatment), 
the course of disease was very heterogeneous. Although anemia on average developed 
9 days earlier in subsequent pregnancies without IVIg treatment, 11 out of 28 fetuses in 








Table 1. Patient demographics and baseline characteristics













Fetal or neonatal 
death
15 (63) 12 (44) 37 8 (32) 9 (36) -7
Gestational age at 
onset of anemia, 
weeks+days
20+0 [16-36] 23+0 [17-31] -66 24+0 [16-36] 21+0 [17-31] 4
IUTs before 20 weeks, 
n(%)
11 (46) 3 (11) 85 5 (19) 4 (14) 15





























Number of previous 
births
3 [1-9] 3 [1-8] -7 3 [1-9] 2 [1-8] 1
Maternal age at first 
IUT, years
33 [24-41] 32 [24-43] 10 37 [24-41] 29 [24-43] 129
Maternal body mass 
index
24 [20-41] 28 [22-38] -72 24 [20-41] 26 [22-38] -11
Laboratory predictor 
of disease
















IVIg dose, g/kg 
maternal weightd
0.63 [0.32-0.73] - - - - -
Number of days 
between IVIg 
treatments
7 [7-28] - - - - -
Treated with 
plasmapheresis
8 (33.3) 0 82 4 (15) 0 46
Data presented in median [range] or N (%). Abbreviation: N, number of index pregnancies; SMD, Standardized 
Mean Difference; IUT, Intrauterine transfusion; IVIg, intravenous immunoglobulins.
aWeighted by the propensity score.
bFor variables expressed in N (%), the weighted N was calculated from the weighted proportions and 
rounded.
cIf no death occurred.
dAmount of IgG1 and IgG3 administrated, calculated as IVIg dose in g/kg maternal weight * percentage IgG in 
substrate * percentage IgG1 and IgG3.
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Figure 1. Gestational age at onset of 
severe anemia in previous and index 
pregnancy. Grey lines reflect earlier 
onset of severe anemia in the index 
pregnancy compared to previous preg-
nancies, red lines reflect later anemia. 
The pink, bold lines reflect the weight-
ed estimated means. (A) Group treated 
with intravenous immunoglobulins. (B) 
Reference patients without intravenous 
immunoglobulin treatment in index preg-
nancy. (C) Subgroup treated with intrave-


































































































The development of fetal anemia before and after 20 weeks’ gestation, in patients 
treated or not treated with IVIg and in the subcohort of patients treated with early IVIg, 
is displayed in Figure 2. In the subcohort in which immunoglobulin treatment was started 
before 13 weeks, anemia developed 31% less before 20 weeks’ gestation (54% compared 
to 23%) than in the previous pregnancy. In pregnancies with early onset of anemia (before 
20 weeks, N=9) IVIg was started at a median of 14 weeks, this was 12 weeks and 4 days in 
pregnancies in which anemia developed later (N=15). The dose of IgG administered was 
0.67 g/kg (range 0.32-0.69) and 0.54 g/kg (range 0.32-0.73) maternal weight respectively, 
in pregnancies with early and later anemia.
In five pregnancies, IVIg was continued after the first IUT and the second IUT was 
performed a median of 18 days later (range 13-26 days).
Other clinical outcomes
Overall survival was 45/51 (88%) and did not differ between treatment groups (adjusted 
OR 1.2 (0.1-11.7), P=.894; Table 2). In the index pregnancies of the IVIg group, one fetal and 
one neonatal death occurred, respectively due to a CMV infection at 18 weeks’ gestation 
and to necrotizing enterocolitis. In the non-IVIg group, four index pregnancies ended 
in fetal death, following the first IUT performed at gestational ages of 18, 21, 22 and 27 
weeks. The cause of fetal death in these cases was either procedure-related or due to 
the compromised fetal condition.
The decisive MCA Doppler measurement, used to set the indication IUT, was 1.69 MoM 
in the IVIg group and 1.84 in the non-IVIg group (adjusted estimated mean difference 
-0.3 MoM, CI -0.6 to 0 MoM, P=.043). In both treatment groups, patients received 0.8 
MCA Doppler measurements per week, or one MCA Doppler measurement every 8 to 9 
days (adjusted estimated mean difference 0.1 measurement/week, CI -0.2-0.3, P=.537).
In both treatment groups, three first transfusions were performed intraperitoneally 
without intravascular access. For 8 non-IVIg patients the degree of anemia was measured 
in hematocrit only. Consequently, a fetal Hb measurement was available for 20/23 IVIg 
(and IUT) treated and 14/28 non-IVIg pregnancies. At the time of first IUT, fetuses in 
both groups had similar Hb levels: 6.4 SD’s below the mean for gestational age in the 
IVIg group and 7.6 SD’s in the non-IVIg group (adjusted estimated mean difference 0.9 
SDs less deviation from the mean in the IVIg group, CI -0.4 to 2.3 SDs, P=.171).59 Fetuses 
in the non-IVIg group had signs of hydrops in 24% at the time of first IUT, compared to 
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4% in IVIg-treated subjects (adjusted OR 0.03, CI 0-0.5, P=.011). After birth, 2/22 (9%) IVIg 
treated neonates with available neonatal data required an exchange transfusion, which 
was significantly less than the 7/19 (37%) newborns in the non-IVIg group (adjusted OR 
0.1, 95% CI 0-0.5, P=.009).
Sensitivity analyses
The results of the sensitivity analyses are shown in supplemental Table 1. The estimated 
mean differences of the difference (‘delta’) in gestational age at onset of anemia in 
the index and previous pregnancy between treatment groups were all in favor of IVIg 
treatment, although not statistically significant. The largest raw and adjusted effect sizes 
were seen in patients with D antibodies only, where fetal anemia occurred on average 
18 days later in IVIg treated pregnancies, compared to previous pregnancies, and 14 
days earlier in pregnancies from women not treated with IVIg, compared to previous 
pregnancies (adjusted estimated mean difference between groups 10 days, 95% CI -6 
to + 26, P=.202).
In eight patients IVIg treatment was combined with plasmapheresis. Additionally, one 
of these patients received corticosteroids. None of the patients in the non-IVIg group 
received plasmapheresis or other additional treatments. The sensitivity analysis without 
pregnancies in which plasmapheresis was performed had a similar result to the original 


























Figure 2. Onset of fetal anemia before and after 20 weeks’ gestation in previous and index pregnan-









In patients that were monitored with MCA Doppler in the participating center at least 
twice before IUT was performed, hydrops was noted in none of the 21 IVIg-treated 
fetuses and in 4/18 fetuses of the non-IVIg group (weighted P<.001).
Table 2. Primary and secondary outcomes

































Gestational age at 


























































Hydrops at time of 







.092 1 (3) 12 (46) 0.03 (
0-0.5)
.011










first IUT, n (%)
0.3 (0-2.6) .261 0.2 (0-2.1) .159















 Fetal death 0 4 (15)e 0 3 (12)
Need for exchange 
transfusion, n (%)
2/22 (9) 7/19 (37) 0.2 (0-0.96) .045 1 (6) 9 (47) 0.1 (0-0.5) .009
Data presented in estimated mean (95% CI) or N (%). Abbreviation: N, number of index pregnancies; PROM, 
premature rupture of membranes.
aExpressed in estimated mean difference (95% CI) for numerical outcomes or OR (95% CI) for proportions.
bFor variables expressed in N (%), the weighted N was calculated from the weighted proportions and 
rounded.
cDifference in gestational age at onset of severe anemia between index and previous pregnancy.
dIf no death occurred.
ePROM led to fetal death.
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COMMENT
In this study, 12 fetal therapy centers from Europe, North-America, Australia and 
New Zealand collaborated to evaluate the effect of IVIg on the onset of fetal anemia 
in pregnant women with severe fetal anemia in a previous pregnancy. We found that 
the onset of severe fetal anemia was later in IVIg treated pregnancies, compared to 
previous pregnancies. A larger (unadjusted) effect size was seen in the subgroup where 
IVIg was started ≤13 weeks. In the pregnancies not treated with IVIg, severe fetal anemia 
occurred earlier than in previous pregnancies. The adjusted difference between groups 
in this ‘delta gestational age’ was a non-statistically significant 4 days in favor of the 
IVIg group. The largest effect was observed in pregnancies with HDFN resulting from D 
immunization. IVIg started at or before 13 weeks appeared to positively influence the 
number of transfusions before 20 weeks’ gestation.
Additionally, we observed that only one fetus of the 24 IVIg-treated pregnancies 
developed hydrops, whereas 6/28 of the non-IVIg fetuses did. Furthermore, the neonatal 
exchange transfusion rate was impressively and significantly lower for neonates from 
the IVIg group compared to those of the non-IVIg group.
Our international collaborative study is the first study in the past two decades on the 
effect of IVIg in severe HDFN, comparing fetuses from IVIg treated pregnancies with 
non-IVIg treated pregnancies. The only comparable study was published in 1997, 
when monitoring of fetal anemia was entirely different, and mainly based on serial 
amniocentesis for bilirubin levels.112 Nevertheless, in an IVIg-treated group of 30 severely 
alloimmunized pregnancies, they found less hydrops, less fetal death and a mean delay 
in the need for intrauterine treatment of 1,5 weeks, compared to 39 controls. Their 
conclusion that ‘IVIg treated patients seem to have better fetal outcome’ is similar to ours.
The positive effect of IVIg treatment on the time of onset of severe fetal anemia was not 
statistically significant. However, the point estimates of all outcomes point in the same 
positive direction, supporting a potential clinically relevant and beneficial effect of IVIg 
on the course of HDFN. For example, IVIg was associated with less fetal hydrops and a 
lesser need for neonatal exchange transfusions compared to treatment without IVIg. 
Furthermore, early IVIg treatment appeared to delay the onset of severe anemia with 








We hypothesize that the effect of IVIg on time of onset of fetal anemia may have been 
underestimated. Although fetuses in both groups were monitored with equal intervals, 
those in the IVIg group might have been monitored more thoroughly, as decisive Doppler 
measurements before IUT were lower than compared to pregnancies without IVIg. This 
may reflect an earlier suspicion of severe fetal anemia and intervention with IUT in 
IVIg treated pregnancies compared to non-IVIg treated pregnancies. A more expectant 
management in the IVIg group could have resulted in longer recorded time to onset of 
anemia.
Mothers in the IVIg group seemed to have a history of more aggressive course of disease 
(based on the onset of anemia and the number of previous deaths), however we found 
strikingly less hydrops in currently IVIg-treated pregnancies. This is in accordance with 
the study of Voto et al.112 Although in our study, there may be an effect of relatively early 
IUT timing in the IVIg group, a real preventive effect of IVIg on the development of fetal 
hydrops cannot be ruled out and needs further investigation. Preventing fetal hydrops 
is known to be very beneficial for perinatal survival and long-term outcome.32
A new finding was the reduced need for neonatal exchange transfusions after prenatal 
IVIg treatment. The rate of exchange transfusions in the IVIg group appeared to be 
significantly lower than in the non-IVIg group and comparable to the expected 15% 
observed in other (D-only) studies.173,174 Apart from the limited sample sizes, a restriction 
in this finding is the relatively high number of missing data in the non-IVIg group, as 
chances on missing data are higher in cases were no exchange transfusion is performed. 
In the scenario that indeed none of these patients with missing data would have received 
an exchange transfusion, the difference in exchange transfusion rate would still be 6 vs 
23% in favor of the IVIg group. If this could be confirmed in a prospective study, it would 
be highly relevant for the clinical setting. These complex procedures become increasingly 
rare, with only a few centers able to maintain the necessary skills, and the risks and 
complications are often underestimated.175
Lastly, this study is the first to provide valuable insight in the course of disease in 
subsequent pregnancies with a high risk of HDFN. A surprising finding was the relatively 
high number of women in the non-IVIg group (11/28) in which the disease did not worsen 
in the subsequent pregnancy. Although caution is needed in challenging the accepted 
concept that the disease is more severe in every following pregnancy, we feel that this 
deserves further study.
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Strengths of this study were the relatively large dataset, obtained through international 
multicentre collaboration, and the performance of weighted analyses based on the 
propensity score, to correct for potential confounders. All centers used practically 
identical strategies for diagnosis and treatment of fetal anemia. As it is possible that 
centers that do not offer IVIg treatment may serve a less severely affected patient 
population, the propensity score analysis may be influenced by this unmeasured ‘case 
mix’176 differences in population between centers. We addressed this by performing 
a sensitivity analysis including only centers that offer IVIg, which resulted in a similar 
outcome.
Furthermore, we addressed other potential differences in disease or management by 
performing additional sensitivity analyses. The effect sizes of these analyses all appeared 
to be similar to the original analysis (supplemental Table 1).
The most important limitation of our study was the heterogeneity of the groups, due to 
the rarity of severe HDFN, the heterogeneous course of disease and the retrospective 
nature of the study. Only a prospective, preferably randomized and ideally blinded study 
could overcome this issue. Together with the still limited sample size, and the rarity 
of adverse outcomes, absence of statistical significance of observed differences was 
not unexpected. However, all observed differences point towards a potential clinically 
relevant benefit of IVIg in this group of alloimmunized pregnancies with very high risk 
on severe disease.
Another limitation is that the definition of ‘onset of severe fetal anemia’ is relatively broad. 
Patients are not monitored daily and anemia may be present a few days before their 
scheduled appointment. Although this can never be fully circumvented, we did perform 
a sensitivity analysis without patients in which this uncertainty was larger than a few days 
(for example, fetal death noticed at a scheduled appointment). The result of this analysis 
was similar to the original analysis.
Finally, despite the propensity analysis, a possible residual confounding effect of the 
type of antibody remained. This is reflected by the standardized mean difference of this 
variable being >10% (Table 1), which is the proposed threshold below which imbalance 








Despite the limitations, we feel that gathering the international experience on the use of 
IVIg in red cell alloimmunization in a conjoint cohort, is an important first step for future 
research on this subject.
Conclusion
In women pregnant with a fetus at high risk for early hemolytic disease, treatment with 
weekly IVIg seems to positively influence the course and severity of disease. To truly 
assess the beneficial effects of IVIg, a prospective and preferably randomized controlled 
trial would be required, and is planned. Due to the rarity of the disease, conducting such 
a study will be challenging and requires further intensive international collaboration.
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SUPPLEMENTAL MATERIAL
Glossary of terms
GEE – generalized estimating equations. This type of analysis does not require that all 
observations are independent. This is important in the present study, as pregnancies 
of the same woman are by definition interrelated.
HDFN – hemolytic disease of the fetus and newborn
IUT – (intravascular) intrauterine transfusion
IVIg – intravenous immunoglobulins
Propensity score –in retrospective studies, there is usually a reason that treated subjects 
received the treatment and untreated subjects didn’t. The propensity score calculates 
the baseline probability the studied treatment was assigned to each study subject, based 
on the characteristics of these patients. The aim of the propensity score is to balance the 
treatment groups in order to distribute the values of covariates equally between treated 
and untreated subjects, like in randomized trials.172
SMD - Standardized mean difference. This value represents the balance of a covariate 
between groups and is presented in the % difference in the value of this covariate. For 
example, if the means of a specific variable differ 50% between groups, the sample is 
less balanced than if only 10% difference exists. If the SMD is below 10%, the imbalance 
is thought to be neligible.177
List of participating centers
 ۛ the Leiden University Medical Center, the Netherlands;
 ۛ Liverpool Hospital, Australia;
 ۛ University Hospitals KU Leuven, Belgium;
 ۛ The queen Elizabeth Hospital, Scotland;
 ۛ Karolinska University Hospital, Sweden;
 ۛ Children’s Memorial Hermann Hospital, USA;
 ۛ Pränatal Medizin München, Germany;
 ۛ University of Birmingham, United Kingdom;








 ۛ Copenhagen University Hospital Rigshospitalet, Denmark;
 ۛ Evergreen Hospital, USA;
 ۛ Auckland District Health Board, New Zealand.
Propensity analysis
Included factors were gestational age at onset of anemia in the previous pregnancy, years 
between previous and index pregnancy and the number of previous births (continuous 
variables), type of antibody (D or Kell), maternal BMI and number of IUTs performed in the 
previous pregnancy. Body mass index (BMI) was categorized based on the overall cohort 
median (27 kg/m2) to create ‘low’, ‘high’ and ‘missing’ categories. For the number of IUTs, 
a categorical variable was made based on the overall cohort median (5 transfusions) to 
create ‘low’, ‘high’ and ‘unable to determine’ categories. This last category consisted of 
pregnancies ending in fetal or neonatal death or missing values for the number of IUTs. 
Two index pregnancies were excluded in the adjusted analyses, as the propensity score 
could not be generated due to missing values in any of the factors.
For analyses with <90% of all pregnancies included, new propensity scores were 
calculated based on the same confounders. ‘GA at birth’ could be corrected for all 
abovementioned potential confounders except for maternal BMI due to smaller numbers 
in this analysis.
Sensitivity analyses
Seven sensitivity analyses were performed for the primary outcome:
 ۛ By center: to examine whether the results were influenced by ‘case-mix’1 differences 
between centers that do and centers that do not offer IVIg, we repeated the analyses 
with only pregnancies managed in hospitals that did offer IVIg;
 ۛ Certain GA only: to examine whether the results were influenced by using the 
(possibly imprecise) gestational age at determination of fetal death as a cut-off for 
‘onset of anemia’, we selected pregnancies with a more precisely known moment 
of onset of anemia;
 ۛ By early IVIg treatment: exclusion of the pregnancies in which IVIg was started after 
13 completed weeks.
 ۛ D antibodies only: all Kell pregnancies were excluded;
 ۛ Every woman included once: to evaluate whether the inclusion of multiple 
pregnancies for some women influenced the results, we repeated the analysis with 
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every woman included just once, with the pregnancy that was most comparable to 
the other treatment group;
 ۛ No plasmapheresis performed: all patients that received both plasmapheresis and 
IVIg were excluded;
 ۛ By early previous anemia: as alloimmunization in patients with a previous fetal or 
neonatal death at later gestation might be different from patients requiring IUT 
before 24 weeks, the analysis was repeated with only patients in which anemia 
occurred before 24 weeks’ gestation in the previous pregnancy.
As hydrops could also occur as a result of late referral, we performed an additional 
sensitivity analysis with only patients that were monitored with MCA Doppler in the 





















By center N=24 N=16 N=24 N=16
 Delta GAa 15 (0-31) -11(-23-2) 26 (6-47) .011 1 (-11-13) -9 (-21-4) 10 (-8-27) .274
Certain GA only N=20 N=20 N=20 N=18
 Delta GAa 25 (10-40) -6 (-16-4) 31 (13-49) .001 -2 (-11-8) -4 (-14-5) 3 (-11-16) .700
By early IVIg 
treatment
N=13 N=28 N=13 N=25
 Delta GAa 25 (10-41) -9 (-19-1) 34 (15-52) <.001 -1 (-29-26) -6 (-17-5) 5 (-25-34) .746
D antibodies only N=19 N=19 N=19 N=17
 Delta GAa 18 (0-36) -14 (-24- -4) 32 (11-52) .003 2 (-11-14) -9 (-19-1) 10 (-6-26) .202
Every woman 
included once
N=24 N=22 N=24 N=20
 Delta GAa 15 (0-31) -6 (-18-6) 21 (1-41) .036 3 (-9-16) -1 (-10-7) 4 (-11-19) .573
No plasmapheresis 
performed
N=16 N=25 N=16 N=23
 Delta GAa 13 (-3-29) -10 (-20-0) 23 (3-42) .021 -2 (-11-8) -6 (-16-5) 4 (-11-18) .587
By early previous 
anemia
N=21 N=21 N=21 N=21
 Delta GAa 21 (4-37) 3 (-5-12) 17 (-1-36) .063 9 (-9-27) 8 (-4-20) 2 (-20-23) .879
By timely referral N=21 N=18 N=21 N=16
 Hydrops 0 (0) 4 (22) -b .037 b 0 (0) 7 (41) - b <.001 b
Data presented in estimated mean (95% CI). Abbreviation: EMD, estimated mean difference; N, number of 
index pregnancies; GA, gestational age; IVIg, intravenous immunoglobulins.
aDifference in gestational age at onset of severe anemia between index and previous pregnancy.
bDue to zero counts, an odds ratio was not estimable and comparing proportions with a generalized 
estimated equation was not possible. A (weighted) Fisher exact test was used for this comparison.
CHAPTER 7
IMMUNOGLOBULIN FOR ALLOIMMUNE 











Exchange transfusion and phototherapy have traditionally been used to treat jaundice 
and avoid the associated neurological complications. Because of the risks and burdens 
of exchange transfusion, intravenous immunoglobulin (IVIg) has been suggested as an 
alternative therapy for alloimmune hemolytic disease of the newborn (HDN) to reduce 
the need for exchange transfusion.
Objectives
To assess the effect and complications of IVIg in newborn infants with alloimmune HDN 
on the need for and number of exchange transfusions.
Search methods
We performed electronic searches of CENTRAL, PubMed, Embase (Ovid), Web of Science, 
CINAHL (EBSCOhost), Academic Search Premier, and the trial registers ClinicalTrials.gov 
and controlled-trials.com in May 2017. We also searched reference lists of included and 
excluded trials and relevant reviews for further relevant studies.
Selection criteria
We considered all randomized and quasi-randomized controlled trials of IVIg in the 
treatment of alloimmune HDN. Trials must have used predefined criteria for the use of 
IVIg and exchange transfusion therapy to be included.
Data collection and analysis
We used the standard methods of Cochrane and its Neonatal Review Group. We 
assessed studies for inclusion and two review authors independently assessed quality 
and extracted data. We discussed any differences of opinion to reach consensus. We 
contacted investigators for additional or missing information. We calculated risk ratio 
(RR), risk difference (RD) and number needed to treat for an additional beneficial outcome 
(NNTB) for categorical outcomes. We calculated mean difference (MD) for continuous 
variables. We used GRADE criteria to assess the risk of bias for major outcomes and to 
summarize the level of evidence.
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Main results
Nine studies with 658 infants fulfilled the inclusion criteria. Term and preterm infants 
with Rh or ABO (or both) incompatibility were included. The use of exchange transfusion 
decreased significantly in the immunoglobulin treated group (typical RR 0.35, 95% CI 0.25 
to 0.49; typical RD -0.22, 95% CI -0.27 to -0.16; NNTB 5). The mean number of exchange 
transfusions per infant was also significantly lower in the immunoglobulin treated group 
(MD -0.34, 95% CI -0.50 to -0.17). However, sensitivity analysis by risk of bias showed 
that in the only two studies in which the treatment was masked by use of a placebo and 
outcome assessment was blinded, the results differed; there was no difference in the 
need for exchange transfusions (RR 0.98, 95% CI 0.48 to 1.98) or number of exchange 
transfusions (MD -0.04, 95% CI -0.18 to 0.10). Two studies assessed long-term outcomes 
and found no cases of kernicterus, deafness or cerebral palsy.
Authors’ conclusions
Although overall results show a significant reduction in the need for exchange transfusion 
in infants treated with IVIg, the applicability of the results is limited because of low to 
very low quality of evidence. Furthermore, the two studies at lowest risk of bias show no 
benefit of IVIg in reducing the need for and number of exchange transfusions. Based on 
these results, we have insufficient confidence in the effect estimate for benefit of IVIg to 
make even a weak recommendation for the use of IVIg for the treatment of alloimmune 
HDN. Further studies are needed before the use of IVIg for the treatment of alloimmune 
HDN can be recommended, and should include blinding of the intervention by use of 











Is IVIg effective in reducing the need for exchange transfusion in newborns with 
alloimmune hemolytic disease of the newborn (HDN)?
Background
In alloimmune HDN, maternal antibodies (circulating proteins that are produced by the 
immune system in response to the presence of a foreign substance) are produced against 
fetal blood cells. These antibodies are transferred across the placenta and destroy 
red blood cells, leading to fetal anemia (deficiency of red cells in the unborn baby). 
Intrauterine (within the womb) blood transfusion is used to treat severe fetal anemia. 
After birth, the antibodies persist in the infant and cause hyperbilirubinemia (a raised 
blood level of an orange-yellow pigment (bilirubin, a waste product of a degrading red 
blood cell)) with the risk of serious brain damage (kernicterus) and anemia. Traditional 
treatment of hyperbilirubinemia consists of (intensive) phototherapy (light treatment) 
and exchange transfusion (where the baby’s blood is replaced with that of a donor; ET). 
Because ET is an invasive, high risk procedure, alternative treatments such as intravenous 
immunoglobulin (IVIg), have been investigated. IVIg is thought to reduce the rate of 
hemolysis and consequently the need for ETs.
Study characteristics
We searched the medical literature to 19 May 2017 and found nine randomized (clinical 
studies where people are randomly put into one of two or more treatment groups) or 
partly (quasi) randomized trials (including 658 participants) that assessed the efficiency 
of IVIg in infants with alloimmune HDN.
Key results
Analysis of all included studies showed a reduction in the need for and number of ETs in 
infants treated with IVIg combined with phototherapy compared to infants treated with 
phototherapy only. However, this was not confirmed in an analysis of the two placebo-
controlled studies (where a pretend treatment was given). There was no difference in 
the need for or number of top-up transfusions.
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Quality of evidence
The evidence from the studies was very low quality. However, two studies used a placebo, 
thereby minimizing bias and allowing blinding of the researchers assessing the response. 
These studies were consistent with each other and yielded moderate quality evidence 
(with a relatively small total number of participants involved (172) being the only reason to 
not regard the level of evidence from them as high) that IVIg was ineffective in preventing 
ET or top-up transfusions.
Conclusion
Based on all included studies, we could make no conclusions on the benefit of IVIg 
in preventing ET or top-up transfusion. However, the two placebo-controlled trials 
provided evidence of moderate quality that IVIg was ineffective in preventing ET or top-up 
transfusion, and therefore routine use in alloimmune HDN should not be recommended. 
However, since there was some evidence that IVIg reduced hemolysis (in laboratory 
studies), future high-quality studies are needed to determine whether IVIg has limited 








SUMMARY OF FINDINGS FOR THE MAIN COMPARISON
Intravenous immunoglobulin plus phototherapy compared to phototherapy alone for alloimmune 
hemolytic disease in neonates
Patient or population: neonates with alloimmune hemolytic disease
Settings: -
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329 per 1000 214 fewer per 
1000
(247 fewer to 
168 fewer)











153 per 1000 3 fewer per 
1000
(80 fewer to 150 
more)






- The mean ETs 
per infant for all 
studies was 0
MD 0.34 lower
(0.5 lower to 
0.17 lower)
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130 per 1000 6 more per 1000
(45 fewer to 89 
more)
Use of top-up 
transfusion after 










219 per 1000 35 more per 
1000









- The mean 
maximum serum 
bilirubin (µmol/L) 
for all studies 
was 0
MD 25.39 lower
(34.07 lower to 
16.7 lower)
aThe risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the 
comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; ET: exchange transfusion; IVIg: intravenous immunoglobulin; MD: mean difference; 
RCT: randomized controlled trial; RR: risk ratio.
GRADE Working Group grades of evidence
High quality: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate quality: we are moderately confident in the effect estimate: the true effect is likely to be close to 
the estimate of the effect, but there is a possibility that it is substantially different.
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Low quality: our confidence in the effect estimate is limited: the true effect may be substantially different 
from the estimate of the effect.
Very low quality: we have very little confidence in the effect estimate: the true effect is likely to be 
substantially different from the estimate of effect.
1In three studies, the method of randomization was not stated and there was inadequate concealment of 
random sequence (selection bias). In seven studies, there was no blinding of personnel (performance bias) 
and in five studies, no blinding of outcome assessment (detection bias). Among other potential sources of 
bias were that mean bilirubin levels at study entry were already higher than the threshold for the outcome 
(ET) in one study, differences between study groups despite randomization (one study), postrandomization 
withdrawals or cross-over between study groups (two studies) and criteria for ET differing between treatment 
arms (one study).
2Substantial heterogeneity: Χ2 = 34.63, df = 8 (P = 0.0003), I2 = 77%.
3Four studies did not clearly specify use of intensive phototherapy (which should be a routine intervention for 
infants at high risk of ET).
4Total number of participants in these two trials was low, increasing the risk of possible bias.
5Only a few infants needed a second ET.
6In one trial, the methods of randomization and allocation concealment were not stated. In two studies, there 
was no blinding of personnel (performance bias).
7Combined studies were underpowered for use of top-up transfusion in 1st week. A total of 378 infants were 
enrolled in all four trials, and the overall frequency of top-up transfusion was low (13.8%).
8Substantial heterogeneity: Χ2 = 15.60, df = 5 (P = 0.008); I2 = 68%.
9Due to small differences between treatment groups, the combined studies were underpowered for use of 
top-up transfusion after 1st week.
10Four studies used no method of blinding the intervention.
11Substantial heterogeneity: Χ2 = 14.82, df = 5 (P = 0.01); I2 = 66%.
12Peak serum bilirubin in the control group varied 1.86-fold between studies; there was considerably greater 
variation between studies than between groups within studies.
 BACKGROUND
Description of the condition
The use of anti-D immunoglobulin prophylaxis in D-negative women has led to a marked 
decline in Rh hemolytic disease of the newborn (HDN).134 Sensitization can occur 
despite immunoprophylaxis, particularly if it is given too late or in insufficient dose. A 
proportion of HDN is caused by antibodies to antigens other than D and is, therefore, 
not preventable with anti-D immunoglobulin. Fetal therapy has significantly improved 
outcome in Rh sensitized fetuses, but it does not comprehensively prevent need for 
neonatal treatment (van Kamp 2004). Primary modes of postnatal therapy include 
phototherapy and exchange transfusion (ET) to reduce risk of mortality and kernicterus. 
Top- up transfusions are used to treat early and late anemia. In contemporary perinatal 
centers, 15% to 40% of neonates admitted for Rh or ABO HDN require at least one ET. 
174,175
The safety of ET has been reported for over 50 years. Published mortality rates 








premature infants than in healthy term infants.175,178-180 Risks related to ET include adverse 
cardiorespiratory events; catheter-related complications; those related to the use of 
blood products; metabolic derangements; and other serious complications such as 
pulmonary hemorrhage, necrotizing enterocolitis and bowel perforation. In the last two 
decades, ET-related risks have been reported to be as high as 74%, although the incidence 
of severe adverse events is approximately 3-10%.175,181,184,185. Because improved perinatal 
care has reduced the need for ET, the complication rate could increase as clinicians 
become less experienced with the procedure.175 However, Steiner 2007 reported that 
over a 21-year period, despite a sharp decline in the number of ETs performed, there 
was no increase in morbidity and mortality.
Description of the intervention
Intravenous immunoglobulin (IVIg) is an alternative therapy that may be effective 
in treating alloimmune HDN. In 1987, the first report of successful treatment of late 
anemia due to E-incompatibility with IVIg was published.186 Subsequent case reports 
and case series reported success of IVIg treatment in neonates with both Rh or ABO 
incompatibility.187-189 However, Hammerman 1996a found a reduced or no response to 
IVIg treatment in infants with ABO incompatibility who had early and severe hemolysis. 
Since the early 1990s, several quasi-randomized or randomized controlled trials on the 
use of IVIg (including variations on timing of administration and dose) to reduce ET have 
been published.173,174,190-207
The potential benefits of IVIg over ET include that the treatment is less complicated and 
less labor intensive. In addition, IVIg could allow safe treatment of some infants in less 
sophisticated neonatal units, or avoid delaying treatment while transferring infants for 
ET. Comprehensive assessment of IVIg in premature infants, particularly in the treatment 
of sepsis, has shown that it is safe and well tolerated.208 It is a well-established therapy 
for alloimmune thrombocytopenia due to maternal and fetal human platelet antigen 
incompatibility.209 The risk of transmission of viral infection is extremely low.210 Hemolysis 
and acute renal failure are uncommon complications of IVIg treatment.211 One study 
showed an increased incidence of sepsis in premature infants receiving prophylactic 
IVIg.212 Since about 2010, several cases of necrotizing enterocolitis in infants with HDN 
treated with IVIg have been reported.213-215 Other rare serious adverse effects of IVIg have 
been described in pediatric and adult cohorts, but not in newborns.216
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How the intervention might work
IVIg might reduce the rate of hemolysis in alloimmune HDN by nonspecific blockade 
of Fc-receptors on the macrophages that are thought to mediate the destruction of 
antibody-coated red cells.217 Ergaz 1995 demonstrated a decline in carboxyhemoglobin 
levels in four of five infants treated with IVIg for alloimmune HDN.218 Hammerman 1996b 
demonstrated a significant reduction in carboxyhemoglobin levels in 19 of 26 Coombs-
positive infants treated with IVIg.219 Carboxyhemoglobin levels are a sensitive index 
of hemolysis and hence these studies suggest that immunoglobulin could decrease 
hemolysis. IVIg is typically formulated in 6% to 12% solutions, so at doses of 0.5 g/kg to 1 
g/kg the volume administered is 4 mL/kg to 16 mL/kg. It is possible that this is a sufficient 
fluid bolus to reduce bilirubin levels modestly through dilution, temporarily slowing their 
rate of rise and allowing more time for intensive phototherapy to have effect.
Why it is important to do this review
This is an update of a Cochrane Review first published in 2002. Although results of the 
previous review showed a significant reduction in the need for ET in infants treated with 
IVIg, the applicability of the results was limited because none of three included studies 
was at low risk of bias. Nevertheless, American Academy of Pediatrics (AAP) guidelines 
recommend the administration of 0.5 g/kg to 1 g/kg IVIg in alloimmune HDN if total serum 
bilirubin (TSB) is rising despite intensive phototherapy or if TSB level is within 34 μmol/L 
to 51 μmol/L (2 mg/dL to 3 mg/dL) of exchange level.220 As a result of these guidelines, 
despite the equivocal conclusions of the previous Cochrane Review, the use of IVIg in 
alloimmune HDN has become widespread in many countries. However, supplies of IVIg 
are limited and it does present some hazards. Therefore, use of IVIg should be restricted 
to treatment of conditions for which it is of confirmed benefit.
OBJECTIVES
To assess the effect and complications of IVIg in newborn infants with alloimmune HDN 









Criteria for considering studies for this review
Types of studies
All randomized and quasi-randomized controlled trials of IVIg in the treatment of 
alloimmune HDN.
Types of participants
Neonates with alloimmune HDN due to either Rh (or other red cell antigens) or ABO blood 
group antibodies with or without any other blood group antibodies.
Types of interventions
IVIg given for treatment of alloimmune HDN versus control (placebo or ’standard care’). 
Phototherapy, which is widely regarded as a safe and effective standard treatment may 
have been used in both IVIG and control groups. Early and late IVIg administration were 
defined (for this review) as IVIg started within (early) or after (late) the first 12 hours of 
life. Studies must have included predefined criteria for both IVIg and ET therapy.
Types of outcome measures
Primary outcomes
Efficacy:
 ۛ use of ET (proportion of infants receiving one or more ETs);




 ۛ use of top-up transfusion(s) in first week of life (% of infants);
 ۛ number of top-up transfusions performed in first week of life per infant;
 ۛ use of top-up transfusion(s) after first week of life (% of infants);
 ۛ number of top-up transfusions performed after first week of life per infant;
 ۛ maximum TSB (μmol/L (mg/dL));
 ۛ duration of phototherapy (days);
 ۛ duration of hospitalization (days);
 ۛ incidence of sensorineural hearing loss (any severity);
 ۛ incidence of kernicterus;
 ۛ incidence of cerebral palsy.
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Safety:
 ۛ neonatal mortality;
 ۛ incidence of adverse reactions possibly related to the use of IVIg or ET (statement 
of adverse events from individual trials only).
Search methods for identification of studies
Electronic searches
We performed electronic searches of the Cochrane Central Register of Controlled Trials 
(CENTRAL, the Cochrane Library), PubMed, Embase (Ovid), Web of Science, CINAHL 
(EBSCO- host), Emcare and Academic Search Premier. The subject query was applied in all 
databases taking into account the terminological differences between these databases. 
The query consisted of the combination of four subjects: immunoglobulins, alloimmune 
hemolytic jaundice, newborn infants and randomized controlled trials. Various synonyms 
and related terms for all subjects were used. Two search strategies were used: the first 
strategy was limited to randomized trials and systematic reviews, the second strategy 
included only the subjects immunoglobulins and alloimmune hemolytic disease (and 
synonyms and related terms for those subjects). The search was performed on 19 May 
2017. The bibliographic databases yielded 1565 references in total of which titles and 
abstracts were screened. The complete search strategy is attached in the appendix 
“Complete Search Strategy.” In addition to database searches, we searched the trial 
registers ClinicalTrials.gov and controlled-trials.com. We applied no language restrictions.
Searching other resources
We searched the reference lists of all included and excluded trials and relevant reviews 
for further relevant studies.
Data collection and analysis
We used the standard method of Cochrane and its Neonatal Review Group.
Selection of studies
Two review authors independently screened the titles and abstracts of all references 
for possible inclusion using predefined criteria for inclusion (see below). We obtained 
a full-text version of the article if a report appeared to meet inclusion criteria for the 
review, or if it was not clear based on title and abstract. We resolved any disagreements 
through discussion with other review authors. The inclusion criteria for this review were:








 ۛ study compared IVIg with any definition of “standard care” plus placebo, or with any 
definition of “standard care” without placebo;
 ۛ study included neonates with alloimmune HDN due to either ABO or Rh blood group 
antibodies with or without any other blood group antibodies;
 ۛ study measured ETs (primary outcome) for each study arm or at least one of the 
secondary outcomes (see below) (or both) for each study arm;
 ۛ study used predefined criteria for both IVIg and ET therapy.
Data extraction and management
Two review authors independently extracted data using a data collection form that 
was pilot tested before use. We resolved any disagreements through discussion and if 
necessary with the help of a third review author blinded to trial author, institution and 
journal of publication. One review author contacted authors of studies that did not report 
all required data or information. One review author entered data into Review Manager 
5, and at least one review author checked them.
Assessment of risk of bias in included studies
Two review authors independently assessed the risk of bias of included studies using 
the ’Risk of bias’ tool as described in the Cochrane Handbook for Systematic Reviews of 
Interventions.221 The following items for risk of bias were assessed: random sequence 
generation, allocation concealment, blinding of participants and personnel, blinding of 
outcome assessment, incomplete outcome data, selective reporting and other sources 
of bias. Each item was rated as ’low risk of bias’, ’unclear risk of bias’ or ’high risk of 
bias.’ Any differences of opinion were discussed with a third blinded review author until 
consensus was reached. For selective reporting, we used the following criteria to rate a 
study as ’low risk of bias:’
 ۛ for studies enrolling neonates with Rh or both Rh and ABO HDN: reporting (in paper 
or subsequent correspondence) at least one outcome related to each of ET, bilirubin 
and top-up transfusion, plus adverse effects and hospitalization.
 ۛ for studies enrolling only neonates with ABO HDN: reporting (in paper or subsequent 
correspondence) at least one outcome related to each of ET and bilirubin, plus 
adverse effects and hospitalization. Top-up transfusion was not considered to be 
a preferred outcome measure because anemia requiring treatment is an unusual 
consequence of ABO alloimmune hemolysis;
 ۛ study protocols or methods section of papers should not describe an intention to 
report outcomes that were not subsequently reported in the paper.
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Measures of treatment effect
We calculated the risk ratio (RR) and risk difference (RD) for categorical outcomes, such 
as the incidence of ET. We calculated the mean difference (MD) for continuous variables, 
such as the maximum bilirubin level. We also calculated the number needed to treat for 
an additional beneficial outcome (NNTB) to avoid ET, where the assumed control risk was 
derived from the mean baseline risk from the studies.222 We presented 95% confidence 
intervals (CI).
Dealing with missing data
We contacted investigators for missing information about study design, results or both.
Assessment of heterogeneity
We assessed clinical heterogeneity by determining whether clinical characteristics of 
participants, interventions, outcome measures and timing of outcome measurements 
were similar for included studies. We assessed statistical heterogeneity using Χ2 and 
I2 tests. An I2 statistic of 50% or greater was considered as substantial or considerable 
heterogeneity according to the Cochrane Handbook for Systematic Reviews of 
Interventions.221
Assessment of reporting biases
We contacted investigators to request missing outcome data when selective reporting 
bias was suspected based on the criteria described under Assessment of risk of bias 
in included studies. If the data remained unavailable and the absence was thought to 
introduce serious bias, the study was excluded.
Data synthesis
We used Review Manager 5 to synthesize the available data (RevMan 2014). Whether we 
used a fixed-effect model or a random-effects model depended on the level of clinical 
heterogeneity and the results of the Χ2 test and I2 statistic for heterogeneity.221 If there 
was substantial heterogeneity, we used a random-effects model was used and examined 
the sources of heterogeneity. If there was no substantial statistical heterogeneity, we 
used a fixed-effect model.
Quality of evidence
We used the GRADE approach, as outlined in the GRADE Handbook,222 to assess the 








 ۛ use of ET (proportion of infants receiving one or more ETs; assessment for all studies 
and separately for placebo-controlled studies;
 ۛ ETs per infant; assessment for all studies and separately for placebo-controlled 
studies;
 ۛ use of top-up transfusion(s) in first week of life (% of infants); all studies;
 ۛ use of top-up transfusion(s) after first week of life (% of infants); all studies;
 ۛ maximum serum bilirubin; all studies.
Two review authors independently assessed the quality of the evidence for each of the 
outcomes. We considered evidence from randomized controlled trials as high quality but 
downgraded the evidence one level for serious (or two levels for very serious) limitations 
based upon the following: design (risk of bias), consistency across studies, directness 
of the evidence, precision of estimates and presence of publication bias. We used the 
GRADEpro Guideline Development Tool to create a ’Summary of findings’ Table to report 
the quality of the evidence.
The GRADE approach results in an assessment of the quality of a body of evidence in 
one of four grades.
 ۛ High: we are very confident that the true effect lies close to that of the estimate of 
the effect.
 ۛ Moderate: we are moderately confident in the effect estimate: the true effect is 
likely to be close to the estimate of the effect, but there is a possibility that it is 
substantially different.
 ۛ Low: our confidence in the effect estimate is limited: the true effect may be 
substantially different from the estimate of the effect.
 ۛ Very low: we have very little confidence in the effect estimate: the true effect is likely 
to be substantially different from the estimate of effect.
Subgroup analysis and investigation of heterogeneity
Subgroup analyses were conducted to determine if effects depend on:
 ۛ population:
 o Rh incompatibility;
 o gestational age at birth (less than 37 weeks and 37 weeks or greater);
 ۛ intervention:
 o early administration of IVIg: start of IVIg 12 hours or less after birth;
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 o late administration of IVIg: start of IVIg more than 12 hours after birth;
 o single versus multiple doses.
As in contemporary care intensive phototherapy is standard care for ABO incompatibility 
and therefore ETs hardly ever occur in this subgroup nowadays, no subgroup analysis 
was performed for ABO incompatibility only.
Sensitivity analysis
We conducted a sensitivity analysis based on whether or not the included studies used 
a placebo and treatment blinding (which had potential to reduce performance bias and 
detection bias). The two studies that used a placebo were also at low risk of other forms 
of bias in that they used random sequence generation, allocation concealment, reported 




See Characteristics of included studies; Characteristics of excluded studies; and 
Characteristics of studies awaiting classification tables.
Results of the search
The search conducted up to 19 May 2017 identified 1565 references (see: Appendix 
1). After title and abstract screening, the full text of 27 references was screened. After 
full text screening, nine studies were included in the meta-analysis.173,174,190-196 Details 
of the studies are given in the Characteristics of included studies Table. Eleven studies 
were permanently excluded from this review. Details of these studies are given in the 
Characteristics of excluded studies Table. We found no additional studies searching 
reference lists of included and excluded studies and relevant reviews. A flow diagram of 
the study selection process is presented in Figure 1. No additional studies were included 









Figure 1. Flow diagram of study selection process. IVIg: intravenous immunoglobulin; RCT: randomized 
controlled trial.
Included studies
The review included nine randomized controlled trials published between 1992 and 2013.
Participants
The nine studies included 658 participants. Five studies included only infants with Rh 
incompatibility.173,174,191,192,195 One study included only infants with ABO incompatibility.193 
Two studies enrolled mostly infants with ABO incompatibility but also some with Rh 
incompatibility and both ABO and Rh incompatibility.190,194 Tanyer 2001 included 34 infants 
with ABO incompatibility, 18 with Rh incompatibility, two with “subgroup” incompatibility 
and seven with “more than one incompatibilities.”196 Only Nasseri 2006 reported results 
for each type of incompatibility separately and Alpay 1999 provided this information 
through correspondence.190,194 Four studies enrolled only term infants of 37 weeks of 
gestation or greater.190,192,194,196 None of the studies only included premature infants of 
less than 37 weeks of gestation. Rübo 1992 did not describe details of the gestational age 
at birth of enrolled infants.195 Santos 2013 and Smits-Wintjens 2011 provided outcomes 
for term and preterm infants separately.173,174
141
Cochrane Review on neonatal IVIg
Interventions
Seven of nine studies that met the inclusion criteria examined the effect of a single 
dose of IVIg in combination with phototherapy.173,174,190-193,195 One study examined multiple 
doses,194 and one study compared groups treated with a single dose or multiple doses 
with a control group,196 but was inconsistent in describing which group received a single 
dose or multiple doses of IVIg and therefore this study was excluded from the (planned) 
subgroup analysis of single and multiple doses. Two studies used a placebo in addition to 
phototherapy for the control groups.173,174 The intensity and topography of phototherapy 
fits the definition of intensive phototherapy in only three studies.173,174,192 Tanyer 2001 
used an obsolete model with three overhead lights from a single angle and Miqdad 2004 
did not use a phototherapy blanket beneath the baby.193,196 The remainder of included 
studies did not describe the intensity and topography of phototherapy in sufficient 
detail to allow a conclusion as to whether it is reasonable to describe it as intensive 
phototherapy. Five studies started IVIg 12 hours or less after birth,173,174,191,192,195 and three 
studies started IVIg more than 12 hours after birth.190,194,196 Miqdad 2004 started IVIg 
within 12 hours in nine neonates and more than 12 hours in 47 neonates, but they did 
not report outcomes for early and late IVIg administration separately.193
Since phototherapy was used in both treatment and control groups in all studies and 
is now considered standard of care in HDN, this review is effectively an analysis of the 
effectiveness of IVIg plus phototherapy versus phototherapy alone.
Outcomes
All included studies reported ET as the primary outcome. Six studies reported mean (or 
median) number of ETs per infant174,194 or supplied enough data to calculate these.191,192,195,196 
The authors of four studies provided unpublished data (standard deviation or mean, or 
both) for ET.173,174,190,193 Four studies reported the maximum bilirubin level.173,174,191,195 Two 
studies provided unpublished data on maximum bilirubin levels.190,192 Although all studies 
commented on the duration of phototherapy in their results, only seven studies reported 
or subsequently provided the numerical.173,174,190,192-194,196 These studies all used predefined 
criteria for commencing phototherapy but not all for ceasing it. Six studies reported or 
subsequently provided numerical data on the duration of hospitalization.173,174,190,192-194 
Only two studies reported (after correspondence) predefined criteria for hospital 
discharge.173,193 Six studies included top-up transfusion as an outcome.174,190,191,193-195 Three 
studies provided additional data on top-up transfusions.173,174,192 Smits-Wintjens 2011 did 








life, but subsequently provided this information.174 Elalfy 2011 had a follow-up period of 
only one week after discharge.192 Three studies reported predefined criteria for top-up 
transfusions,174,190,194 and one study later provided data through correspondence.173 All 
studies reported short-term adverse events. None of the included studies reported 
data on neurodevelopmental outcomes. Two studies provided additional information 
on neurodevelopmental outcomes.173,193
Excluded studies
We excluded 11 studies. One study only compared groups with a high or a low dose 
of IVIg,199 and four studies were only reported in abstract form and our request for 
additional information was not (sufficiently) answered.200,202,203,205 Three studies did not 
report predefined criteria for the primary outcome ET.198,201,207. One study did not report 
any outcome in a usable form for meta-analysis.206 Two studies were excluded due to 
methodological or ethical (or both) concerns.197,204 Details of excluded studies are given 
in the Characteristics of excluded studies Table.
Additional data
We attempted to contact the authors of all studies (except for the six studies that were 
identified for the previous review190,191,195,196,205,206 to request further methodological 
information and results. We successfully contacted the authors of 11 papers173,174,190,192,19
3,195,200,201,204 (including contact for the previous review)) in order to obtain additional data 
or to assist with the determination to include or exclude the study.
Risk of bias in included studies
For details of risk of bias of included studies, see the Characteristics of included studies 
Table and Figure 2.
Allocation
Only five studies reported an adequate method of randomization.173,174,191-193 Miqdad 
2004 and Elalfy 2011 provided information on randomization method only through 
correspondence. One quasi-randomized controlled trial allocated participants by order 
of admission.196 This study was rated as high risk of bias for both random sequence 
generation and allocation concealment. Alpay 1999 did not state what method of 
randomisation was used either in the paper or in response to a query from the review 
authors, commenting only that that the group allocation was decided by attending 
neonatologists who differed from those who were conducting the study, which we 
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construed to mean that the allocation was not random, and that the allocation was at 
high risk of bias. Nasseri 2006 and Rübo 1992 stated that babies were randomly assigned 
to treatment groups but did not provide any detail about the method used and the 
allocation was therefore considered at unclear risk of bias.
Blinding
Only two studies used a placebo in the control group,173,174 and were therefore rated 
as low risk for performance bias and detection bias. After correspondence with the 
authors of two additional studies, the risk of detection bias was rated as low; Miqdad 









2004 explained that data were kept and entered to their database by personnel who 
were not involved in the management of the cases and Elalfy 2011 explained that the 
person who performed the randomization was different from the one who conducted 
the study and the one who analyzed the data. None of the other studies described any 
method of blinding of intervention after allocation and, therefore, they were rated as 
high risk of bias on both items.
Incomplete outcome data
Reporting of outcome data was at low risk of bias in seven studies.173,174,190,191,193-196 For six 
of these studies, there were no missing data. In Rübo 1992, the amount of and reasons 
for missing data were similar between groups (low risk). One study was at high risk of 
bias because of a substantial amount of missing data on bilirubin levels.192
Selective reporting
Reporting bias was suspected in four studies because important outcomes were either 
not reported or were not reported in a form that was useable for meta-analysis, or that 
allowed judgment about local treatment practices (e.g. if the authors only stated that 
there was no significant difference between groups).191,192,195,196 The remaining studies 
were at low risk of bias.
Other potential sources of bias
Elalfy 2011 had non-random cross-over after randomization and another study used an 
additional criterion for ET in the control group only.192,193 These two studies were at high 
risk of bias. Dagoglu 1995 used post-randomization consent and although follow-up was 
complete for all infants for whom consent was obtained, four infants (two randomized to 
each arm of the study) were excluded because consent was withheld. Two infants were 
also excluded post-randomization in one other study because of “protocol violations” 
but no details were given.195 The latter two studies were rated at unclear risk of bias 
because the review authors were unable to assess the impact of these withdrawals on 
overall outcomes. Three other studies were rated as unclear risk of bias,190,194 or low risk 
of bias174 for a potential risk of bias. For details see ’Risk of bias’ tables.
Effects of interventions
See: Summary of findings for the main comparison (page 130).
145
Cochrane Review on neonatal IVIg
D A T A A N D A N A L Y S E S
Comparison 1. Intravenous immunoglobulin plus phototherapy versus phototherapy




participants Statistical method Effect size
1 Use of exchange transfusion (≥
1)
9 658 Risk Ratio (M-H, Fixed, 95% CI) 0.35 [0.25, 0.49]
1.1 Studies without a placebo
group
7 486 Risk Ratio (M-H, Fixed, 95% CI) 0.26 [0.18, 0.39]
1.2 Placebo-controlled studies 2 172 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.48, 1.98]
2 Exchange transfusions per
infant, by study quality
9 658 Mean Difference (IV, Random, 95% CI) -0.34 [-0.50, -0.17]
2.1 Studies without a placebo
group
7 486 Mean Difference (IV, Random, 95% CI) -0.44 [-0.64, -0.25]
2.2 Placebo-controlled studies 2 172 Mean Difference (IV, Random, 95% CI) -0.04 [-0.18, 0.10]
3 Use of top-up transfusion in 1st
week by study quality
4 378 Risk Ratio (M-H, Fixed, 95% CI) 1.05 [0.65, 1.69]
3.1 Studies without a placebo
group
2 206 Risk Ratio (M-H, Fixed, 95% CI) 0.71 [0.24, 2.12]
3.2 Placebo-controlled studies 2 172 Risk Ratio (M-H, Fixed, 95% CI) 1.18 [0.70, 2.00]
4 Top-up transfusions in 1st week
per infant by study quality
3 262 Mean Difference (IV, Fixed, 95% CI) 0.05 [-0.07, 0.17]
4.1 Studies without a placebo
group
1 90 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.2 Placebo-controlled studies 2 172 Mean Difference (IV, Fixed, 95% CI) 0.05 [-0.07, 0.17]
5 Use of top-up transfusion after
1st week by study quality
7 507 Risk Ratio (M-H, Fixed, 95% CI) 1.16 [0.97, 1.38]
5.1 Studies without a placebo
group
5 335 Risk Ratio (M-H, Fixed, 95% CI) 1.40 [1.08, 1.82]
5.2 Placebo-controlled studies 2 172 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.80, 1.27]
6 Top-up transfusions after first
week per infant, by study
quality
4 316 Mean Difference (IV, Fixed, 95% CI) -0.00 [-0.12, 0.12]
6.1 Studies without a placebo
group
2 144 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.2 Placebo-controlled studies 2 172 Mean Difference (IV, Fixed, 95% CI) -0.00 [-0.12, 0.12]
7 Maximum total serum bilirubin
(µmol/L) by study quality
6 451 Mean Difference (IV, Fixed, 95% CI) -25.39 [-34.07, -16.
70]
7.1 Studies without a placebo
group
4 279 Mean Difference (IV, Fixed, 95% CI) -29.05 [-38.32, -19.
78]
7.2 Placebo-controlled studies 2 172 Mean Difference (IV, Fixed, 95% CI) 0.93 [-23.94, 25.79]
8 Duration of phototherapy (days)
by study quality
7 585 Mean Difference (IV, Random, 95% CI) -0.98 [-1.31, -0.66]
8.1 Studies without a placebo
group
5 413 Mean Difference (IV, Random, 95% CI) -1.06 [-1.41, -0.72]
8.2 Placebo-controlled studies 2 172 Mean Difference (IV, Random, 95% CI) -0.50 [-1.24, 0.24]
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Intravenous immunoglobulin plus phototherapy versus control (phototherapy only)
Primary outcomes
Exchange transfusion
The results of nine included studies could be entered into the meta-analysis.173,174,190-196 
Most studies found a statistically significant reduction in the use of ET for IVIg treated 
infants.190-196 Two studies concluded that the use of (one or more) ETs was not reduced 
despite using early IVIg in combination with phototherapy.173,174 The meta-analysis of all 
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1 Use of exchange transfusion (≥ 1).
Analysis 1.1. Comparison 1 Intravenous immunoglobulin plus phototherapy versus phototherapy, Outcome
1 Use of exchange transfusion (≥ 1).
Review: Immunoglobulin for alloimmune hemolytic disease in neonates
Comparison: 1 Intravenous immunoglobulin plus phototherapy versus phototherapy
Outcome: 1 Use of exchange transfusion (≥ 1)
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Studies without a placebo group
Alpay 1999 8/58 22/58 20.3 % 0.36 [ 0.18, 0.75 ]
Da o lu 1995 4/22 15/19 14.9 % 0.23 [ 0.09, 0.58 ]
Elalfy 2011 2/40 11/50 9.0 % 0.23 [ 0.05, 0.97 ]
Miqdad 2004 4/56 16/56 14.8 % 0.25 [ 0.09, 0.70 ]
Nasseri 2006 3/17 11/17 10.2 % 0.27 [ 0.09, 0.81 ]
Rübo 1992 2/16 11/16 10.2 % 0.18 [ 0.05, 0.69 ]
Tanyer 2001 3/40 7/21 8.5 % 0.23 [ 0.06, 0.78 ]
Subtotal (95% CI) 249 237 87.8 % 0.26 [ 0.18, 0.39 ]
Total events: 26 (Treatment), 93 (Control)
Heterogeneity: Chi2 = 1.26, df = 6 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 6.70 (P < 0.00001)
2 Placebo-controlled studies
Santos 2013 6/46 7/46 6.5 % 0.86 [ 0.31, 2.36 ]
Smits-Wintjens 2011 7/41 6/39 5.7 % 1.11 [ 0.41, 3.01 ]
Subtotal (95% CI) 87 85 12.2 % 0.98 [ 0.48, 1.98 ]
Total events: 13 (Treatment), 13 (Control)
Heterogeneity: Chi2 = 0.13, df = 1 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 0.07 (P = 0.94)
Total (95% CI) 336 322 100.0 % 0.35 [ 0.25, 0.49 ]
Total events: 39 (Treatment), 106 (Control)
Heterogeneity: Chi2 = 11.32, df = 8 (P = 0.18); I2 =29%
Test for overall effect: Z = 6.23 (P < 0.00001)
Test for subgroup differences: Chi2 = 10.07, df = 1 (P = 0.00), I2 =90%
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0.35, 95% CI 0.25 to 0.49; typical RD -0.22, 95% CI -0.27 to -0.16; NNTB 5) (Analysis 1.1). 
However, overall, we rated this as very low quality evidence, because, although it was 
derived from randomized trials, there was very serious risk of bias in most trials, and 
moderate heterogeneity and serious indirectness, related to the fact that some trials did 
not use intensive phototherapy, which would be considered standard practice.
Subgroup analysis of infants with only Rh incompatibility supported a reduction in the 
use of ET with IVIg treatment (371 participants, typical RR 0.38, 95% CI 0.25 to 0.58; NNTB 
5) (Analysis 2.1).173,174,190-192,194,195
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In only those infants born at 37 weeks of gestation or greater, IVIg reduced the use of ETs 
(391 participants, typical RR 0.39, 95% CI 0.25 to 0.61; NNTB 6) (Analysis 6.1).173,174,190,192,194,196 
In the subgroup of infants born at less than 37 weeks of gestation, IVIg did not reduce 
the use of ETs (82 participants, typical RR 0.77, 95% CI 0.31 to 1.91; NNTB 20) (data not 
shown).173,174
Five studies found reductions in the use of ET where IVIg was used 12 hours or less 
after birth (335 participants, typical RR 0.41, 95% CI 0.26 to 0.66; NNTB 6) (Analysis 
3.1).173,174,191,192,195 Reductions were also found in the three studies which used IVIg more 
than 12 hours after birth (211 participants, typical RR 0.31, 95% CI 0.18 to 0.53; NNTB 
4) (data not shown).190,194,196 Subgroup analyses of infants receiving a single dose of IVIg 
and infants receiving multiples doses of IVIg supported a reduction in the use of ET with 
IVIg treatment, although there was insufficient evidence to support a dose-response 
effect (single dose of IVIg: 563 participants, typical RR 0.37, 95% CI 0.26 to 0.53; NNTB 6; 
Analysis 4.1; );173,174,190-193,195 multiple doses of IVIg: 34 participants, RR 0.27, 95% CI 0.09 
to 0.81; NNTB 1; Analysis 5.1).194
However, despite these apparently promising results, analysis of the only two placebo-
controlled studies at low risk of all forms of bias showed no reduction in the use of ET 
(172 participants, typical RR 0.98, 95% CI 0.48 to 1.98) (Analysis 1.1.2).173,174
Furthermore, when all studies were considered, heterogeneity was moderate for use of 
ET (Χ2 = 11.32, degrees of freedom (df ) = 8 (P = 0.18); I2 = 29%) and was high for ETs per 
infant (Tau2 = 0.04; Chi2 = 36.77, df = 8 (P < 0.0001); I2 = 78%), whereas the results of both 
these outcomes for the placebo-controlled trials were highly consistent (I2 = 0% for both). 
We rated the quality of evidence from the two placebo-controlled studies as moderate, 
downgrading it only for imprecision because of the low total number of participants.
Overall, immunoglobulin treatment also led to a reduction in the mean number of 
ETs per infant (658 participants, MD -0.34, 95% CI -0.50 to -0.17). We assessed the 
level of evidence from the whole group of studies as very low, again downgrading the 
evidence from randomized trials because of very serious risk of bias, high heterogeneity, 
indirectness and imprecision. In contrast, analysis of the two placebo-controlled studies 
were consistent with each other and when considered alone, yielded moderate quality 
of evidence that IVIg did not reduce the number of ETs (172 participants, MD -0.04, 95% 









Top-up transfusions during and after the first week
The results of four studies could be entered in the meta-analysis of the use of top-up 
transfusions in the first week of life173,174,190,192 and of seven studies for the use of top-up 
transfusions after the first week of life.173,174,190,191,193-195 IVIg did not increase the need 
for top-up transfusions during the first week (378 participants, typical RR 1.05, 95% 
CI 0.65 to 1.69) (Analysis 1.3) or in the period after the first week (507 participants, 
typical RR 1.16, 95% CI 0.97 to 1.38) (Analysis 1.5). IVIg also did not increase the need 
for top-up transfusions in the first week and after the first week of life in the following 
subgroups: infants with Rh incompatibility only (first week: typical RR 1.08, 95% CI 0.65 
to 1.77 (Analysis 2.3); after first week: typical RR 1.09, 95% CI 0.92 to 1.28 (Analysis 2.5)); 
infants born 37 weeks or more of gestation (first week: typical RR 0.91, 95% CI 0.48 to 
1.74 (Analysis 6.3); after first week: typical RR 1.18, 95% CI 0.81 to 1.71 (Analysis 6.5)); 
infants born less than 37 weeks of gestation (first week: typical RR 1.39, 95% CI 0.70 
to 2.73; after first week: typical RR 1.24, 95% CI 0.93 to 1.67 (data not shown)); infants 
treated with IVIg 12 hours or less after birth (first week: typical RR 1.18, 95% CI 0.70 to 
2.00 (Analysis 3.3); after first week: typical RR 1.04, 95% CI 0.89 to 1.22 (Analysis 3.5)); 
and in infants treated with a single dose of IVIg (first week: typical RR 1.05, 95% CI 0.65 
to 1.69 (Analysis 4.3); after first week: typical RR 1.13, 95% CI 0.95 to 1.33 (Analysis 4.5)). 
Although the need for top-up transfusions during the first week of life was not increased 
for the subgroup of infants treated with IVIg more than 12 hours after birth (typical RR 
0.71, 95% CI 0.24 to 2.12) (data not shown), the need for top-up transfusions after the first 
week of life was increased with late IVIg treatment (typical RR 8.00, 95% CI 1.03 to 62.26) 
(data not shown). However, the CIs were very large and the lower CI limit was nearly one. 
For infants treated with multiple IVIg doses, the use of top-up transfusions after the first 
week of life was not increased (typical RR 5.65, 95% CI 0.25 to 126.87) (Analysis 5.3) and 
not estimable for the first week of life.
For the subgroup of infants included in placebo-controlled studies only, at low risk of 
all forms of bias, the need for top-up transfusions in the first week of life and thereafter 
was also not altered in infants treated with IVIg (first week: 172 participants, typical RR 
1.18, 95% CI 0.70 to 2.00 (Analysis 1.3.2); after first week: typical RR 1.01, 95% CI 0.80 to 
1.27 (Analysis 1.5.2)).173,174
Smits-Wintjens 2011 and Santos 2013 were the only studies included in the analysis of 
the number of top-up transfusions per infant. In the first week of life and thereafter, the 
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number of top- up transfusions was not altered in IVIg treated infants (first week: MD 
0.05, 95% CI -0.07 to 0.17 (Analysis 1.4); after first week: MD -0.00, 95% CI -0.12 to 0.12 
(Analysis 1.6)).
When all studies reporting these outcomes were considered, there was low to very 
low quality evidence (downgraded for risk of serious to very serious bias, and serious 
imprecision) that IVIg did not alter the risk of early or late top-up transfusion. These 
results were consistent with the findings of the placebo-controlled trials.
Maximum total serum bilirubin
Six studies reported results for maximum serum bilirubin. 173,174,190-192,195 The meta-analysis 
of all six studies showed that the mean maximum serum bilirubin decreased by 25.39 
Analysis 1.2. Comparison 1. Intravenous immunoglobulin plus phototherapy versus phototherapy, Outcome 
2 Exchange transfusions per infant, by study quality.
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Outcome: 2 Exchange transfusions per infant, by study quality





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Studies without a placebo group
Alpay 1999 58 0.19 (0.51) 58 0.5 (0.68) 12.4 % -0.31 [ -0.53, -0.09 ]
Da o lu 1995 22 0.18 (0.39) 19 1.05 (0.71) 9.0 % -0.87 [ -1.23, -0.51 ]
Elalfy 2011 40 0.05 (0.22) 50 0.22 (0.42) 14.4 % -0.17 [ -0.30, -0.04 ]
Miqdad 2004 56 0.07 (0.26) 56 0.29 (0.46) 14.3 % -0.22 [ -0.36, -0.08 ]
Nasseri 2006 17 0.17 (0.39) 17 1.11 (0.99) 6.3 % -0.94 [ -1.45, -0.43 ]
Rübo 1992 16 0.13 (0.34) 16 1.06 (0.93) 6.6 % -0.93 [ -1.42, -0.44 ]
Tanyer 2001 40 0.08 (0.27) 21 0.38 (0.59) 11.2 % -0.30 [ -0.57, -0.03 ]
Subtotal (95% CI) 249 237 74.4 % -0.44 [ -0.64, -0.25 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 27.15, df = 6 (P = 0.00014); I2 =78%
Test for overall effect: Z = 4.47 (P < 0.00001)
2 Placebo-controlled studies
Santos 2013 46 0.13 (0.34) 46 0.2 (0.5) 13.5 % -0.07 [ -0.24, 0.10 ]
Smits-Wintjens 2011 41 0.22 (0.53) 39 0.21 (0.52) 12.1 % 0.01 [ -0.22, 0.24 ]
Subtotal (95% CI) 87 85 25.6 % -0.04 [ -0.18, 0.10 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.29, df = 1 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 0.57 (P = 0.57)
Total (95% CI) 336 322 100.0 % -0.34 [ -0.50, -0.17 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 36.77, df = 8 (P = 0.00001); I2 =78%
Test for overall effect: Z = 4.03 (P = 0.000056)
Test for subgroup differences: Chi2 = 10.94, df = 1 (P = 0.00), I2 =91%
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μmol/L in infants receiving IVIg (MD -25.39 μmol/L, 95% CI - 34.07 to -16.70) (Analysis 1.7). 
Furthermore, subgroup analyses showed that IVIg decreased maximum bilirubin levels in 
infants with Rh incompatibility, infants of more than 37 weeks of gestation, infants treated 
early or late, and infants treated with a single dose of IVIg. However, subgroup analyses 
of the only two placebo- controlled studies173,174 and of infants born at less than 37 weeks 
of gestation173,174 showed that IVIg did not reduce maximum serum bilirubin (placebo-
controlled trials: MD 0.93 μmol/L, 95% CI - 23.94 to 25.79 (Analysis 1.7.2); infants born 
at less than 37 weeks of gestation: MD -18.91 μmol/L, 95% CI -54.49 to 16.68 (data not 
shown)). The quality of evidence regarding maximum serum bilirubin was very low, with 
evidence from six randomized controlled trials downgraded for risk of bias and serious 
inconsistency; (heterogeneity: Χ2 = 14.82, df = 5 (P = 0.01); I2 = 66%). Of note, the peak 
serum bilirubin in the control groups varied nearly two-fold between studies, indicating 
that there were likely to be very different thresholds for ET between the studies.
Duration of phototherapy
Results of seven studies could be included in the meta-analysis of the duration 
of phototherapy.173,174,190,192-194,196 Although all studies gave criteria for commencing 
phototherapy, only five studies described or provided predefined criteria for ceasing 
phototherapy.173,174,190,192,196 Analysis of all seven studies showed that duration of 
phototherapy decreased by 0.98 days with IVIg treatment (MD -0.98 days, 95% CI -1.31 to - 
0.66) (Analysis 1.8). All subgroup analyses showed a decrease in duration of phototherapy 
in IVIg-treated infants varying from a mean decrease of 1.12 days in infants treated with 
a single dose of IVIg (MD -1.12 days, 95% CI -1.30 to -0.94) (Analysis 4.8) to 1.24 days 
in infants treated with IVIg 12 hours or less after birth (MD -1.24 days, 95% CI -1.44 
to -1.03 (Analysis 3.8)). However, as for maximum bilirubin levels, analyses of the two 
placebo-controlled studies and of infants born less than 37 weeks of gestation showed 
no reduction in duration of phototherapy (placebo-controlled trials: MD -0.50 days, 95% 
CI -1.24 to 0.24 (Analysis 1.8.2); infants born less than 37 weeks of gestation: MD -0.91 
days, 95% CI -1.96 to 0.14) (data not shown)).
Duration of hospitalization
Results of six studies could be entered in the meta-analysis.173,174,190,192-194 None of these 
studies described predefined criteria for hospital discharge and only two studies 
provided them through correspondence.173,193 The analysis showed that IVIg treatment 
shortened duration of hospitalization by 1.34 days (MD -1.34 days, 95% CI -1.60 to -1.09) 
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(data not shown). All subgroup analyses showed a shorter duration of hospitalization 
with IVIg treatment (data not shown).
Incidence of adverse reactions
All studies reported or subsequently provided data on adverse reactions, although for 
most of the trials, we did not know any details of what protocols were used to identify 
adverse events or how they were defined. Nine studies reported that there were no 
adverse reactions of IVIg treatment.173,174,190-196 None of the adverse reactions were 
necrotizing enterocolitis. In the study by Alpay 1999, two control infants receiving ET 
developed hypoglycemia and hypocalcemia after ET. In the study by Rübo 1992, one 
control infant who required ET developed sepsis and one control infant who required 
ET developed inspissated bile syndrome. However, the authors stated that a causal 
relationship with ET could not be established in either infant. In the study by Dagoglu 
1995, one control infant developed inspissated bile syndrome. Miqdad 2004 described 
that “no immediate adverse effects related to IVIg were noted, including fever, allergic 
reactions, volume overload or hemolysis;” however, they also stated that “ten of the 
babies who had ET, from both groups, had to be treated for blood culture-positive 
or clinical sepsis.” In the study by Smits-Wintjens 2011 one infant from the IVIg group 
developed a Bacillus cereus sepsis with brain abscesses a few days after ET. Sterility tests 
on the used IVIg batches and cultures of all donor blood products used for intrauterine 
transfer (IUT) and ET were sterile. The sepsis may have been related to the umbilical 
venous catheterization and ET. A case report provided information on this exceptional 
case.174
Long-term outcomes
Only two studies had a relatively long follow-up period of one year173 and two years.193. 
In both studies, there were no cases of kernicterus, deafness or cerebral palsy. All 
participants of the Smits-Wintjens 2011 study were included in a subsequent long-term 
follow-up study and neurodevelopmental outcome in children of at least two years of age 
was equal in children treated with IVIg and children treated with placebo.223 The authors 
stated that their findings may have been limited by a small sample size.
Neonatal mortality








Incidence of adverse reactions possibly related to the use of intravenous 
immunoglobulin or exchange transfusion
None of the studies reported Incidence of adverse reactions possibly related to the use 
of IVIg or ET.
DISCUSSION
Summary of main results
Data from nine studies with 658 participants provided limited evidence that IVIg treatment 
in neonates with alloimmune HDN reduced the need for ET. Although this review update 
showed a significant reduction in the need for ET, most of the included studies were at high 
risk of bias. IVIg treatment was also associated with a significant reduction in maximum 
bilirubin level and duration of phototherapy when all included studies were analyzed 
and for most of the subgroup analyses based on type of alloimmunization, gestational 
age at birth, and timing and number of doses of IVIg. Duration of hospitalization was 
significantly reduced when analyzing all studies that reported this outcome and for 
almost all subgroup analyses, including the analysis of studies at low risk of bias only. 
Although there was some evidence that IVIg reduced hemolysis and shortened hospital 
stay, these results should be interpreted with considerable caution because the studies 
reporting these benefits were not blinded, only two studies used predefined criteria for 
hospital discharge, and criteria for stopping phototherapy were not reported in most 
studies. In addition, since the late 1980s, guidelines for phototherapy have recommended 
using it more promptly for infants at risk of hemolysis.224 In many hospitals, the quality 
of phototherapy has also improved over the years. Nevertheless, the quality/intensity of 
phototherapy can still vary today, especially in low-resource settings and if good quality 
control is not applied. The incidence of late top-up transfusions is an important outcome, 
especially in areas where follow-up of infants is difficult or where supply of safe blood for 
transfusion is limited. However, as thresholds for top-up transfusions in neonates vary 
widely, this outcome is susceptible to bias, particularly in unblinded studies. Seven of 
nine studies were included in the analysis of the incidence of top-up transfusion after the 
first week of life.173,174,190,191,193-195 However, only five of the seven studies used predefined 
criteria for top-up transfusions.173,174,190,193,194 In addition, the predefined criteria varied 
between studies, thus conclusions were limited. Data on adverse events of IVIg seemed 
to indicate that it can be used safely. Although we found reports of a higher incidence 
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of NEC in infants with HDN treated with IVIg in the literature,213-215 there were no cases 
of NEC in the current meta-analysis.
Importantly however, subgroup analysis of the only two studies that were placebo-
controlled, blinded, at low risk of all forms of bias, including 172 participants, were very 
consistent with each other and showed that IVIg treatment had no effect on the need 
for ET or the number of ETs per infant.173,174 As for ET, analysis of these two studies at 
low risk of bias demonstrated no difference in maximum bilirubin level and duration of 
phototherapy.
Overall completeness and applicability of evidence
This review included all (quasi-) randomized controlled trials on the use of IVIg in 
alloimmune HDN. We identified 27 trials, of which nine trials, comprising 658 infants, 
fulfilled inclusion criteria for the review. The only two included studies that were placebo-
controlled comprising a total of 172 infants, enrolled only infants with Rh HDN and the 
intervention consisted of a single dose of 0.5 g/kg to 0.75 g/kg IVIg administered within 
four to six hours after birth.173,174 Santos 2013 included infants of 32 gestational weeks 
or greater and Smits-Wintjens 2011 included infants of 35 gestational weeks or greater. 
Criteria for phototherapy and ET were similar in both studies. Evidence from subgroup 
analysis of these two studies with 172 participants showed that early administration of 
IVIg in a single dose of 0.5 g/kg to 0.75 g/kg did not reduce ETs or had other benefits in 
the treatment of Rh HDN. There was no clear evidence from this review that a higher dose 
improved efficacy. The only randomized controlled trial comparing the effect of two doses 
of IVIg in Rh HDN showed that 0.5 g/kg and 1 g/kg had a similar effect on the duration of 
phototherapy, duration of hospitalization and ET requirements.199 However, this study 
was not powered to detect a difference in the need for ET. Only two studies examined 
long-term neurodevelopmental outcome, which found no cases of kernicterus, deafness 
or cerebral palsy in a follow-up period of one year173 and two years.193 All participants of 
the Smits-Wintjens 2011 study were included in a subsequent long-term follow-up study 
and neurodevelopmental outcome in children of at least two years of age was equal in 
children treated with IVIg and children treated with placebo.223
American Academy of Pediatrics guidelines of 2004 recommend the administration of 
0.5 g/kg to 1 g/kg IVIg in alloimmune HDN if TSB is rising despite intensive phototherapy 
or if TSB level is within 34 μmol/L to 51 μmol/L (2 to 3 mg/dL) of exchange level.220 Based 








risks,211-213 and supplies of IVIg are limited, we do not recommend routine use of IVIg. 
However, since there is some evidence that it reduces hemolysis and it appears safe 
in infants with alloimmune HDN, it might be reasonable to consider using it in special 
circumstances, such as during transfer of an infant to a location that can perform an 
ET, where the risk of ET is considered to be much higher than usual, such as in very or 
extremely low birth weight infants, or in the context of a future research study.
Quality of the evidence
The quality of included studies ranged from fulfilling none of the ’risk of bias’ criteria to 
fulfilling all criteria (see ’Risk of bias’ section of Characteristics of included studies Table, 
and Summary of findings for the main comparison). Only two of nine trials ful-filled all 
criteria to be rated as high-quality studies. We made the decision to evaluate the quality 
of evidence using GRADE criteria separately for the seven studies at high risk of bias 
and the two studies at low risk of bias, because evaluation of the seven studies at high 
risk of bias as a group also demonstrated other concerns including inconsistency and 
indirectness. For the outcomes of use and number of ETs in the first week, the quality of 
evidence from the seven studies at high risk of bias was very low, whereas the evidence 
from the two studies at low risk of bias was moderate (down- graded only for small 
number of participants). For the outcome of top-up transfusions after the first week, we 
evaluated the level of evidence only for Rh HDN and only for the two studies at low risk 
of bias, because we deemed this outcome to usually be irrelevant for infants with ABO 
incompatibility (who are at much lower risk of late anemia) and because of incomplete 
reporting of data in other studies. The evidence was of very low quality. Analysis of the 
effect of IVIg on the need for ET in infants with ABO incompatibility included only three 
studies at high risk of bias,190,193,194 because other studies only enrolled infants with Rh 
HDN, did not use predefined criteria for top-up transfusion or did not provide sufficient 
detail to separate Rh- and ABO-affected infants. The quality of evidence for IVIg for ABO 
incompatibility was very low (GRADE analysis not shown). For several of the secondary 
outcomes of the review, the RR (or other relevant statistic) was not estimable for included 
studies (no events in either intervention or control groups), highlighting the extent to 
which these studies were seriously underpowered. In summary, we considered that the 
evidence from the two trials at low risk of bias provided a sufficient quality of evidence 
to guide practice.
It was unclear why placebo-controlled, high-quality trials yielded such different results. 
Possibilities included that when administration of IVIg was not compared with use of a 
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placebo administered in similar dose and over similar duration, there were differences 
in timing of the next bilirubin measurement, meaning that in IVIg-treated infants, 
there was longer exposure to phototherapy before the decision about ET was made. 
Another possibility was that there was bias in the decision to perform an ET, influenced 
by knowledge of group allocation. A third possibility was that rather than a specific 
immunomodulatory effect, IVIg (and where used, the placebo solution) has a sufficient 
non-specific dilutional effect to change the rate of rise of bilirubin, altering duration of 
exposure to phototherapy and decision making about ET.
Potential biases in the review process
We tried to minimize bias by working with two review authors who independently assessed 
eligibility for inclusion of trials, extracted data and assessed risk of bias. However, we 
were aware that these parts of the review process were based on personal judgment 
because reviewing research is influenced by prior beliefs. In addition, one included trial 
was performed by two of the five review authors. Nevertheless, we attempted to review 
all studies in a similar way. In addition, we were unable to contact authors of all potentially 
eligible studies and, therefore, we could not include all available data. While the translator 
of the Turkish included study was a medical doctor from Turkish parents, he may have 
missed some details regarding the risk of bias of that study.
Agreements and disagreements with other studies or reviews
The overall findings of this review were consistent with previous systematic reviews. 
Louis 2014 included 12 studies (813 participants) and concurred with our finding that 
high-quality studies found no effect of IVIg, whereas low-quality studies found IVIg 
effective in HDN. Gottstein 2003 included three studies that were also included in our 
review,190,191,195 and one study that was excluded from our review.206 They concluded that 
with IVIg treatment significantly fewer infants required ET. Duration of hospitalization 
and phototherapy were also significantly reduced in their review. However, based on our 
judgment, none of their included studies was of high quality. Two Chinese systematic 
reviews225,226 also found a reduction in ET requirements, duration of phototherapy 
and hospitalization but concluded that well-designed trials with a larger sample size 
were required for further evaluation of the efficacy and safety of IVIg. Until the date we 
conducted our search, our review was the most recent, extensive and up-to-date review 










Based on the overall outcomes of the review, there is insufficient evidence to conclude 
that intravenous immunoglobulin (IVIg) is beneficial in neonates with hemolytic disease 
of the newborn (HDN). We gave particular weight to the results of the only two studies 
that provide evidence at sufficient low risk of bias to guide routine clinical practice, and 
that show no reduction in the use of exchange transfusion (ET), or improvement in 
any other important outcomes of the review. In addition, IVIg has risks that have been 
identified in other contexts of treatment. Therefore, we believe routine use of IVIg for 
HDN should not be recommended.
The effect of IVIg plus phototherapy compared to phototherapy alone on eventual 
neurodevelopmental outcomes remains unknown, although there was no difference in 
neurodevelopmental outcome between these groups in a (small) long-term follow-up 
study.223 However, since there is some indirect evidence that IVIg reduces hemolysis 
and because it appears safe in neonates with alloimmune HDN (acknowledging that the 
combined sample size of all studies is insufficient to assess uncommon, put potentially 
serious adverse effects), it may have a limited role in special circumstances, such as 
where ET is impossible, or is considered particularly high risk. Nevertheless, undertaking 
preparations for ET, including ensuring earliest possible use of intensive phototherapy, 
and birth at or transfer to a center that can perform ET, would seem to be strongly 
indicated in high-risk infants, and should not be abandoned in the expectation that IVIg 
will be efficacious.
Implications for research
Future research into the role of IVIg in the early treatment of alloimmune HDN may be 
warranted, especially for infants for whom ET carries particularly high risks. Such a trial 
should examine the safety and efficacy of IVIg by recording both short-term outcomes 
such as the need for transfusion therapy and the incidence of adverse events and also 
long-term neurodevelopmental outcomes. Both ETs and (late) top-up transfusions 
should be recorded because reduction of ETs can increase the number of top- up 
transfusions.227 Consideration should also be given to including additional measures 
to assess the severity of hemolysis such as carboxyhemoglobin or end tidal carbon 
monoxide. Based on evidence from the two placebo-controlled trials at low risk of all 
forms of bias, the conclusion of the review authors is that IVIg is of very limited usefulness 
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in Rh HDN. However, neither of these placebo-controlled studies enrolled infants with 
severe established jaundice due to ABO incompatibility. In contrast to Rh incompatibility, 
ABO incompatibility mainly results in hyperbilirubinemia without significant anemia. 
This is primarily due to the relatively few group A and B antigenic sites on neonatal red 
blood cells.228 Furthermore, infants with ABO- mediated hemolysis often present for 
neonatal care when they already have severe jaundice. Due to these differences between 
Rh and ABO incompatibility it is conceivable that IVIg has a different effect in anti-A or 
anti-B-mediated jaundice. Due to the relative rarity of severe jaundice caused by ABO 
incompatibility in many countries and the fact that this condition almost always resolves 
with phototherapy alone,229 exploring the use of IVIg to treat established jaundice would 
require a multicenter randomized controlled trial. Based on the discordance of results 
in this review between trials that were conducted with and without careful blinding of 
the intervention using a placebo, we recommend that any future trials should either 
use a placebo or a robust alternative method for blinding of treatment and outcome 
assessment. Future trials should be well designed and give priority to establishing 
guidelines for the “conventional” management of alloimmune HDN, focusing on the 
criteria for performing both top-up and ETs and on the role of intensive phototherapy.
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DIFFERENCES BETWEEN PROTOCOL AND REVIEW
In addition to analysis of all included studies, analyses were performed of all placebo-
controlled studies. The search method, inclusion criteria and criteria to measure risk of 
bias were more extensively described in the review than in the protocol.
For the 2017 update, we updated the search and included seven new studies. We 
updated the background to include contemporary literature. The eligible participants 
were further specified (from “Neonates with isoimmune hemolytic disease” to “Neonates 
with alloimmune HDN due to either Rh or ABO blood group antibodies with or without 
any other blood group antibodies.” The primary and secondary outcomes were adjusted 
to more relevant outcomes in the current era. Previously, the subgroup analysis for 
timing of IVIg treatment was divided in ’prophylactic use’ and ’treatment of established 
jaundice’. For the current review, this was changed to within 12 hours of life or later. Due 
to the lack of definitions and the possibility of incomplete reporting in regard to adverse 
events, the adverse events of individual trials were stated in the current review, rather 
than combined raw outcomes of all included studies.
A sensitivity analysis for risk of performance or detection bias (or both) was added. 
Furthermore, we incorporated the GRADE criteria and added a ’Summary of findings’ 
Table for the most important outcomes.
SUMMARY AND 
DISCUSSION





SUMMARY AND GENERAL DISCUSSION
Hemolytic disease of the fetus and newborn (HDFN) is a serious condition that, if 
remained untreated, may result in fetal hydrops or even death. In the past decades, much 
has changed in the prevention, screening, monitoring and (intrauterine) treatment of 
HDFN. Outcome data of pregnancies complicated by even the severest forms of HDFN, at 
least in specialized tertiary care centers, are considered excellent, and generally regarded 
to have reached an ‘as good as it gets’ level. However, even in the best centers, fetal and 
neonatal death due to HDFN still occurs.
The aim of this thesis was to review and critically analyse current management for this 
disease and to assess factors that contributed to reaching this point, in order to provide 
specific tools to further improve outcome.
Chapter 1 provides an overview of the current state-of-the-art setting, technique and 
outcome of intrauterine blood transfusions (IUTs) for HDFN. Additionally, we summarize 
the available literature on two alternative (or additional) prenatal non-invasive treatment 
options: therapeutic plasma exchange and intravenous immunoglobulin treatment. The 
chapter concludes that IUT is nowadays considered a safe procedure in experienced 
hands, although complication rates of IUTs performed in early gestation remain relatively 
high. Maternal treatment with plasma exchange or intravenous immunoglobulins are 
thought to lower the pathogenic alloantibody levels in mother and child. From several 
case series these treatments have been postulated to delay the onset of fetal anemia 
and, hence, to postpone the necessity of early IUTs. To evaluate whether IVIg indeed may 
improve outcome in these cases, we performed an international cohort study, further 
described in Chapter 6 of this thesis.
Pathogenesis and prevention
HDFN is caused by maternal antibodies against fetal red cell antigens, usually provoked by 
fetomaternal hemorrhage during pregnancy or delivery. HDFN is most frequently caused 
by D (formerly known as RhD) alloantibodies, although alloantibodies with other Rh 
specificities (c, C, E, e) or non-Rh alloantibodies (K, Fy, Jk) may also induce fetal hemolysis. 
As a result of several preventive measures, of which anti-D immunoprophylaxis (RhIg) 
is the most important, both Rh and non-Rh alloimmunization in pregnancies is more 




In 2016, 14.6% of the Dutch pregnant population (N=172,414) was D-negative and thus 
at risk for D antibodies. Only 156 pregnant women, out of this total pregnant population 
(D-negative and D-positive,) indeed had D antibodies. 94 were new immunizations; the 
prevalence was thus 0.09%, the incidence 0.05% (rates obtained by cohort study described 
in chapter 3, unpublished data). The prevalence of all types of RBC alloantibodies in 
pregnant women, including D, was 0.29-0.41%.14 Importantly, apart from c-, E- and Kell-
matching of red cell transfusions to women of reproductive age, no preventive measures 
are available to prevent these other immunizations. The pivotal observation in the 
1940s that pregnancies of ABO incompatible couples were less often complicated by 
D immunization, led to a better understanding of the pathogenesis of D immunization 
and eventually to the development of RhIg as an important preventive measure.4,131 
However, as it is unknown whether this is also the case for non-D immunizations, we 
addressed in Chapter 2 both the pathogenesis of these immunizations and the working 
mechanism of RhIg, by evaluating whether ABO incompatibility and RhIg also prevent 
the occurrence of non-D antibodies. We identified women with newly detected non-D 
antibodies, immunized during their first pregnancy and/or delivery. Of these 232 women 
(cases), 11.9% had a possible ABO incompatible pregnancy, significantly less than the 
expected 19.4% in the Dutch pregnant population (controls). We furthermore found 
that the subgroup of 99 women with only non-Rh antibodies had significantly less 
often received RhIg in their first pregnancies. These findings suggest that both ABO 
incompatibility and RhIg not only reduce the risk of D immunization, but also of non-D 
and non-Rh immunizations, respectively, implying that antibody-mediated immune 
suppression (AMIS) by RhIg is not antigen-specific. In our opinion, future attempts to 
manufacture the second generation of anti-D immunoprophylaxis, not dependent on 
the decreasing human donor pool, could focus on a fetal RBC-specific target. By doing 
so, a universal prophylaxis against the fetal red blood cell, to prevent all types of RBC 
alloimmunization, might be achievable.
An additional, perhaps more realistic, future perspective on immunoprohylaxis concerns 
combining the non-invasive prenatal testing (NIPT) for syndromal abnormalities with 
an extensive maternal and fetal antigen typing in the first trimester. Subsequently, a 
personalized tailor-made mix of engineered monoclonal antibodies can be administered 
based on the found incompatibilities. As we found that the AMIS response seems to 











Preventing red blood cell alloimmunization is of utmost importance, as this condition 
may have serious sequelae. A decade ago, Koelewijn et al. performed a nationwide 
Dutch cohort study amongst pregnant women with D immunization and found that 
in primiparae with first detected D antibodies, 19% of children needed an intrauterine 
transfusion (IUT), a neonatal exchange transfusion, or even died.5 In Chapter 3, 
we investigated the expert opinion that disease severity increases in subsequent D 
alloimmunized pregnancies with D-positive children (thus at risk for HDFN), in a new 
nationwide Dutch cohort study. We found that this was indeed true, as most disease 
characteristics were more severe in second pregnancies at risk for HDFN, compared 
to the index (first immunized) pregnancy. For example, second pregnancies at risk 
showed higher titer and ADCC results, more fetuses treated with IUT, more births 
induced prematurely, lower neonatal hemoglobin and higher bilirubin levels and more 
children treated with phototherapy and neonatal red cell transfusions. It seemed that 
antibodies first detected at 27th week screening (‘late’) is in fact a sign of strong maternal 
respondership to a small fetomaternal hemorrhage during pregnancy, rather than a 
weak response to a previous birth. Although the group in which antibodies were already 
found at first trimester screening were most often immunized after giving birth to a 
D-positive child (relatively large hemorrhagic event) and had the entire extend of the 
pregnancy to develop substantial disease severity, the severity in the index pregnancy 
was equal to the late immunized group. Furthermore, disease severity did increase 
only in the group with late antibody formation, also indicating a more active immune 
response. It is not completely known why women are low or high-responders, although 
authors have postulated associations with certain HLA-DRB1 types.154,230 Identification 
of ‘high responders’ early in pregnancy in the future might enable the administration 
of additional early RhIg, before antibody formation can occur. The antibody dependent 
cell-mediated cytotoxicity (ADCC) test result showed predictive for severe disease: if it 
did not exceed 10% in the index pregnancy, 94% of second D-positive children at risk 
did not need intrauterine transfusion(s). Based on the moment of antibody detection, 
antibody characteristics as reflected by ADCC test results and the disease severity in the 
index pregnancy, parents can now be properly counselled on the risk of severe disease 
in a subsequent pregnancy.
Already in the second pregnancy complicated by D immunization, almost a third of 
patients were in need for antenatal intervention by intrauterine transfusion (IUT). 
The Leiden University Medical Center has served as the national referral center for 
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fetal therapy since the introduction of intraperitoneal intrauterine transfusion in the 
Netherlands in the 1960s. In that era, no routine first trimester antibody screening was 
performed and patients referred for IUT often presented with (severe) fetal hydrops,49 
a condition associated with poor outcome on both the short and the long term.31,32 The 
intraperitoneal IUT was gradually replaced by the ultrasound-guided intravascular IUT 
from 1987 onwards and routine early screening was implemented in 1998. Chapter 
4 describes how this and other measures have led to the near disappearance of 
severe alloimmune hydrops in the complete 30-year cohort of 645 fetuses treated 
with intravascular IUT in the Netherlands. Since routine screening before week 13 was 
introduced in 1998, fetuses at risk for anemia are identified and treated more timely. This 
is reflected by the finding that the proportion of fetuses first presenting with hydrops 
significantly declined from 40 to 16%. Strikingly, during the last six years of the study, only 
one fetus presented with severe hydrops. Thus, if hydrops occurs nowadays, it is usually 
mild. As mild hydrops is known not to be associated with impaired outcome,31 survival 
of fetuses with and without hydrops is currently almost equal, rising up to or above 
95%. This is a major gain in the outcome of fetuses suffering from HDFN in the Dutch 
setting. We postulate that this improvement is likely the result of a cascade of measures, 
including: the introduction of early screening for alloantibodies in all pregnancies, use of 
national guidelines and the availability of both national reference laboratories and the 
pooling of knowledge and expertise in a single referral center for fetal therapy.
Intrauterine transfusion
Another important step forward in the survival of IUT treated fetuses was to optimize 
transfusion techniques in order to lower complication rates. In Chapter 5 we found, in 
approximately the same cohort as in Chapter 4, that the procedure-related fetal loss 
rate is currently as low as 1.8%. This rate decreased significantly over time and was 
relatively low compared to that of most other centers (this thesis, Table 2 of Chapter 
1). An important factor probably influencing this decrease is the large number of IUTs 
performed annually in our center, as a result of the Dutch approach to centralize fetal 
therapy. Thus all IUTs, a critical and skill-demanding procedure, that are needed in 
the Dutch pregnant population of approximately 180,000 pregnant women annually, 
are performed in our national referral center. These large volumes both enable the 
identification of technical risk factors, such as transfusing into a free loop of cord or 
refraining from applying fetal paralysis, to optimize the methods used, and the existence 
of a highly experienced team of operators, sonographers and specialized nurses, to 









centralization of fetal therapy in larger volume centers to profit from the 24/7 availability 
of an optimally trained team to consult and refer to and to benefit from up to date 
knowledge and care.
The safest transfusion techniques, as described in Chapter 5 and other studies, are 
transfusing into the placental cord insertion or the intrahepatic part of the umbilical 
vein.89 In Chapter 4 an additional advantage of the intrahepatic technique was presented: 
the possibility to leave an intraperitoneal blood deposit, in order to potentially prolong 
the inter-procedure interval. If performed at the last intrauterine transfusion, such a 
deposit was associated with a higher neonatal hemoglobin level.
Our finding that current monitoring and treatment of HDFN affected fetuses has reached 
a ‘as good as it gets’ state, does not apply to fetuses in need for early transfusion. It is 
known, and confirmed in Chapter 5, that transfusions performed before 20-22 weeks’ 
gestation carry a substantially higher risk for adverse outcome.96-99 Probably due to the 
technical difficulties of transfusion at this early gestational period, fetal death rate in this 
group unfortunately did not decrease significantly over time in our cohort. Therefore, 
evidence based alternative treatment options to postpone or entirely preclude the need 
for IUT are urgently required.
Alternative treatment options
As summarized in Chapter 1, therapeutic plasma exchange (TPE) and/or intravenous 
immunoglobulins (IVIg) are frequently proposed as alternatives for early intrauterine 
transfusion. The current experience mostly concerns case series with promising yet 
contradicting results, prospective trials performed on this topic are lacking. Probably, 
this results from the fact that such severe HDFN is very rare, troubling the sample size of 
single center studies. We therefore performed an international multicenter study among 
women with a history of severe HDFN. The results of this PETIT study (Postponing Early 
intrauterine Transfusion with Intravenous immunoglobulin Treatment) are described in 
Chapter 6.
Pregnancies of mothers with a previous first IUT before 24 weeks or a previous HDFN-
related fetal or neonatal death that were treated with IVIg in the next pregnancy, 
were compared to non-IVIg treated mothers with a similar history. As clinical reasons 
undoubtedly have influenced the choice whether or not to treat these women with IVIg, 
we aimed to adjust for this ‘confounding by indication’ by performing propensity analysis.
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We found that IVIg treatment was associated with less fetal hydrops and less neonatal 
exchange transfusions. Furthermore, treatment with IVIg postponed the first IUT with 15 
days, compared to that in the previous pregnancy, and with a non-significant adjusted 4 
days compared to the non-IVIg group. If IVIg was started early, before 13 weeks’ gestation, 
the effects were more profound. In general, the estimates of all outcomes pointed in 
the same direction: a possible clinically relevant effect of IVIg on the course and severity 
of disease in this severely affected group of patients. A prospective, multicenter and 
preferable randomized trial (RCT) is needed to truly settle the dispute whether IVIg 
postpones the onset of alloimmune anemia and thus the need for early transfusions. 
Based on our results however, it is unlikely that IVIg will completely preclude the need for 
treatment with IUT and therefore other immunomodulatory agents should additionally 
be evaluated.
The reasons that we advocate performing a randomized trial on the effect of IVIg, 
although our results already indicate a beneficial effect, are described in Chapter 7 of 
this thesis. This chapter contains a Cochrane systematic review on the use of neonatal 
IVIg to prevent the need for postnatal exchange transfusion. Although IVIg appeared 
favourable in case series and even in small randomized trials, such a beneficial effect of 
IVIg administration to the newborn was not found in two high quality randomized and 
double blinded RCT’s. No differences were seen in the need for exchange transfusions or 
in the number of exchange transfusions per infant in these two studies at low risk of bias. 
Furthermore, IVIg is expensive and concerns have been raised on a possible correlation 
between neonatal IVIg treatment and necrotizing enterocolitis. Lastly, the use of high 
quality intensive phototherapy gradually precludes the need for exchange transfusions 
in developing countries. The review concludes that there is insufficient evidence of the 
efficacy of neonatal IVIg for HDFN and therefore the neonatology department of the 










Again, I want to take you back to the 1960s with the quote of professor Jack Bennebroek 
Gravenhorst, the pioneer of intrauterine transfusions in the Netherlands:
‘Hoofdzaak is het bestrijden van de anemie. Bij het voortschrijden van de technische 
mogelijkheden en door uitgebreidere toepassing van de laatstgenoemde methode zal 
ongetwijfeld een elegantere methode gevonden worden voor de toediening van het bloed, 
waardoor bezwaren, die thans ongetwijfeld bestaan, uit de weg geruimd zullen worden.’ 35
In English, this quote would be: ‘The main issue is to counter the anemia. The broadening 
of technical possibilities and more extensive application of the abovementioned method will 
undoubtedly lead to a more distinguished method for the administration of blood. Hereby the 
objections, that at present surely exist, will be eliminated.’35
More than 50 years later, times have changed drastically for patients with HDFN. 
The primary goal (‘hoofdzaak’ ) is evolving. It is no longer solely to treat fetal anemia 
(‘bestrijden van anemie’ ), but also preventing it. Preventing red cell alloimmunization 
with RhIg and matched blood transfusions, preventing the resultant fetal anemia with 
immunomodulatory agents and preventing hydrops with early antibody screening. 
Evaluation and adjustment of intrauterine transfusion techniques (‘voortschrijden van de 
technische mogelijkheden’ ) and extensive team experience (‘uitgebreidere toepassing’ ) have 
led to a tremendous reduction in procedure risks. Professor Bennebroek Gravenhorst 
was certainly right, most of the hesitancies about IUT that were still abundant in the 
early years, have disappeared. HDFN has become a rare disease, with a reliable standard 
therapy. The future is exciting: the development of new immunomodulatory therapies 




Rode bloedcellen, die zuurstof door het lichaam transporteren, hebben op hun 
oppervlak bepaalde kenmerken (antigenen) die van persoon tot persoon kunnen 
verschillen. De meest bekende kenmerken of bloedgroepen zijn A, B en AB. Een 
ander bloedgroepsysteem is het Rhesus-systeem. Het komt nagenoeg nooit voor dat 
alle bloedgroepkenmerken van twee personen exact overeenkomen. Wanneer het 
bloed van iemand zonder een bepaald bloedgroepkenmerk (‘antigeen-negatief’) in 
aanraking komt met bloed waarin dit bloedgroepkenmerk wel aanwezig is (‘antigeen-
positief’), kan de antigeen-negatieve persoon antistoffen maken tegen het onbekende 
bloedgroepkenmerk. Dit proces heet alloimmunisatie. 
Alloimmunisatie kan ontstaan als gevolg van een bloedtransfusie of een 
orgaantransplantatie, of tijdens een zwangerschap of na de bevalling van een antigeen-
positief kind. Het kind draagt in dat geval bloedgroepkenmerken die onbekend zijn 
voor de moeder, omdat deze geërfd zijn van de vader. De door de moeder gemaakte 
antistoffen worden actief over de placenta naar het kind getransporteerd en kunnen 
daar de foetale rode bloedcellen afbreken (hemolyse). Het gevolg is dat de foetus 
bloedarmoede kan ontwikkelen, een ziekte die bekend staat als hemolytische ziekte 
van de foetus en pasgeborene (HZFP). Indien de foetus nog te prematuur is om geboren 
te worden, kan de bloedarmoede intra-uterien worden gecorrigeerd door middel van 
een intra-uteriene bloedtransfusie (IUT). De meeste gevallen van HZFP hebben echter 
geen prenatale gevolgen, maar uiten zich na de geboorte door een hoge concentratie 
van het afbraakproduct van rode bloedcellen, het bilirubine (hyperbilirubinemie ofwel 
geelzucht) en/of bloedarmoede.
De preventie en behandeling van HZFP heeft in de afgelopen decennia grote 
ontwikkelingen doorgemaakt. Met kennis en ervaring van nu lijken de immunisatiecijfers 
en het risico van IUT’s in ontwikkelde landen en centra met een ervaren team voor 
management en behandeling van HZFP tot een minimum beperkt zijn. Dit proefschrift 
bevat een samenvatting en kritische analyse van de huidige stand van zaken, geeft 
nieuwe inzichten in de pathogenese en verduidelijkt welke factoren hebben bijgedragen 
aan het optimaliseren van de zorg voor de foetus en pasgeborene met HZFP.
In Hoofdstuk 1 van dit proefschrift hebben we het huidige beleid voor de behandeling 









ongeveer 95% van de foetussen die IUT’s nodig hebben. Dit geldt helaas niet voor 
foetussen die al voor 20 tot 22 weken zwangerschapsduur een transfusie moeten 
ondergaan. In deze groep met vroege en dus zeer ernstige HZFP is het risico op 
perinatale sterfte verviervoudigd. Het evalueren van non-invasieve therapeutische 
mogelijkheden om deze risicovolle vroege IUT’s uit te stellen is derhalve van levensbelang. 
De toediening van intraveneuze immunoglobulinen voor dit doel wordt in Hoofdstuk 6 
verder beschreven.
Pathogenese en preventie
HZFP is meestal het gevolg van antistoffen tegen het Rhesus-D (RhD) antigeen, maar 
antistoffen tegen andere Rh-antigenen (RhC, Rhc, RhE, Rhe), anti-Kell, anti-Duffy en 
anti-Kidd kunnen ook ernstige HZFP veroorzaken. Om RhD-immunisatie te voorkomen, 
wordt in ontwikkelde landen aan alle vrouwen die zwanger zijn van een RhD-positief 
kind rond de 30e week en na de bevalling anti-D immunoprofylaxe toegediend (anti-D). 
Deze immunoprofylaxe is zeer effectief gebleken, het risico op RhD-immunisatie na een 
bevalling van een D-positief kind is hierdoor afgenomen van 5% naar 0.3%. Voor het 
voorkomen van andere antistoffen is echter geen immunoprofylaxe beschikbaar. Wel 
worden bloedtransfusies aan vrouwen in de vruchtbare leeftijd preventief zo uitgekozen 
dat deze wat betreft de Rhc, RhE en Kell bloedgroepen overeenkomen met die van de 
vrouw.
In de jaren 60 van de vorige eeuw merkte Levine en collega’s op dat RhD-
zwangerschapsimmunisatie minder vaak voorkwam bij stellen die ook verschilden 
in hun ABO bloedgroep (ABO-incompatibel). Dit leidde tot een beter begrip van 
hoe RhD-immunisaties ontstaan en uiteindelijk tot de ontwikkeling van anti-D 
profylaxe. In Hoofdstuk 2 van dit proefschrift hebben we daarom onderzocht of 
ABO-incompatibiliteit ook beschermt tegen andere immunisaties dan het RhD-type. 
Bovendien is de beschermende werking van anti-D tegen non-Rh (Kell, Duffy, Kidd, 
etc.) immunisaties geëvalueerd. We vonden dat in zwangerschappen waarin non-RhD-
antistoffen voorkwamen, de ouderparen minder vaak ABO-incompatibel waren dan in 
de rest van de bevolking. Dit suggereert dat in ABO-incompatibele zwangerschappen, 
net als RhD-antistoffen, ook non-RhD-antistoffen minder snel ontstaan, wijzend op een 
beschermende werking van ABO-incompatibiliteit. Ook viel op dat vrouwen met non-Rh 
antistoffen minder vaak dan verwacht anti-D hadden gehad in een vorige zwangerschap. 
Deze bevinding impliceert een niet-antigeen specifieke werking van anti-D profylaxe, 
waardoor anti-D niet alleen beschermt tegen de vorming van RhD-antistoffen, maar 
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ook van antistoffen van het non-Rh type (bijvoorbeeld Kell, Duffy en Kidd). Deze nieuwe 
inzichten ondersteunen het  ontwikkelen van een universele immunoprofylaxe gericht 
tegen een antigeen dat alleen voorkomt op de foetale rode bloedcel, waardoor maximale 
preventie van alloimmunisatie theoretisch haalbaar is.
Ziekte-ernst
Wanneer ondanks bovengenoemde preventieve maatregelen toch alloimmunisatie 
optreedt, ziet men een grote variatie in ziekte-ernst. Al decennia lang heerst de 
aanname dat HZFP in een volgende zwangerschap ernstiger zal verlopen dan in de 
voorafgaande geïmmuniseerde zwangerschap. Deze veronderstelling werd getoetst in 
Hoofdstuk 3 van dit proefschrift. Er werd een nationaal cohortonderzoek uitgevoerd, 
waarin alle zwangere vrouwen met RhD-antistoffen in Nederland werden geïncludeerd. 
De verzamelde informatie over de huidige en alle voorgaande zwangerschappen van 
deze geïmmuniseerde vrouwen bracht ons tot de conclusie dat de HZFP inderdaad 
meestal ernstiger verloopt in een volgende zwangerschap, maar niet altijd. Vooral die 
vrouwen waarbij de antistoffen zich pas laat in de eerst geïmmuniseerde zwangerschap 
ontwikkelden, kregen in de volgende zwangerschap vaker een kind met ernstigere 
HZFP. Dit impliceert dat late antistofvorming juist geassocieerd is met een sterke 
immuunrespons op een incompatibiliteit in de huidige zwangerschap, terwijl dit eerder 
werd geduid als een zwakke respons op de foetale bloedgroepantigenen in de vorige 
zwangerschap. Deze nieuwe hypothese wordt ondersteund door onze bevinding 
dat de kinderen uit zwangerschappen met late antistofvorming (en dus relatief korte 
blootstelling) even ziek waren als kinderen uit eerst geïmmuniseerde zwangerschappen 
waarin al vroeg, en dus gedurende de hele zwangerschap, antistoffen aanwezig waren. 
Als de groep vrouwen die laat, maar wel nog voor hun routine anti-D profylaxe bij 30 
weken, antistoffen aanmaken, in de toekomst al vroeg geïdentificeerd kunnen worden, 
kan alloimmunisatie mogelijk door een extra vroege anti-D gift worden voorkomen.
In de tweede opvolgende zwangerschap die door HZFP gecompliceerd wordt, heeft bijna 
een derde van de foetussen een IUT nodig. Deze therapie is in Nederland gecentraliseerd 
in één gespecialiseerd centrum voor foetale therapie, het Leids Universitair Medisch 
Centrum (LUMC). In de jaren zestig werden hier voor het eerst IUT’s uitgevoerd, toen 
nog met transfusie in de foetale buikholte. In die periode werd niet routinematig op 
antistoffen gescreend in de zwangerschap, met het gevolg dat een groot deel van 
de foetussen ten tijde van hun eerste IUT ernstige anemie hadden, zich uitend in 









alle compensatiemechanismen tekort schieten. Het hart faalt en er hoopt vocht op 
in de foetale buikholte, rond het hart, de longen en/of in de huid. Ingrijpen voor het 
ontstaan van deze preterminale conditie door middel van IUT is dus van levensbelang. 
Door de ontwikkeling van echoscopie werd het vanaf 1987 in Nederland mogelijk direct 
in de foetale bloedvaten (intravasculair) te transfunderen. In 1998 werd een routine 
antistofscreening voor de 13e zwangerschapsweek voor alle zwangeren ingevoerd, 
waardoor zwangerschappen ‘at risk’ voor ernstige HZFP en foetale hydrops nu vroeg 
kunnen worden geïdentificeerd. Hoofdstuk 4 beschrijft, in een 30-jarig cohort van 645 
foetussen die met intravasculaire IUT zijn behandeld in Nederland, hoe deze screening en 
andere beleidswijzigingen ertoe hebben geleid dat ernstige hydrops tegenwoordig bijna 
niet meer voorkomt. Het percentage hydrops (mild en ernstig) ten tijde van de eerste 
transfusie is aanzienlijk gedaald, van 40% voor de invoering van vroege antistofscreening 
tot 16% daarna. Opvallend is dat hydrops, als het toch voorkomt, veelal mild verloopt. 
Deze positieve ontwikkeling heeft ertoe geleid dat foetussen met en zonder hydrops 
tegenwoordig gelijke overlevingskansen hebben, namelijk beiden meer dan 95%. De 
afname van hydrops lijkt het gevolg van een cascade van veranderingen: de invoering 
van vroege antistofscreening, landelijke richtlijnen voor diagnostiek en verwijzing, 
centralisatie van laboratoriumtesten en foetale therapie en innovatie in neonatale 
opvang en behandeling.
Intra-uteriene transfusie
Een andere aanzienlijke stap voorwaarts in de overleving van foetussen met HZFP is het 
verbeteren van de intra-uteriene transfusietechniek, met het doel het complicatierisico 
te verlagen. In Hoofdstuk 5 vonden we, in hetzelfde cohort als in Hoofdstuk 4, dat het 
percentage foetussen dat sterft als gevolg van een IUT tegenwoordig nog maar 1.8% is. 
Dit percentage heeft een indrukwekkende daling doorgemaakt in de afgelopen jaren, 
en is relatief laag vergeleken met andere centra voor foetale behandeling (Tabel 2 van 
Hoofdstuk 1). Het grote aantal procedures dat jaarlijks in het LUMC wordt verricht, als 
gevolg van het centraliseren van alle foetale therapie in één Nederlands centrum, speelt 
hierin waarschijnlijk een grote rol. Deze clustering van alle IUT’s die nodig zijn voor een 
populatie van 175.000 zwangere vrouwen per jaar maakt het mogelijk in Hoofdstuk 5 
potentiële risicofactoren voor IUT complicaties te identificeren en zo de uitkomsten 
te optimaliseren. Voorbeelden hiervan zijn transfusies in een losse navelstrenglus en 
het verrichten van een IUT zonder de foetus eerst een spierverslapper toe te dienen 
(zodat deze stil blijft liggen tijdens de procedure). Bovendien maakt de centralisatie van 
deze complexe ingreep het mogelijk om 24/7 een gespecialiseerd team van operateurs, 
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echoscopisten en gespecialiseerde verpleegkundigen beschikbaar te hebben voor acute 
zorg. Dit, en het feit dat IUT’s door voldoende aantallen jaarlijkse ingrepen per operateur 
op kwalitatief hoog niveau verricht kunnen worden, zijn argumenten die het pleidooi 
ondersteunen om wereldwijd de HZFP zorg te bundelen in grote gespecialiseerde centra.
In Hoofdstuk 5 werden tevens de twee veiligste routes voor transfusie in een foetaal 
bloedvat geïdentificeerd: de insertieplaats van de navelstreng op de placenta en transfusie 
in een grote ader in de foetale lever (zie Afbeelding 2 van de General Introduction). Een 
voordeel van de tweede methode is de mogelijkheid om ook bloed achter te laten in 
de foetale buikholte, met het doel het interval tussen twee transfusies te verlengen. 
Bovendien blijkt een bloeddepot in de buikholte na de laatste IUT geassocieerd met een 
hoger neonataal hemoglobinegehalte (Hoofdstuk 4).
De bevinding dat de huidige complicatierisico’s zeer laag zijn, mogelijk zelfs zo laag als met 
de huidige middelen redelijkerwijs mogelijk is, geldt niet voor foetussen die al voor 20-22 
weken zwangerschapsduur een IUT nodig hebben. De bekende hogere sterftecijfers 
na vroege transfusies (Hoofdstuk 1) werden in Hoofdstuk 5 wederom bevestigd en zijn 
waarschijnlijk te wijten aan de technische moeilijkheden bij de zeer jonge foetus. In deze 
meest ernstig aangedane groep is het risico op IUT-gerelateerde sterfte in de periode 
van onze studie dan ook niet significant afgenomen in de tijd, hetgeen de urgentie van 
onderzoek naar evidence based alternatieve behandelmogelijkheden groot maakt. 
Alternatieve behandelopties
Zoals eerder aangegeven in Hoofdstuk 1, is een veelbesproken en frequent onderzochte 
alternatieve behandelmethode het wekelijks maternaal toedienen van intraveneuze 
immunoglobulinen (IVIg). De tot heden gepubliceerde resultaten van studies naar IVIg 
therapie met het doel vroege transfusies te voorkomen zijn veelbelovend, hoewel ook 
tegenstrijdig. Deze studies zijn vaak retrospectieve verzamelingen van IVIg cases uit één 
behandelcentrum. Mede door de zeldzaamheid van gevallen van zeer vroege en ernstige 
HZFP is de studiepopulatie van alle studies veelal te klein is voor het trekken van harde 
conclusies. Ons antwoord op dit dilemma is de internationale PETIT studie (‘Postponing 
Early intrauterine Transfusion with IVIg Treatment’), uiteengezet in Hoofdstuk 6.
In deze studie werden uit 12 gespecialiseerde centra voor foetale therapie alle cases van 
zeer ernstige HZFP, gedefinieerd als een vorige zwangerschap met HZFP-gerelateerde 









zonder IVIg behandeling in de volgende zwangerschap zijn onderling vergeleken door 
middel van propensity analyse. Dit is een statistische manier om te corrigeren voor de 
mogelijkheid dat patiënten waarbij voor IVIg is gekozen ernstiger ziek waren dan de 
patiënten zonder IVIg. 
In onze PETIT studie wezen alle uitkomsten in dezelfde richting: een mogelijk voordelig 
effect van IVIg in patiënten met zeer ernstige HZFP. We vonden significant minder hydrops 
bij de eerste IUT en minder postnatale wisseltransfusies in de IVIg groep. Vergeleken met 
de vorige zwangerschap stelde IVIg de eerste IUT met 15 dagen uit, een niet-significant 
gecorrigeerd verschil van 4 dagen ten opzichte van de groep zonder IVIg. Bij vroege IVIg 
toediening, voor 13 weken zwangerschapsduur, was het effect duidelijker aanwezig. Om 
definitief een eind te kunnen maken aan de discussie of IVIg wel of niet de eerste IUT 
uit kan stellen, is een prospectieve gerandomiseerde multicenter studie nodig. Omdat 
zelfs in het LUMC, een landelijk verwijscentrum met grote aantallen IUT’s, slechts één 
of twee patiënten per jaar voor een dergelijke studie in aanmerking zouden komen, zou 
dit een grote logistieke uitdaging zijn. Bovendien lijkt het op basis van onze resultaten 
onwaarschijnlijk dat IVIg de noodzaak van IUT’s compleet kan doen verdwijnen. Om die 
reden zou ook verder onderzoek naar andere immunomodulatoire therapieën gedaan 
moeten worden.
In Hoofdstuk 7 wordt een Cochrane systematische review betreffende de neonatale 
behandeling met IVIg ter preventie van wisseltransfusies beschreven. Net als prenatale 
IVIg behandeling, leek neonatale IVIg behandeling veelbelovend in verschillende case 
series en in kleine gerandomiseerde studies (RCT’s). Nadere analyse toonde gebreken in 
de opzet van deze RCT’s, wat de betrouwbaarheid van deze studies negatief beïnvloedt. 
De enige twee RCT’s in onze Cochrane review met laag risico op bias lieten geen positief 
effect zien van het neonataal toedienen van IVIg op het aantal wisseltransfusies. Deze 
uitkomst, tezamen met de kosten van IVIg en de mogelijke bijwerkingen, maakt dat de 
neonatologie afdeling van het Leids Universitair Medisch Centrum tegen het routinematig 
gebruik van IVIg voor de preventie van wisseltransfusies pleit.
Conclusie
Er is in de afgelopen decennia veel verbeterd in de zorg voor patiënten met HZFP. 
Aanvankelijk liep men vaak achter de feiten aan: er werd niet gescreend op de 
aanwezigheid van alloantistoffen in de zwangerschap en als de moeder werd verwezen 
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in verband met foetale anemie, was er veelal sprake van ernstige hydrops. Ook al werd 
therapie alsnog gestart, de uitkomst van deze zwangerschappen bleef suboptimaal.
Tegenwoordig ligt de nadruk in de HZFP ketenzorg vooral op preventie. Preventie van het 
ontstaan van HZFP door het toedienen van anti-D profylaxe aan RhD-negatieve moeders 
die zwanger of bevallen zijn van een RhD-positief kind. Preventie van hydrops door 
routinematige antistofscreening vroeg in de zwangerschap, landelijke richtlijnen voor 
optimale diagnostiek van foetale anemie en tijdige verwijzing naar een gespecialiseerd 
behandelcentrum. Preventie van complicaties door optimalisatie van de IUT techniek 
en door toediening van IVIg aan moeders met een voorgeschiedenis van zeer ernstige 
HZFP. Met behulp van al deze maatregelen is HZFP, ooit de belangrijkste oorzaak van 
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wetenschappelijk groentje mijn intrede deed in het LUMC, nam jij me onder je hoede. In de 
jaren die volgden, werkten we probleemloos zij aan zij. Jouw rust, relativeringsvermogen 
en gezelligheid waardeer ik enorm en mijn keuze om jou als paranimf te vragen was dan 
ook snel gemaakt.
Lieve familie, schoonfamilie en vrienden. Dank voor alle interesse en afleiding tijdens de 
totstandkoming van dit proefschrift.
Lieve Mart, zoals het een broer betaamt heb jij me vroeger weerbaar gemaakt voor de 
grote mensenwereld. Ik vind het heel fijn jouw kleine zusje te zijn.
Maaik, lief zusje, jij bent mijn grote voorbeeld. Ik bewonder jouw doorzettingsvermogen 
en waardeer dat jouw deur werkelijk altijd voor me open staat. Bedankt!
Lieve pap en mam, ik ben jullie ontzettend dankbaar dat jullie me geleerd hebben 
zelfstandig te zijn en vertrouwen te hebben in mijn eigen kwaliteiten. Dankzij jullie 
onvoorwaardelijke steun sta ik hier vandaag.
Liefste Ro, ik mis onze gezamenlijke onderzoeksdagjes in Zeewolde nu al! Wat ben ik 
blij dat jij er bent om mijn gedachten te ordenen en alle kleine en grote problemen te 










LIST OF ABBREVIATIONS 
ADCC - antibody-dependent cell-mediated cytotoxity assay
ET – exchange transfusion
GEE – generalized estimating equations. 
HDFN – hemolytic disease of the fetus and newborn
HZFP – hemolytische ziekte van de foetus en pasgeborene
IUFD – intrauterine fetal death
IUT – (intravascular) intrauterine transfusion
IVIg – intravenous immunoglobulins
LUMC – Leiden University Medical Center
MCA-PSV – middle cerebral artery peak systolic velocity
NPR – non procedure-related
PR – procedure-related
RBC – red blood cell
Rh – Rhesus
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